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ABSTRACT
NK1 receptor antagonists represent an emerging class of putative antidepressants. These 
compounds may act through an interaction with 5-HT and / or noradrenaline (NA), the 
targets of established antidepressants. Pilot microdialysis studies in our laboratory have 
demonstrated that cortical NA efflux is 2-fold higher in halothane-anaesthetised NK1-/- 
mice compared with NK1+/+ mice. These current studies were, therefore, primarily 
aimed at investigating the autoregulatory a 2-adrenoceptor, which controls the firing-rate 
and release of NA from noradrenergic neurones.
NA efflux was monitored following systemic administration of the a 2-adrenoceptor 
antagonist RX821002, during anaesthetised (0.3 mg /kg i.p.), and freely-moving (0.3,
1.0 and 3.0 mg / kg i.p.), in vivo microdialysis. NA efflux and the behavioural response 
to an aversive, naturalistic stimulus were investigated using the light / dark exploration 
box (LDEB), in naive and RX821002 pre-treated mice. Localisation and density of 
ct2-adrenoceptors were examined using immunohistochemistry, Western blot analysis 
and [3H]RX821002 autoradiography. Adrenaline-stimulated [35S]GTPyS binding 
analysed the functional status of the a 2-adrenoceptors.
Basal NA efflux was 4-5-fold higher in halothane-anaesthetised NK1-/- mice compared 
with NK1+/+ mice. No difference in NA efflux between genotypes was found during 
freely-moving mouse microdialysis. Treatment with RX821002, increased NA efflux in 
NK1+/+ mice, only. Of the 12 behaviours scored in the LDEB, 5 were genotype 
dependent. With the exception of rearing activity, these were not dependent on the 
genotype difference in locomotor activity. In the LDEB pre-treatment with RX821002 
modified the behavioural response in 4 of the 12 behaviours, and increased NA efflux in 
NK1+/+ mice, only. However, no difference in net NA efflux was found between 
groups. No difference between NK1+/+ and NK1-/- mice in the localisation, density or 
functional activity of the a 2-adrenoceptors was found.
These results suggest that genetic disruption of the NK1 receptor, modifies the 
regulation of the noradrenergic system, which can, at least in part, be attributed to a 
decreased sensitivity of the ct2-adrenoceptor.
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1 INTRODUCTION
Background
Depression is one of the most prevalent and costly brain disorders, with health and 
social effects similar to those for chronic diseases like hypertension, congestive heart 
failure or diabetes (WHO, 2005). Depression affects 5-10 % of the population of 
Western Europe (WHO, 2005), with 1 in 10 women and 1 in 50 men suffering at some 
stage in their life. It is a highly heritable disorder; genetic factors comprise roughly 
50 % of the risk for depression (Nestler et al., 2002). However, we still lack a detailed 
understanding of genes that increase risk for depression, and of the changes in the brain 
that may underlie the diverse symptoms of depression (for review see: (Merikangas et 
al., 2 0 0 2 )).
Depression is often associated with co-morbid psychiatric disorders especially anxiety 
disorders. Chronic environmental stress / anxiety may also contribute to development of 
depressive states. Depression can, therefore, be viewed as a complex, polygenic 
disorder, arising from a complex interplay of environmental stress and developmental 
insults affecting multiple aspects of monoamine modulation.
Three main treatments are used: usually antidepressants, psychotherapy or 
electroconvulsive therapy (ECT). The main classes of established antidepressants act to 
increase the monoamines noradrenaline (NA) and / or serotonin (5-HT) in all brain 
areas. However, therapeutic lag before clinical efficacy, poor patient
tolerance / compliance, the risk of overdose and faster efficacy, necessitates the 
development of new improved treatments.
Substance P (SP) belongs to the tachykinin family of neuropeptides, found throughout 
the central and peripheral nervous systems. It mediates many physiological responses 
for example those provoked by stress. The last ten years have seen dramatic progress in 
the development of potential new medicines targeting SP or its receptor. This is due, at 
least in part, to the cloning of the SP-preferring neurokinin 1 (NK1) receptor (Yokota et 
al., 1989).
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NK1 receptor antagonists are emerging as a class of putative anxiolytic / antidepressant 
compounds (Kramer et al, 2004). Unlike established antidepressants, which target the 
monoamines 5-HT and / or NA in all brain areas, NK1 receptor antagonists act by 
inhibiting the actions of the neuropeptide SP within the central nervous system (CNS). 
Although, it should also be noted that phase III clinical trials with the NK1 receptor 
antagonist, aprepitant, demonstrate aprepitant is not more effective than placebo 
(Kramer et al, 2004).
It is possible that NK1 receptor antagonists produce behavioural effects via modulation 
of central noradrenergic and / or serotonergic neurotransmission. Previous studies in 
other laboratories have focused on the role of NK1 receptors in modulating serotonergic 
neurotransmission (Froger et a l , 2001; Santarelli et a l , 2001).
The locus coeruleus (LC) is the main source of central noradrenergic nerve terminals 
(Dahlstrom and Fuxe, 1964; Aston-Jones et al, 1986). LC neurones are innervated by 
SP containing fibres (Halliday et a l , 1988), express NK1 receptors (Shults et a l , 1984) 
and are activated by SP (Cheeseman et al., 1983). Investigations into the mechanism of 
action of NK1 receptor antagonists are also beginning to focus on the effects of SP on 
the activity of noradrenergic neurones (Haddjeri & Blier, 2000; Maubach et a l , 2002), 
therefore. The studies contained in this thesis are, particularly focused on the role the 
NK1 receptor may play in modulating noradrenergic neurotransmission.
1.1  Ta c h y k in in s  a n d  t h e ir  r e c e p t o r s
Three main tachykinin peptides are recognised; substance P (SP), neurokinin A (NKA) 
and neurokinin B (Nakanishi et al., 1993), characterized by a common C-terminal 
amino acid sequence (for review see: (Otsuka & Yoshioka, 1993)). Each binds 
specifically and with different affinities to the NK1, NK2 or NK3 receptors, 
respectively, which differ in respect of their distribution throughout the CNS (Pinto et 
a l , 2004).
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1.1.1 Distribution o f the NK1 receptor
Extensive distribution of the NK1 receptor is found throughout the central nervous 
system (CNS). Heavy expression is found in the olfactory bulbs, the striatum, the 
amygdala, the habenula, the periaqueductal grey (PAG), the superior colliculus, the 
parabrachial nucleus and the LC (Gadd, 2004). The NK1 receptor is also found in high 
levels in the superficial laminae of the spinal cord, where it is expressed on neurones 
that are activated by SP released from nociceptive C-fibres (Nakaya et al., 1994).
1.1.2 Signalling through the NK1 receptor
The undecapeptide SP [Arg-Pro-Lys-Pro-Gln-Gln-Phe-Phe-Gly-Leu-Met-NH2] was 
initially isolated in the 1930s (von Euler and Gaddum 1931). The release of SP upon 
neuronal excitation evokes a number of cellular responses, mediated by activation of the 
NK1 receptor. Tachykinins usually evoke a slow long-lasting membrane depolarisation 
in neurones and smooth muscle fibres which is excitatory and often accompanied by a 
fast excitatory post-synaptic potential. The evoked cellular responses include blockade 
of an inwardly rectifying K+ channel, resulting in membrane depolarisation and an 
increased excitability of the neurones (Nicoll, 1978; Nowak & Macdonald, 1982; 
Stanfield et al., 1985; Yamaguchi et al., 1990; Shen & North, 1992).
The main signalling pathway activated by SP and related tachykinins is activation of 
G proteins (Gq/n, Gas and Ga0) mediating inositol phospholipid hydrolysis via 
phospholipase Cp activation and formation of diacylglycerol. Inositol phospholipid 
hydrolysis yields inositol phosphates, e.g. 1,4,5-trisphosphate (IP3) (Taylor et al., 1986; 
Nakajima et al., 1992; Takeda et al., 1992; Seabrook & Fong, 1993; Roush & Kwatra,
' ji
1998). IP3 triggers release of Ca from internal stores and the subsequent activation of
^ I
calcium-calmodulin-dependent kinases. IP3 may also promote Ca influx, leading to
1
elevated [Ca ]i, while DAG activates protein kinase C (Merritt & Rink, 1987; Sugiya et 
al., 1987; Womack et al., 1988; Seabrook & Fong, 1993).
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1.1.3 Distribution o f Substance P in the central nervous system
SP-immunoreactive cell bodies and terminal networks are found in most areas of the 
brain (Ljungdahl et al., 1978a), in close association with 5-HT and NA-containing 
neurones (Ljungdahl et al., 1978b; Hokfelt et al., 1987) the target of all established 
antidepressant drugs (Figure 1.1).
Distribution of Substance P in the brain
Noradrenaline pathways Serotonin pathways
Emxfedorvgcckjt 
B acJaterd  aT v g aaa Cenfromedd crvcpaa \
a f tr io ry  & '  '  ~
ertahnd aniC8SMirTTYYTYf, ^
Raid raphe nyd 
Ccucdrcphe
Hippoocmpus
inlracereb
nudei
Vagd-sditcryaonnaTospind
a id
Substance P
F i g u r e  1.1: Distribution of the SP pathways in close association with the 5-HT and 
noradrenaline pathw ays in the brain.
Structures within the limbic system, which governs mood and cognition, express a high 
density of NK1 receptors. These brain structures include the striatum, hippocampus, 
nucleus tractus solitarius, raphe nuclei and LC (Otsuka & Yoshioka, 1993). Areas such 
as the amygdala, septum, hippocampus, hypothalamus and periaquaductal grey (PAG), 
involved in Tear processing’, also express SP and NK1 receptors (Mantyh et al., 1984; 
Arai & Emson, 1986). On this basis, it can be speculated that SP may influence limbic 
behaviours such as affective responses.
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1.1.4 Substance P  and aversive/stressful stimuli
Noxious / stressful stimuli are associated with changes in the release of SP in a 
region-specific manner. Evidence, from studies on rodents, suggests that following 
noxious stimulation for example heating, tail pinch or cold stimulation, SP synthesis 
and release is increased within areas of the CNS such as the dorsal root ganglion 
(Noguchi et a l , 1988), substantia gelatinosa (Lang & Hope, 1994), and PAG (Xin et al., 
1997).
Neurochemical studies have provided evidence for either an increase or decrease in the 
content of SP in particular brain regions in response to anxiogenic / stressful stimuli. 
For example, in rats, SP-like immunoreactivity in the dorsal PAG is increased following 
social isolation (Brodin et al., 1994) and following subcutaneous saline injection (Rosen 
et al., 1992). However, a reduction in SP-like immunoreactivity in the ventromedial and 
dorsomedial hypothalamus is observed after foot-shock (Siegel et al., 1987) and a 
reduction in SP-like immunoreactivity in the accumbens is observed following saline 
injection (Rosen et al., 1992).
Species-specific defensive behavioural changes are observed following 
intracerebroventricular (i.c.v.) administration of SP or selective tachykinin NK1 
receptor agonists e.g. escape behaviour (such as locomotion), vocalisation (guinea-pigs) 
(Piot et al., 1995; Rupniak et al., 2000) hind-paw tapping (gerbils) (Bristow & Young, 
1994; Rupniak & Williams, 1994), and grooming (mice) (Elliott & Iversen, 1986; 
Elliott et al., 1992). I.c.v. infusion of SP produces 4anxiety-like’ behaviours in a range 
of tests used to screen anxiolytic and antidepressant compounds e.g. the elevated 
plus-maze (Aguiar & Brandao, 1996; Teixeira et al., 1996), conditioned place aversion 
(Aguiar & Brandao, 1994) and aggression (Shaikh et al., 1993). Cardiovascular changes, 
specifically resembling the defence response to threatening stimuli (Culman & Unger,
1995), are also reported.
The medial amygdala is crucial for the mediation of SP transmission in anxiety-like 
responses (Ebner et al., 2004). Aversive stimuli such as immobilization stress, elevated 
plus-maze exposure and maternal separation result in the release of SP in the amygdala, 
and NK1 receptor antagonism prevents the vocalisations associated with these stimuli
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(Kramer et a l, 1998; Smith et al., 1999; Boyce et al., 2001; Steinberg et al., 2002; 
Ebner et al., 2004). These behavioural and physiological effects suggest that SP is 
released in response to noxious / aversive stimulation.
1.1.5 Behavioural and neurochemical effects o f NK1 receptor antagonists
A number of reports support the anxiolytic / antidepressant profile of NK1 receptor 
antagonists in a variety of pre-clinical behavioural tests (Table 1.1).
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NK1
receptor
antagonist
Behavioural
test
Species Effect Reference:
FK888 Elevated
plus-maze
Mice
Rats
Anxiolytic (Teixeira et al., 1996; 
Teixeira & De Lima, 
2003)
(Duarte et al., 2004; 
Gavioli et al., 2002)
Forced swim 
test
Rats Reduces
immobility
(Dableh et al., 2005).
NKP608 Social
interaction test
Rats Anxiolytic (File, 2000)
Chronic mild 
stress
Rats Antidepressant (Papp et al., 2000)
CGP49823 Social
interaction test
Rats Anxiolytic (File, 1997)
L-760735 Social
interaction test
Gerbils Anxiolytic (Cheeta et al., 2001)
Table 1.1: Anxiolytic / antidepressant profile of NK1 receptor antagonists in 
behavioural tests used to determine anxiolytic / antidepressant activity.
The compound MK869, its close analogue L-760735, and a structurally unrelated 
compound, L-733060, have been studied in a range of preclinical tests. These 
compounds completely inhibited stress-induced vocalisations in guinea-pig pups 
induced by transient separation from their mother (one of a number of behavioural 
assays used to detect antidepressant compounds) (Kramer et al, 1998). The NK1 
selectivity of this response was confirmed by the use of the enantiomers L-770765 and
8
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L-733061, which have low affinity for the NK1 receptor; these compounds produced no 
inhibition of vocalisation. The results were confirmed using established antidepressant 
drugs, fluoxetine (a serotonin re-uptake inhibitor, SSRI) and imipramine (a tricyclic 
antidepressant), which also markedly decreased separation-induced vocalisations in 
guinea-pigs. It was these observations that led to the first clinical investigation of the 
NK1 receptor antagonist MK869 in depressed patients (Kramer et al., 1998; Rupniak & 
Kramer, 1999). In humans, MK869 was shown to alleviate major depressive disorder 
with moderately high anxiety (Kramer et al., 1998).
However, preclinical evaluation of NK1 receptor antagonists, using traditional screens 
for antidepressant drugs in rodents, is complicated by marked species differences in 
NK1 receptor pharmacology (Gitter et al., 1991; Beresford et al., 1991)(Table 1.2) and 
poor brain penetration (Rupniak et a l , 1997). Poor brain penetration is overcome by 
administration of compounds at high doses. However, this results in non-specific ion 
channel effects, conferring activity in in vivo assays independent of NK1 receptor 
blockade (Rupniak et al., 1993; Rupniak & Jackson, 1994).
Development of the NK1-/- mouse has provided a valuable research tool (De Felipe et 
al., 1998). The NK1-/- mouse has enabled investigation into the contribution made by 
the NK1 receptor, in adaptive responses to stress, in a species for which there are, as yet, 
no suitable pharmacological antagonists. However, compensatory effects, resulting from 
disruption of the receptor, must always be kept in mind.
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NK1 receptor 
antagonist
Species
Binding affinity 
(nM)
Reference:
RP67580 Rat 7.9 (Barr & Watson, 1993)
RP67580 Human 194 (Barr & Watson, 1993)
CP-96,345 Rat 2 1 0 (Barr & Watson, 1993)
CP-96,345 Human 0.99 (Barr & Watson, 1993)
CP-96345 Cow 0 . 6 (Gitter et al., 1991)
CP-96345 Guinea-pig 0.32 (Gitter et al., 1991)
CP-96345 Rabbit 0.54 (Gitter et al., 1991)
CP-96345 Mouse 32 (Gitter et al., 1991)
CP-96345 Rat 35 (Gitter et al., 1991)
CP-96345 Chicken 156 (Gitter et al., 1991)
Spantide Rat 602
(Fardin& Garret, 1991; 
Appell et al., 1992)
Spantide Guinea-pig 247
(Fardin & Garret, 1991; 
Appell et al., 1992)
L688169 Rat 602 (Fardin & Garret, 1991)
L688169 Guinea-pig 247 (Fardin & Garret, 1991)
Table 1.2: Species differences in binding affinity of NK1 receptor antagonists.
1.1.6 The NKl-/-mouse has an antidepressant / anxiolytic-like phenotype
Behavioural and neurochemical analysis of NK1-/- mice has revealed a number of 
features consistent with chronic treatment with an antidepressant.
1.1.6.1 Anxiolytic-like behavioural phenotype
The NK1-/- mouse shows a marked reduction in aggressive behaviour in the resident 
intruder test and a decrease in separation-induced neonatal vocalisation (De Felipe et al., 
1998; Rupniak et al., 2000; Santarelli et al., 2001; Rupniak et al., 2001) compared to its 
wildtype counterpart. Both these behaviours are modified in NK1+/+ mice, by 
antidepressants e.g. fluoxetine, in such a way that NK1+/+ mice are indistinguishable 
from the NK1-/- mice. An increase in exploratory behaviour in the open field, a
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reduction in anxiety-like behaviour in the elevated plus-maze, novelty suppressed 
feeding (Santarelli et al., 2001; Santarelli et a l , 2002) and in the forced swim test 
(Rupniak et al., 2001) are also reported by certain laboratories using NK1-/- mice bred 
with a 129/SvEv background. However, no difference between genotypes in the open 
field, novel object exploration and elevated plus-maze was found by De Felipe et al., 
(1998) and Rupniak et al., (2001) using NK1-/- mice derived from hybrid 129/SvEv X 
C57BL/6 mice. However, both these groups do report a reduction in aggression in the 
resident intruder test in NK1-/- mice (Rupniak et al., 2001; De Felipe et al., 1998). 
Strain differences of the NK1-/- mice could, therefore, account for the discrepancies in 
the behavioural response of these two groups.
1.1.6.2 Increased neurogenesis
The long time course needed to increase neurogenesis and proliferation resembles the 
delayed time course needed before the therapeutic action of antidepressants is apparent. 
Electroconvulsive shock treatment (ECT), another treatment for depression, increases 
neurogenesis in the adult rat (Madsen et al., 2000; Malberg et al., 2000; Hellsten et al.,
2002). Consistent with an antidepressant-like phenotype, the NK1-/- mouse shows an 
increase in neurogenesis in the dentate gyrus of the hippocampus (Morcuende et al.,
2003). Brain derived neurotrophic factor (BDNF) protein has been shown to have 
antidepressant-like effects when injected into the hippocampus (Shirayama et al., 2002; 
Sairanen et al., 2005) and antidepressant treatment can result in increased BDNF (Chen 
et al., 2001). NK1-/- mice show a 2-fold increase in BDNF compared to NK1+/+ mice 
in the hippocampus (Morcuende et al., 2003). The 29.3 % increase in neurogenesis in 
the dentate gyrus of NK1-/- mice, is approximately the same as that seen in rats treated 
with an SSRI (Malberg et al., 2000).
The monoamines 5-HT and NA both play an important role in regulating neurogenesis 
(for a review see: (Delgado, 2004; Marien et al., 2004)). Depletion of NA, using the 
noradrenergic neurotoxin DSP-4, decreases proliferation, but not survival and 
differentiation of cells, in the adult rat hippocampus (Kulkami et al., 2002). Thus there 
may be an interaction between the monoamine systems and NK1 receptors in 
controlling neurogenesis.
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1.1.6.3 Downregulation and desensitisation o f 5-HT)A autoreceptors
Previous studies, by other groups, have demonstrated that either disruption of the NK1 
receptor or, administration of an NK1 receptor antagonist, results in profound changes 
in the regulation of the serotonergic system, suggesting that NK1 receptor antagonists 
exert their therapeutic effects through modulation of the serotonergic system.
The 5-HTia receptor has an inhibitory influence on the firing-rate of dorsal raphe (DR) 
serotonergic neurones, and hence release of 5-HT in terminal projection areas, for 
example, the hippocampus. Chronic antidepressant treatment results in downregulation 
of the autoregulatory 5-HTia receptor (Blier & de Montigny, 1983; Jolas et al., 1994; 
Le et al., 1995). The 5-HTiA receptor in the NK1-/- mouse is also downregulated and 
desensitised (Froger et al., 2001; Santarelli et a l , 2001). Administration of a selective 
serotonin re-uptake inhibitor (SSRI) e.g. paroxetine, results in an increase in 5-HT, 
however, this increase is hampered by the autoregulatory 5-HTia receptor. In NK1-/- 
mice, therefore, downregulation / desensitisation of the 5-HTia receptor results in an 
enhancement of 5-HT release following challenge with the selective serotonin re-uptake 
inhibitor (SSRI) paroxetine compared to their wildtype counterpart (Froger et al., 2001; 
Santarelli et al., 2001).
Although several studies support modulation of the serotonergic system in the 
anxiolytic / antidepressant mechanism of action of NK1 receptor antagonists, we are 
particularly interested in the contribution made by the noradrenergic system, in 
mediating the therapeutic actions of NK1 receptor antagonists.
1.2 N o r a d r e n a l i n e  i s  im p lic a  t e d  in  a n x i e t y / d e p r e s s i o n
A major difficulty in unravelling the neurobiological basis of depression is that it is not 
a simple, unitary disorder (Stanford, 2001c). Although the role of monoamines, such as 
NA and 5-HT, in mood disorders has long been recognised, (for review see: (Ressler & 
Nemeroff, 1999; Millan, 2004), the precise nature of any defects remains equivocal , 
and no consistent biochemical markers have emerged to provide a firm link (Table 1.3).
12
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Marker Tissue Usual finding in depression
NA or MHPG 
concentrations
Post-mortem brain, 
urine, CSF, plasma
NCC
Tyrosine
hydroxylase
immunoreactivity
Post-mortem brain NCC
a  i-adrenoceptor 
binding
Post-mortem brain I Some brain areas
a.2 -adrenoceptor
binding
Post-mortem brain
l High-affinity site in some brain 
areas
pi-adrenoceptor 
binding
Platelets
Post-mortem brain
NCC
i Certain cortical areas of suicide 
victims
P2-adrenoceptor
binding
-cAMP response
Lymphocytes 1
i
Table 1.3: Neurochemical markers for depression. Measurements in depressed 
patients compared with normal subjects, euthymic controls or patients suffering 
from unrelated psychiatric disorder. NCC: No consistent change. (Taken from 
Stanford, 2001a).
More convincing evidence is available for a link between monoaminergic transmission 
and the therapeutic effects of antidepressants. Depletion of NA (by administration of the 
NA synthesis inhibitor, a-methyl-p-tyrosine) demonstrates the importance of 
functionally competent monoaminergic pathways for treating depressive states (Delgado, 
2000). Depletion of NA causes a recurrence of depression in patients who are in 
remission following treatment with antidepressants that selectively target noradrenergic 
neurones (Stanford, 2001a).
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The LC contains the majority of noradrenergic neurones projecting to forebrain regions 
(Dahlstrom and Fuxe, 1964). The LC-noradrenergic system is important in activation of 
the autonomic nervous system (Elam et al., 1986b; Elam et al., 1986a; Reiner, 1986; 
Svensson, 1987; Guo et al., 2002). In the CNS it plays an important role in arousal, 
selective attention (Delagrange et al., 1993; Aston-Jones et al., 1994; Aston-Jones et al., 
2001; Jones, 2003), mood, (Osaka & Matsumura, 1994; Kayama & Koyama, 1998; 
Kayama & Koyama, 2003), and pain regulation (Stenberg, 1989; Jones, 1991), states 
which are profoundly altered in depressive disorder.
All antidepressant treatments alter the noradrenergic system in some way, 
demonstrating that monoamine systems are integral to the mechanism of action of 
antidepressants. Most classes of antidepressants restore compromised activity of 
corticolimbic noradrenergic pathways by 1 ) blockade of pre-synaptic noradrenaline 
transporter proteins, which sequester extracellular transmitter 2 ) inhibition of 
monoamine oxidase, which degrades monoamine neurotransmitters and 3) inhibition or 
excitation of pre-synaptic receptors that regulate monoamine transmitter release and / or 
firing-rates and so increase release. Treatment with antidepressants results in significant 
alteration of NA neuronal activity and alteration of noradrenergic receptors. It is these 
alterations that are believed to mediate recovery from depression. Alterations may arise 
from changes in neurotrophin release and synaptic plasticity, or through altered 
interactions of the brain stem modulatory systems. In a similar manner to the 5-HTia 
receptors, the expression of <X2-adrenoceptors is also changed following antidepressant 
treatment. ECT leads to downregulation of ct2-adrenoceptors (Stanford & Nutt, 1982). 
The effect of chronic antidepressant treatment on 012-adrenoceptors is more variable, 
with some groups reporting an increase (Reisine., 1980), a decrease (Smith et al., 1981), 
or no effect, depending on the brain region studied (see: (Stanford et al., 1983)). Since 
the 5-HTia autoreceptor in NK1 -/- mice is downregulated / desensitised resembling 
treatment with an SSRI, it is, therefore, also possible that the 012-adrenoceptor in NK1-/- 
mice may be altered in someway.
Although the protein targets of antidepressants are known and their effects occur within 
the CNS almost immediately, the therapeutic lag means that clinical effects are not 
significantly different from placebo treated controls for at least 3-5 weeks. This suggests
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slow adaptive processes downstream of structures, within the limbic system, that 
receive monoaminergic projections.
1.3 Locus c o e r u l e u s :  T h e  m a in  s o u r c e  o f  n o r a d r e n a l i n e  a n d  i t s  i m p l i c a  t i o n
IN DEPRESSION
1.3.1 Topography and efferent projections
Although the noradrenergic system of the rat has been extensively mapped (Foote et al., 
1980a; Loughlin et al., 1982; Loughlin et al., 1986b; Loughlin et al., 1986a; Maeda et 
al., 1991; Iijima, 1993), little is known about the distribution of noradrenergic axons 
and terminals within the mouse CNS. The brainstem contains the soma of noradrenergic 
neurones localised bilaterally in seven groups (A1-A7; Figure 1.2).
Thalamus CerebellumNeocortex
Septum
Amygdala
A 7 Spinal cordA5
Hypothalamus Central tegmental tract
Dorsal bundle Ventral bundle
F i g u r e  1.2: Distribution of noradrenergic neurones in the rat brain. The cell 
bodies are clustered in nuclei (A1-A7) in the pons / medulla regions of the 
brainstem and their axons project both rostrally and caudally to most regions of 
the neuraxis. The major nucleus is the locus coeruleus (A4 and A6 ) (Taken from 
Stanford, 2001b).
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The LC (catecholaminergic cell group A4 and A6 ) of the rat brain stem, supplies 40 % 
of the total noradrenergic neurones in the CNS. LC projections innervate most of the 
cortical and subcortical areas in addition to the spinal cord (Figure 1.2). The LC is 
generally viewed as a widely projecting, topographically organised afferent system (see: 
(Ressler & Nemeroff, 1999)).
Using 3-D reconstruction of the LC it has been shown that the LC consists of a densely 
packed globular core and three extended poles: an anterior pole, a ventral cell group and 
the A4 group projecting dorso-posteriorly from the LC (Loughlin et al., 1982). Six 
morphologically defined subpopulations of LC cells exist, differing in localization, 
morphology and / or efferent projections. The following morphological and spatial 
organisation of the LC in the rat has been proposed by (Loughlin et al., 1986b):
1) Anterior large multipolar cells:; these are believed to project to the hypothalamus.
2) Fusiform cells; along the dorsal edge of the LC reported to project to the 
hippocampus and cortex.
3) Fusiform cells; in the A4 region (dorsal edge) project to hippocampus and cortex.
4) Medium-sized multipolar cells; within compact dorsal LC, also known as core cells. 
These are morphologically the predominant population in the LC and contribute a major 
portion of all LC efferent projections (Loughlin et al., 1986b). Cortical efferents arise 
from the medium sized multipolar cells (Loughlin et a l , 1982). Dorsal cells project to 
the hippocampus and ventral cells project to the spinal cord.
5) Large multipolar cells; in the ventromedial pole of the LC project to the spinal cord.
6 ) Small round cells; within the LC, sustaining axons projecting to the hypothalamus.
Single LC axons terminate in both deep and superficial layers of a given region of 
cortex. Layers I, IV and V of the cortex primarily receive projections from the LC. It is, 
therefore, likely that activation of the LC results in the release of NA which affects 
multiple, functionally distinct areas (Loughlin et al., 1982).
1.3.2 Afferent projections to the LC
The LC is innervated by neurones from only a few brain regions. A dense plexus of LC 
neuronal processes, primarily dendrites, extend beyond the borders of the LC forming
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the pericoerulear region (Shipley et al., 1996) which receives input from a greater 
number of brain regions. The bulk of afferents to the LC complex (A6  and A4) arise 
from two rostral medullary nuclei, particularly important in driving LC neuronal firing 
(Aston-Jones et al., 1986; Pieribone & Aston-Jones, 1988), (for review see: (Aston- 
Jones et a l , 1991b; Williams et al., 1991; Berridge & Waterhouse, 2003)) .
One, an excitatory pathway mediated by the amino acid glutamate, arises from the 
nucleus paragigantocellularis (PGi) (Ennis & Aston-Jones, 1988). The other, an 
inhibitory pathway, arises from GABAergic neurones from the prepositus hypoglossi 
(PrH) (Ennis & Aston-Jones, 1989). The LC may also receive an inhibitory 
noradrenergic input thought to arise from dendrites of LC neurones themselves and via 
a noradrenergic inhibitory collateral input (Aghajanian et al., 1977; Cedarbaum & 
Aghajanian, 1978).
The PGi participates in somatic, autonomic, and visceral functions. It is also the 
principal source of corticotrophin releasing factor (CRF) projections to the LC and may 
play a key role in the interaction between the stress response and NA leading to 
systemic arousal.
The PrH integrates velocity-coded saccadic inputs (Goldman et al., 2002) to drive 
horizontal eye movements, supporting a role for this nucleus in the modulation of 
attentional changes that accompany visual shifts. Additional input sources to the LC 
arise from areas that participate in the mediation of the stress response and autonomic 
function, e.g. the paraventricular nucleus, the intermediate zone of the spinal cord, the 
PAG, the lateral hypothalamus, the medial preoptic area and the pericoerulear region 
(see: (Singewald & Philippu, 1998)).
The pericoerulear region is the target of a large number of pre-synaptic fibres, arising 
from the prefrontal cortex, central nucleus of the amygdala, lateral hypothalamus, bed 
nucleus of the stria terminalis (BNST) and DR (Pickel et al., 1977; Amsten & 
Goldman-Rakic, 1984; Peyron et al., 1998; Van Bockstaele et al., 1996b; Van 
Bockstaele et al., 1996a; Van Bockstaele et al., 1998; Van Bockstaele et al., 1999a; Van 
Bockstaele et al., 1999b). In addition, the LC receives an inhibitory input from the 
frontal cortex (Amsten & Goldman-Rakic, 1984; Sara & Herve-Minvielle, 1995). This
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provides further support for a role of the NA system in integrating the peripheral and 
central responses to stress and arousal.
LC noradrenergic neurones fire spontaneously. Under basal conditions, LC neurones 
fire action potentials asynchronously but, in response to a strong synaptic input, they 
fire in synchrony (Aston-Jones & Bloom, 1981b; Ennis et al., 1992). Electrotonic 
coupling exists among the noradrenergic neurones of the LC (Ishimatsu & Williams,
1996), particularly between dendrites of the pericoerulear region, and it is believed that 
these electrical interactions between the dendrites of the pericoerulear region could lead 
to the synchronous activity within the nucleus (Ishimatsu & Williams, 1996).
LC neurones can be activated by a wide variety of noxious and non-noxious sensory 
stimuli (Foote et al., 1980b) and are actively inhibited during REM sleep (Aston-Jones 
& Bloom, 1981a). Neurones of the LC may, therefore, weigh input from the major 
afferent inputs, and widely distribute a uniform message over its divergent efferents 
(Aston-Jones et al., 1986).
1.3.3 NK1 receptor antagonists increase activity of the locus coeruleus
Noradrenergic neurones of the LC demonstrate both immunoreactivity (Chen et al., 
2000) and contain mRNA (Maeno et al., 1993) for the NK1 receptor. The LC is densely 
innervated by SP-containing fibres (Ljungdahl et al., 1978b). Electron microscopy 
shows that SP-containing axon terminals form asymmetric axodendritic synapses with 
catecholamine-containing neurones in the LC (Pickel et al., 1979). As yet, there is a 
lack of direct evidence reporting the origin of SP afferents to the LC. However, one 
study does demonstrate that a single LC noradrenergic neurone forms both symmetrical 
synapses from GABAergic afferents and asymmetric synapses from SPergic afferents 
(Tamiya, et al., 1994). It is possible that SP containing afferents arise from either the 
PGi (Dean et al., 1993) or the PrH the main afferent projection areas to the LC. Direct 
application of SP to the LC of an anaesthetised rat, or in vitro slice preparations, 
increases the firing-rate of most cells in the LC (Guyenet & Aghajanian, 1977; 
Cheeseman et al., 1983) through NK1 receptors expressed on LC neurones.
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However, dialysis and electrophysiological studies have shown that NK1 receptor 
antagonists also increase cortical NA efflux, and increase the firing-rate of LC 
noradrenergic neurones. Treatment with the NK1 receptor antagonist L-760735, 
induced burst-firing of neurones in the guinea-pig LC (Maubach et al., 2002). The 
selective NK1 receptor antagonist GR205171 dose dependently elevated cortical NA 
efflux in freely-moving rats (Millan et al., 2001) and increased the firing-rate of 
noradrenergic cells in the LC of anaesthetised rats (Millan et al., 2001). However, a 
single intravenous injection of the NK1 receptor antagonists WIN51, 708 and 
CP-96, 345 did not modify the spontaneous firing-rate of noradrenergic neurones in rats 
(Haddjeri & Blier, 2000). However, WIN51, 708 and CP-96, 345 attenuated the 
suppressant effect of the a 2-adrenoceptor agonist clonidine, so the authors concluded 
that NK1 receptor antagonists markedly affect the noradrenergic system via attenuation 
of the a 2-adrenoceptors on the cell bodies of noradrenergic neurones (Haddjeri & Blier, 
2 0 0 0 ), providing further evidence to suggest that a 2-adrenoceptors may be different 
between NK1+/+ and NK1-/- mice. Available evidence, therefore, suggests that 
blockade of NK1 receptors may facilitate the activity of noradrenergic pathways in the 
LC via attenuation of the activity of the a 2-adrenoceptors (Haddjeri & Blier, 2000) or an 
increase in firing-rate of noradrenergic neurones (Millan et al., 2001; Maubach et al., 
2 0 0 2 ).
Although nothing is known about the firing-rate of LC neurones in NK1-/- mice, the 
effect of NK1 receptor disruption and NK1 receptor antagonism on the firing-rate of 
serotonergic DR neurones is well documented. These studies report either no difference 
in basal firing-rate of DR neurones (Froger et al., 2001), or a higher basal firing-rate in 
NK1-/- mice (Santarelli et al., 2001). The reason for this discrepancy in the basal firing 
rate could be due to different strains of mice used by each group. Froger et al, (2001) 
used 129/SvEv NK1-/- mice whereas Santerelli et al, (2001) used NK1-/- mice derived 
from a pure 129/SvEv background.
The close association of SP with noradrenergic neurones, the high expression of NK1 
receptors on LC neurones, and the effect of NK1 receptor antagonists on LC 
noradrenergic neurones, has prompted these current studies to investigate the effect of 
NK1 receptor disruption on noradrenergic neurones.
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1.3.3.1 Noradrenaline efflux is higher in NK1-/- mice
Pilot microdialysis studies conducted in this laboratory have demonstrated a 2-5 fold 
difference in cortical basal NA efflux between halothane-anaesthetised NK1+/+ and 
NK1-/- mice (Fisher et al., (2003)., Stewart et al., (2004)., Herpfer et al., (2005)). The 
studies contained in this thesis, are, therefore, aimed at investigating possible 
mechanisms that may underlie this difference in NA efflux.
1.4 I n d ic e s  o f  n o r a d r e n e r g i c  d y s r e g u l a  t i o n
1.4.1 In vivo microdialysis coupled with HPLC /  ECD measurement o f  
noradrenaline efflux
Microdialysis is an in vivo sampling technique, used extensively to assess the 
neuropharmacodynamic profile of drugs (see Sections 2.4-2.6 for a more detailed 
description of the technique). The technique continuously samples endogenous solutes, 
in the extracellular fluid of a specific tissue, in restrained, anaesthetised or 
freely-moving animals. Microdialysis, therefore, measures changes in ‘efflux’ of solutes 
harvested through probes. Efflux reflects the net effect of release and re-uptake on 
neurotransmitter concentration, providing an indication of the approximate 
concentration of solutes in the extracellular fluid.
The basic tool for sampling in microdialysis is the microdialysis probe. The probe is 
introduced to the tissue of interest, and perfused with a liquid which stabilises with the 
fluid outside the membrane by diffusion in both directions (Figure 1.3).
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F i g u r e  1.3: Diagram of the probe the basic tool used in these studies. The probe 
has direct access to the interstitial fluid compartment; the solute of interest 
diffuses into the probe down its concentration gradient. Adapted from (Benveniste 
& Huttemeier, 1990).
The average pore size of the probe is large enough (5-20 kDa molecular weight cut-off) 
to allow free diffusion of solute molecules, but small enough to resist diffusion of 
proteins and other macromolecules. The dialysate is collected from the outlet of the 
probe and then injected directly into the analytical system. In these studies sample 
analysis was performed using HPLC / ECD (Figure 1.4).
This technique has demonstrated that halothane-anaesthetised NK1-/- mice possess a 
2-5 fold higher basal NA efflux compared to their NK1+/+ counterparts. For this reason 
the studies contained in this thesis are aimed at investigating possible candidates that 
may contribute to, or be the cause of, this higher basal NA efflux in NK1-/- mice.
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Sample injection
Guard cell Pulse dampener
Pump
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Integrator
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Figure 1.4: Schematic diagram of the HPLC / ECD used in these studies.
1.4.2 Control of noradrenaline synthesis
A number of possibilities may explain the differences in basal NA efflux between 
NK1+/+ and NK1-/- mice found with the pilot study. One may be that there is more NA 
available for release in NK1-/- mice, as a result of more NA being synthesised.
The biosynthetic pathway leading to the production of NA (Figure 1.5) begins with the 
amino acid tyrosine (Carson & Robertson, 2002). The initial and rate-limiting step in 
the production of NA is the hydroxylation of tyrosine by tyrosine hydroxylase (TH) to
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L-dihydroxyphenylalanine (DOPA). Mutation of TH in TH-/- mice is lethal (Kobayashi 
et al., 1995), demonstrating the crucial role played by this enzyme. As TH is the 
rate-limiting enzyme responsible for conversion of the amino acid tyrosine to L-DOPA, 
this enzyme was the initial target of preliminary investigations. However, TH also 
controls the synthesis of NA, dopamine (DA) and adrenaline, so investigations also 
focused on dopamine-P-hydroxylase (DpH), the vesicle-bound enzyme which converts 
DA to NA.
DOPA synthesized by TH is decarboxylated by L-aromatic amino acid decarboxylase to 
DA. In noradrenergic neurones DA is then converted to NA via DpH (Figure 1.5). 
Therefore, DpH would seem a more selective marker for noradrenergic neurones.
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Tyrosine hydroxylase
COOHDOPA
HO CHo-CH— NH-
HO
DOPA decarboxylase
Dopamine- p-hydroxylase
OH
Noradrenaline
HO| H— C H o-N H .
HO
Figure 1.5: The synthetic pathway of noradrenaline. The hydroxylation of the 
amino acid, tyrosine, which forms dihydroxyphenylalanine (DOPA) is the 
rate-limiting step. Conversion of dopamine to noradrenaline is effected by the 
vesicular enzyme, dopamine-p-hydroxylase (DpH) after uptake of dopamine into 
vesicles from the cell cytosol (Taken from Stanford 2001b)
1.4.3 Control o f noradrenaline reuptake
The noradrenaline transporter (NAT) is a Na+ / Cf-dependent 
1 2 -transmembrane-spanning protein residing on pre-synaptic noradrenergic nerve 
terminals (Carson & Robertson, 2002). The majority of NA is removed from the 
synaptic cleft via the NAT (Eisenhofer et al., 1992). The importance of the NAT in 
maintaining neuronal noradrenergic content is demonstrated by the fact that, although 
there is an increase in the activity of TH in NAT-/- mice, overall there is a 55-70 % 
reduction in tissue concentration of NA in the prefrontal cortex, hippocampus and
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cerebellum (Xu et al., 2000). Furthermore, using microdialysis there was a 60 % 
reduction in efflux and a 6 -fold reduction in NA clearance, resulting in a 2-fold 
elevation of extracellular NA (Xu et al., 2000). As the NAT regulates the magnitude 
and duration of NA signalling, by terminating neurotransmission via cellular transport 
(Blakely et al., 1994), it may also represent an important target underlying the 
difference in basal NA efflux between NK1-/- and NK1+/+ mice. It was thought 
possible that the NAT may be functioning less efficiently in NK1-/- mice. Therefore, 
studies in this thesis, focused on investigating the amount of protein of the NAT in the 
frontal cortex, hippocampus and LC of NK1+/+ and NK1-/- mice. Desipramine (DMI) 
is a commonly used antidepressant exerting its actions through inhibition of the NAT. 
Microdialysis studies, therefore, also investigated the effects of local infusion into the 
frontal cortex of the noradrenaline reuptake inhibitor (NRI), DMI, on NA efflux in 
NK1-/- and NK1+/+ mice. If the NAT is the underlying cause for the higher basal NA 
efflux in NK1-/- mice, it was predicted that DMI infusion would result in a greater 
incremental increase in NA efflux in NK1+/+ compared to NK1-/- mice. DMI was 
chosen over another commonly used NRI, reboxetine, due to the known limitations in 
publishing results associated with reboxetine.
1.4.4 Control of release
1.4.4.1 a-adrenoceptors
Physiological responses to NA are mediated via adrenergic receptors. Adrenoceptors 
were first classified into a  and p adrenoceptors by (Ahlquist, 1948). Later they were 
divided into ai-, a 2-, and p-adrenergic receptor types (Bylund, 1988). Figure 1.6 depicts 
the history of the classification of a-adrenoceptors (for review see: (Civantos Calzada & 
Aleixandre de Artinano, 2001).
25
Chapter 1: Introduction
ADRENOCEPTORS
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P
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Figure 1.6: Schematic of the history of the classification of
a-ADRENOCEPTORS. ADAPTED FROM (ClVANTOS CALZADA &  ALEIXANDRE DE
Artinano, 2001).
1.4.4.2 a2-Adrenoceptors
CLi-Adrenoceptors contain seven putative transmembrane a-helices with an extracellular 
N-terminus and a cytoplasmic C-terminus domain (Bikker et al., 1998).
They are G protein-coupled receptors, responsible for mediating inhibitory effects at the 
second messenger level. G0 G proteins predominate; these are pertussis toxin-sensitive, 
rapidly activated and voltage dependent G proteins, in that depolarisation removes the 
Ca channel block. Gi G proteins are pertussis toxin-resistant, slow and voltage 
insensitive. cc2-Adrenoceptors restrain the synthesis, release and turnover of NA, as well 
as the firing-rate of noradrenergic neurones. They, therefore, present a prime candidate 
in elucidating the underlying cause of the higher basal NA efflux in anaesthetised 
NK1-/- mice.
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Activation o f <X2-adrenoceptors results in:
• Attenuation of Ca2+ rate of entry through voltage-gated Ca2+ channels
• Activation of GIRK K+ channels leading to hyperpolarisation
• Inhibition of adenylate cyclase which results in a decrease in cAMP and
consequently a decrease in Ca2+ release from internal stores and a decrease in
activation of Protein kinase A
• Activation of mitogen-activated protein kinases (MAPK), which may result in 
the alteration of gene expression and thereby account for some of the neuronal 
adaptations underlying therapeutic responses to psychotropic drugs as well as 
neuronal differentiation and survival
• Activation of phospholipase A2
(for review see: (Brede et a l 2004; Saunders & Limbird, 1999)).
1.4.4.3 Subtypes
Pharmacological interventions and gene targeting strategies from many species has 
confirmed the existence of three distinct genes for the 012-adrenoceptor encoding 012a, 
ci2b and oi2c (Lomasney et al., 1991; Bylund et al., 1994; Hein & Kobilka, 1995) (for 
review see: (Philipp et al., 2002; Brede et al., 2004)). The 012a and a 2d receptors are 
species variants of the same receptor (Bylund et al., 1994) with the 012a being found in 
humans, and oi2d being found in rodents and cows. For these studies the a 2a/d receptor 
will be referred to as the ot2a-adrenoceptor. Information about their localisation within 
the brain has been provided through in situ hybridisation and immunolabelling 
techniques.
1.4.4.4 Distribution
Immunolabelling and mRNA expression of all three receptor subtypes is found within 
the rat and mouse brain with marked regional differences (Scheinin et al., 1994; Wang 
etal., 1996) (Table 1.4).
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Adrenoceptor
subtype
mRNA Location in the CNS Immunolabelling
a 2a
Locus coeruleus 
Brain stem 
Cerebral cortex 
Septum 
Hypothalamus 
Hippocampus 
Amygdala 
Anterior 
Olfactory nucleus
Diffuse and / or punctate 
perikaryal expression (Talley 
et al., 1996). Expression 
along the plasma membrane 
of soma in the LC, dendritic 
trunks and spines in the cortex 
(Aoki et al., 1994).
a2b
Thalamus 
Purkinje layer of cerebellum
(Scheinine/a/., 1994)*
a2c
Basal ganglia 
Olfactory tubercle 
Hippocampus 
Cerebral cortex
LC (Rosin et al., 1996). 
Immunoreactivity is found 
mainly in the neuronal 
perikarya, with some labelling 
of proximal dendrites (Rosin 
et al, 1996).
T a b l e  1.4: a 2-adrenoceptor subtype immunolabelling in the central nervous 
system. *mRNA expression using in situ hybridisation.
The a 2a-adrenoceptor is the most prevalent within the brain. Approximately 90 % of 
adrenoceptors in the CNS belong to the a 2a-adrenoceptor subtype and the remaining 
10 % comprises oi2b- and a 2C-adrenoceptors (Bucheler et al., 2002). In rats and monkeys 
there appears to be no inter-species difference in the immunolabelling of the 
a,2a-adrenoceptor (Aoki et al., 1994). However, interspecies differences do exist 
between the rat and human hippocampal binding of a 2-adrenoceptors (Zilles et al., 
1993). Higher a 2-adrenoceptor binding is found in the dentate gyrus and CA3 area of 
the human hippocampus compared to the rat brain (Zilles et al., 1993).
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a 2a-Adrenoceptor binding in the human hippocampus ( 1 2 0 0  fmol / mg protein) far 
exceeds that in the rat brain (600 fmol / mg protein).
Localisation of mRNA in the mouse brain follows a similar pattern to the rat; (X2a 
adrenergic mRNA is highly expressed in layer VI of the cortex and the LC. 
a 2b-Adrenoceptors predominate in the thalamus and in the Purkinje layer of the 
cerebellum and ot2C mRNA in the putamen-caudate. Strong expression of both a 2a and 
0C2c mRNA is found in the amygdaloid complex, hypothalamus, olfactory system and 
the hippocampal formation (Wang et al., 1996).
1.4.4.5 Functions
Localisation of the a 2-adrenoceptors, using in situ hybridisation techniques and 
immunolabelling, has not been able to link particular subtypes to physiological 
functions. Furthermore, lack of subtype-selective agonists and antagonists has made it 
difficult to assign a specific physiological function to (X2-adrenoceptor subtypes in vivo. 
Advances in elucidating the physiological functions of a 2-adrenoceptor subtypes has 
been provided by development of mice lacking, over-expressing or bearing a mutation 
in particular subtypes (MacDonald et al., 1997).
The predominant oi2a-adrenoceptor subtype in the brain is the main regulator of 
pre-synaptic autoinhibition of NA release in the CNS (Trendelenburg et al., 1999; 
Trendelenburg et al., 2001): that is, they control the release of NA from the neurone 
itself. The location of the ct2a-adrenoceptor in the LC supports its role as a pre-synaptic 
autoreceptor. These somatodendritic ot2a-adrenoceptors (activated via recurrent 
collaterals) control the firing-rate of LC neurones and NA release from neuronal 
terminals (Cedarbaum & Aghajanian, 1976; Cedarbaum & Aghajanian, 1978; 
Aghajanian et al., 1977; Norenberg et al., 1997; Callado & Stamford, 1999; Owesson et 
al., 2003). a 2a-Adrenoceptors confer a high degree of tonic activity onto noradrenergic 
neurones by mediating feedback inhibition of NA release, ensuring transmitter stores 
are conserved and preventing excessive stimulation of post-synaptic cells.
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Studies using ot2a-adrenoceptor knockout mice have confirmed that the a 2a-adrenoceptor 
subtype mediates pre-synaptic and post-synaptic effects of 012-agonists such as clonidine. 
These effects include hypotension, sedation, analgesia, hypothermia and also an 
anaesthetic-sparing effect, likely mediated by the LC (Scheinin & Schwinn, 1992; 
Guyenet et al., 1994; Lakhlani et al., 1997; Amsten, 1998; Makaritsis et al., 1999) as 
well as suggesting that NA release in the medial prefrontal cortex is mainly regulated by 
a 2a-adrenoceptors (Ihalainen & Tanila, 2002). That NA release in the medial prefrontal 
cortex is mainly regulated by a,2a-adrenoceptors confirms pharmacological reports that 
NA release in terminal areas is tonically modulated by somatodendritic 
a 2a-adrenoceptors located on LC neurones (Mateo et al., 1998; Mateo & Meana, 1999; 
Femandez-Pastor & Meana, 2002).
Although oi2a-adrenoceptor knock out mice, do not demonstrate an increase in basal NA 
efflux in the medial prefrontal cortex (Ihalainen & Tanila, 2002), higher plasma NA has 
been found in a 2a-adrenoceptor knockout mice (Makaritsis et al., 1999), demonstrating 
heightened sympathetic activity in a 2a-adrenoceptor knockout mice. However, in 
a 2a-adrenoceptor knockout mice 012-adrenoceptor agonist induced hypothermia and 
locomotor inhibition using dexmedetomidine is not totally abolished, suggesting a 
contribution from a 2C-adrenoceptors (Lahdesmaki et al., 2003).
Knockout mice have confirmed that 012a and ajc adrenoceptors exist together 
pre-synaptically and, although a 2a-adrenoceptors play the major role in inhibition of NA 
release, the oi2c-adrenoceptor does contribute in the sympathetic nervous system (Hein 
et al., 1999) and CNS (Bucheler et al., 2002). a 2a And a 2C-adrenoceptors can be 
distinguished functionally in that a 2a-adrenoceptors inhibit transmitter release faster and 
at higher action potential frequencies than cc2C-adrenoceptors, which inhibit NA release 
at lower frequencies (low NA concentrations) (Hein et al., 1999). This correlates with 
NA possessing a higher potency for ct2C than for a 2a-adrenoceptors (Hein et al., 1999). 
Furthermore, the a 2C-adrenoceptor subtype has a mainly intracellular localisation (Rosin 
et al., 1996). Ablation of either 012a or aic does not result in an upregulation of the other 
subtype (Bucheler et al., 2002). (X2a and o^c-adrenoceptors, therefore, seem to 
compliment each other in the integration of CNS function and behaviour. Moreover, 
these receptors play an integral role in regulating neurotransmitter release.
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It is, therefore, possible that the higher basal NA efflux observed in NK1-/- mice could 
be attributed to a decrease in either the density or function of these autoregulatory 
012-adrenoceptors. With this in mind, these studies analysed the localisation and density 
of 012-adrenoceptors using immunohistochemistry, Western blot protein analysis and 
autoradiography (see Sections 2.8-2.10 for a more detailed description of these 
techniques). As a 2-adrenoceptors are G protein-coupled receptors, the first step in their 
second messenger signalling pathway (the hydrolysis of GTP to GDP) can be quantified 
using [35S]GTPyS (see Section 2.11 for a more detailed description of this technique). 
Agonist-stimulated GTPyS binding was, therefore, used to provide an indication of the 
functional status of 012-adrenoceptors in NK1+/+ and NK1-/- mice.
1.4.5 Behavioural response to novelty
For a more detailed description of the LDEB see Section 2.7 and Chapter 5. The light / 
dark exploration box (LDEB) uses the non-noxious stressors, novelty / light, to elicit 
behavioural changes that may be attributed to differences in the animals’ noradrenergic 
system. Previous studies in this lab have demonstrated a difference in the behaviour of 
NK1+/+ and NK1-/- in response to the LDEB (Herpfer et al., 2005). We have further 
demonstrated that administration of the a 2-adrenoceptor antagonists, atipamezole 
(Fisher et al, 2003) or yohimbine (Stewart et al., 2002), modify certain behavioural 
responses in the LDEB only in NK1+/+ mice. Both of these 0C2 -adrenoceptor 
antagonists decrease time to return to the light zone after first exit so that NK1+/+ mice 
are indistinguishable from their NK1-/- counterparts treated with either vehicle or the 
equivalent a 2-adrenoceptor antagonist. Supporting the contention that the noradrenergic 
system is different between NK1+/+ and NK1-/- mice, perhaps due to a difference in the 
autoregulatory a 2-adrenoceptor.
The LDEB has the additional benefit in that it can be combined with in vivo 
microdialysis. Previous in vivo microdialysis experiments carried out in this laboratory 
have demonstrated that non-noxious behavioural stimuli e.g. the novel environment, 
results in an increase in NA efflux (Dailey & Stanford, 1995; McQuade et a l, 1999; 
McQuade & Stanford, 2001) which is strain dependent (McQuade & Stanford, 2001). 
Conditioning cues, e.g. a tone to indicate transfer to the novel environment also increase 
NA efflux (McQuade & Stanford, 2000).
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L  5  Us e  o f  cc2-a d r e n o c e p t o r  a n t a  g o n is t s  i n  p h y s io l o g ic a l  s t u d ie s
The use of an antagonist in experiments ideally requires a drug that has high specificity 
for the receptor under investigation (Clarke & Harris, 2002). Studies using 
a 2-adrenoceptor antagonists to elucidate physiological functions of (X2-adrenoceptors 
have generally been hampered by a lack of specificity and subtype selectivity for the 
a 2 -adrenoceptor. Yohimbine, or its enantiomer rauwolscine, were the antagonists of 
choice for probing the physiological function of a 2-adrenoceptors up until the 1980s, as 
they do not bind to non-adrenergic imidazoline binding sites (Brown et al., 1990; Evans 
& Haynes, 1994; Uhlen et al., 1995). However, interpretation of results using these 
compounds is confounded by poor ct2 / ai separation (Doxey et al., 1984) and moderate 
affinity for 5-HTiA receptors (Convents et al., 1989) where they act as agonists (De Vos 
et al., 1991; Newman-Tancredi et al., 1998).
A number of compounds e.g. the a 2-adrenoceptor antagonist, idazoxan, which are active 
at a 2-adrenoceptors, also bind to nonadrenergic imidazoline binding sites (Lehmann et 
al., 1989). These sites have a different neuroanatomical distribution from the 
a 2-adrenoceptor and therefore, mediate effects independent of actions at the 
012-adrenoceptor for example inhibition of the enzymic activity of monoamine oxidase 
activity, (for review see: (Holt, 2003)). RX821002 2-[2-(2-methoxy-
l,4-benzodioxanyl)]imidazolinehydrochloride, the methoxy derivative of idazoxan, has 
no appreciable affinity for non-noradrenergic imidazoline binding sites (^i>10 000 nM; 
(Langin et al., 1990b; Langin et al., 1990a) and was, therefore, chosen for the studies 
described in this thesis. The a i l  ai selectivity ratio of RX821002 is 316, whereas that 
of idazoxan is 151 (Stillings et al., 1985; Welboum et al., 1986). The rat annococcygeus 
muscle, is an assay for a  i-adrenoceptor activity, where, RX821002 shows a low affinity 
ipAi 4.0) for the ai-adrenoceptor.
RX821002 was initially believed to bind preferentially to oi2a-adrenoceptors as it is not 
displaced by prazosin, which has moderate affinity for ci2b and d 2C receptors (Langin et 
al., 1989). However, binding studies have since revealed that RX821002 binds with 
high affinity to all 012-adrenoceptors (O’Rourke et al., 1994) and is therefore, routinely 
used to investigate total a 2-adrenoceptor binding. The high affinity of RX821002 for
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« •  • •  • 3(X2-adrenoceptors is shown by radioligand binding studies with [ HJRX821002 
(Devedjian et al., 1994). These studies demonstrate Kd values of 0.29-0.68 nM for the 
a2a-adrenoceptor subtype, 1.05-2.6 nM for the oi2b-adrenoceptor subtype and 0.37-0.55 
nM for the a2c-adrenoceptor subtype (Uhlen et a l, 1998).
RX821002 in vitro is a surmountable, silent and highly selective antagonist at 
012-adrenoceptors, blocking the actions of the ct2 -adrenoceptor agonist, UK14304, in the 
rat vas deferens with a pAj of 9.4. The affinity of RX821002 for a 2-adrenoceptors is 
generally in the range (1 to 6  nM (Kd) (Clarke & Harris, 2002). It has also been shown 
to behave as an inverse agonist at a 2-adrenoceptors in native tissues expressing normal 
levels of receptors and G proteins (Murrin et al., 2000). Inverse agonists have a higher 
affinity for their receptors in the presence of high GTP concentrations, the opposite to 
what is found with agonists, and they are thought to reduce the functional activity of the 
receptors below the baseline activity observed in the absence of any ligand. RX821002 
has a 5-fold higher affinity, 0.9 nM, for ot2-adrenoceptors in the presence of 100 pM 
GTP, indicating RX821002 has inverse agonist properties at a 2-adrenoceptors in rat 
brain tissue sections (Murrin et a l, 2000).
A drawback of using RX821002 is that it binds with moderate affinity to 
5-HTiA-receptors (Kd 20-30 nM) (Grijalba et a l, 1996; Newman-Tancredi et a l, 1998), 
where it acts as an antagonist (Newman-Tancredi et al, 1998; Ogilvie & Clarke, 1998). 
As there is colocalisation of these two receptors, the potential for confusion between the 
actions at 5-HTia and a 2-adrenoceptors is great and must be considered when 
interpreting results. However, previous studies have shown that systemic administration 
of low doses of RX821002 increases extracellular NA, DA but not 5-HT in the frontal 
cortex (Gobert et a l, 1998). However, it should be noted that the apparent lack of 
RX821002 on extracellular 5-HT, does not necessarily mean that there is no increase in 
release, as an increase in 5-HT release could be masked by reuptake via the serotonin 
transporter.
Alternative compounds available to investigate a 2-adrenoceptor function include 
atipamezole and MK-912. Atipamezole is virtually inactive at 5-HTia receptors 
(Newman-Tancredi et a l, 1998). No published reports are available on the binding 
affinity of MK-912 and atipamezole at imidazoline receptors. Atipamezole, however,
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possesses an imidazoline like structure, and studies show that it binds to non-adrenergic 
sites distinct from Ii, I2 or I3 in the rat lung and kidney (Sjoholm et al., 1999; Sjoholm et 
al., 1995). In the rat spinal cord it is also able to displace dexmedetomidine from 
non-adrenergic sites, which are thought to represent novel imidazoline binding sites 
(Savola & Savola, 1996).
Therefore, drawbacks are associated with all the available (X2-adrenoceptor antagonists 
to date. RX821002 was chosen for these studies as there is little doubt that it does not 
bind to imidazoline receptors, it is commercially available as a tritiated compound, and 
has been characterised in a number of assays.
1 .6  P r o j e c t  o b je c t iv e s
These studies were, therefore, aimed at investigating whether differences exist between 
NK1-/- and NK1+/+ mice in respect of the control of synthesis, release or reuptake of 
NA in the frontal cortex and LC, which could explain the difference in basal efflux 
observed in NK1-/- and NK1+/+ mice.
1.6.1 In vivo microdialysis o f cortical noradrenaline efflux in NK1+/+ and NK1-/- 
mice
• Confirm the preliminary findings that anaesthetised NK1-/- mice possess higher 
basal efflux of NA in the frontal cortex when compared with their wildtype 
counterparts (Fisher et al., 2003; Stewart et al., 2004; Herpfer et al., 2005). This 
involved in vivo microdialysis, a technique that monitors changes in NA efflux 
in the frontal cortex of anaesthetised and freely-moving mice.
• Investigate effect of systemic administration of the 012-adrenoceptor antagonist 
RX821002 (0.3, 1.0 and 3.0 mg/kg i.p.) on NA efflux, in the frontal cortex of 
anaesthetised and freely-moving NK1-/- and NK1+/+ mice.
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1.6.2 Behavioural response to novelty in NK1+/+ and NK1-/- mice
• Determine genotype dependent behavioural differences in response to the 
non-noxious stressor, novelty, using the LDEB.
• Ascertain whether any genotype dependent differences in behaviour can be 
attributed to differences in the noradrenergic system between NK1+/+ and 
NK1-/- mice. This was achieved by analysis of behavioural parameters after 
systemic administration of the ct2-adrenoceptor antagonist RX821002 
(0.3 mg / kg i.p.).
1.6.3 Immunohistochemical analysis o f the a2 -adrenoceptor, noradrenaline 
transporter, dopamine-p-hydroxylose and tyrosine hydroxylase
• Preliminary immunohistochemical investigations of the noradrenergic system in 
NK1-/- and NK1+/+ mice focused on possible differences in the synthesis of NA, 
by profiling the location and density of both TH (the rate limiting enzyme) and 
DpH (the enzyme responsible for the conversion of DA to NA).
• Investigate possible differences in the mechanism of control of NA release and 
re-uptake. Studies, therefore, focused on profiling the location and amount of the 
a 2a-adrenoceptor and the noradrenaline transporter in the frontal cortex and LC 
of NK1-/- and NK1+/+ mice.
1.6.4 Receptor density and Western blot protein analysis
Although immunohistochemistry (IHC) is a useful method for visualising receptors, 
transporters or enzymes, further quantification of the amount of the NAT and 
d 2-adrenoceptor using Western blot protein analysis was required.
• Western blot analysis was used to determine the amount of a 2-adrenoceptor and 
NAT protein in the LC and frontal cortex.
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• Receptor density and localisation were also measured using radiolabelled 
receptor autoradiography with [3H]RX821002.
1.6.5 Functional activity o f a2 -adrenoceptors
The increase in NA efflux in NK1-/- mice may be a cause or consequence of a
■yc
desensitisation of the autoregulatory a,2-adrenoceptor. [ S]GTPyS binding provides a 
measure of receptor-mediated G-protein activation. Activation of ct2-adrenoceptors
o c
results in exchange of GDP for GTP, which is quantified using [ S]GTPyS.
• Investigate the functional status of 012-adrenoceptors in NK1-/- and NK1+/+ 
mice, using the non-hydrolysable GTP analogue, [35S]GTPyS.
The studies contained in this thesis, therefore, use a combination of in vivo 
microdialysis, behavioural and molecular biology approaches to investigate possible 
candidates that may underlie the higher basal NA efflux in halothane-anaesthetised 
NK1-/- mice. Any changes in these candidates may be a cause or a consequence of the 
higher basal NA efflux in anaesthetised NK1-/- mice.
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CHAPTER TWO
MATERIALS AND METHODS
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2 MATERIALS AND METHODS
2.1  I n t r o d u c t io n
The experiments, described in this thesis, combined behavioural, in vivo microdialysis 
and molecular biology approaches to investigate (X2-adrenoceptors in NK1+/+ and 
NK1-/- mice. This chapter presents the background to the techniques used. Protocols for 
each experiment are described in the methods section of each chapter.
2 .2  M ic e
All experiments described in this thesis used mice or the post-mortem tissue from mice. 
Mice were housed in Biological Services, UCL, London, in cages of 1-5 animals. 
Environmental conditions were maintained at 21 °C and 50 % humidity, with tap water 
and food (Harlan Tekland TRM Rat / Mouse Diet; Harlan, Bicester, UK) ad libitum. 
Lights were programmed on a 12:12 cycle (lights on at 08:00 am). All experiments were 
conducted in accordance with the UK animals (Scientific Procedures) Act, 1986, and 
had obtained local ethical approval.
2.2.1 Neurokininl receptor knockout mice
Adult (25-30 g) male NK1-/- and NK1+/+ mice were used. Mice were derived from 
homologous recombination of C57BL/6 blastocysts implanted with 129Sv stem cells 
containing targeted disruption of the NK1 receptor gene (De Felipe et al, 1998); 
Figure 2.1a. In this mouse line, exon 1 of the gene was disrupted by insertion of a 
cassette at a unique Stul site. The cassette consisted of an internal ribosome entry site 
(IRES), the lacZ coding sequence and a neomycin resistance gene expressed from its 
own promoter. These mice were then crossed onto an out bred MF1 background strain 
(Harlan; (Migaud et a l, 1998). Mice were bred from homozygous breeding pairs. 
Weaning occurred at approximately three weeks of age.
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F i g u r e  2.1: Disruption of the NK1 receptor, via homologous recombination, a) 
Schematic of the region of the NK1+/+ locus containing exon 1, the targeting 
(replacement) vector and predicted structure of the targeted NK1 receptor gene 
following homologous recombination, b) Analysis of the offspring from a 
heterozygote NK1+/- intercross using Xbal digestions of tail DNA and 
hybridisation with the external 5’ probe fragment (orange) and Southern blot 
analysis. Homozygous (12 kb), heterozygous (12 kb and 8  kb) and NK1+/+ (8 kb) 
generated at a ratio of 1:2:1. BGal: lacZ coding region; IRES: internal ribosome 
entry site; MCI: MCI promoter; Neo: neomycin resistance gene: TK: Herpes 
simplex virus thymidine kinase gene. Restriction sites indicated by small arrows. 
(Taken from Gadd, 2003; (De Felipe et al., 1998)).
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2.2,2 Verification o f genotype
Genotype was verified by performing the polymerase chain reaction (PCR) on DNA 
extracted from tail tip samples. Three PCR primers are used: NK1-F and NK1-R 
amplify a 350-base section of exon 1 of the gene encoding the NK1 receptor, and NeoF 
and NK1-R amplify a 260-base section of the NK1 receptor gene including the inserted 
cassette. Resolution of these PCR products on a 2 % agarose gel gives a single band at 
260 bases for NK1-/- mice, bands at 260 and 350 bases for heterozygous mice, and a 
single 350-base band for wildtype mice (Figure 2.1b). See Appendix I for genotyping 
method.
2.3 Background to in vivo microdialysis:
Dopamine (DA) and noradrenaline (NA) are amongst the most studied of all transmitter 
substances. Two methods have been developed for studying the extracellular 
concentration of transmitters and their metabolites. These are in vivo voltammetry, in 
which electrochemical measurements are made directly in tissue, and in vivo 
microdialysis in which transmitters are harvested from the extracellular fluid for 
subsequent analysis. Microdialysis is an in vivo brain perfusion method. The technique 
was originally started by (Sama et al.9 1984; Hutson et al., 1984a; Hutson et al., 1984b; 
Hutson et al., 1986). A dialysis probe with a membrane permeable to water and small 
solutes (molecular weight cut-off -5000-50 000 kDa) is continuously flushed with a 
solution devoid of the substance of interest. A concentration gradient is created causing 
diffusion of solutes from the interstitial space across the dialysis membrane and into the 
probe (Benveniste & Huttemeier, 1990). Three separate water filled compartments make 
up the brain: intracellular, interstitial (extracellular) and the vascular space (Chaurasia, 
1999). The dialysis probe samples from the extracellular fluid (ECF) (Benveniste & 
Huttemeier, 1990), thereby following changes of the content of neurotransmitter(s) in 
the ECF compartment of the CNS. Brain dialysis in freely-moving rats has provided 
major contributions to understanding the mechanism of action of centrally acting drugs 
on specific neurotransmitters. Furthermore, this information can be paralleled with 
behavioural changes and with extracellular concentrations of the active drug in drug 
challenge tests (Chiara, 1990).
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One advantage of using microdialysis sampling is that freely-moving animals can be 
used with minimal tissue damage. Secondly, it is feasible to monitor continuously, 
changes of neurotransmitters over time, within the extracellular fluid, at more than one 
probe implantation site (Stenken, 1999). Microdialysis sampling of the tissue takes 
place generally before, during and after the drug treatment, thus each animal serves as 
its own control throughout the experiment. This technique, therefore, significantly 
reduces the number of animals required to complete an experiment. There is also no 
further risk of enzymatic degradation, once the analyte diffuses into the microdialysate, 
as the solute is separated from enzymes and other macromolecules, which may cause 
degradation.
A general problem in microdialysis experiments is that the extremely low concentration 
of monoamine neurotransmitters in the extracellular fluid requires an analytical 
detection limit in the low picomol range. Improvements in chromatographic techniques 
have allowed limits of detection to approach the low femtomol range (Mefford, 1985). 
Microdialysis, however, is an invasive technique, although not as destructive as the 
push-pull cannula, developed by Gaddum in 1961 (Gaddum, 1961). This causes 
extensive tissue damage. Also the perfusion medium is in direct contact with the brain 
and requires high flow rates (typically 150 pi / min). Insertion of the dialysis probe 
(several orders of magnitude larger than the structure under study) does cause some 
tissue damage by breaking blood vessels and disrupting cells (Morgan et a l , 1996). The 
influence of post-probe implantation time is also striking. In the hippocampus 2 h after 
implantation, marked changes in glucose metabolism and blood-flow are detected in the 
implanted area (Benveniste et al., 1987). Spreading depression and depolarization in 
intact neurones also takes place probably as a result of massive K+ release from 
damaged elements (Benveniste et al, 1989). 24 h post probe implantation these changes 
are believed to be resolved (Benveniste et a l, 1987).
The key elements of the microdialysis technique are the dialysis probe, connective 
tubing, perfusion medium and perfusion pump, and sample (dialysate) collection device 
(Chaurasia, 1999) (Figure 2.2).
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F i g u r e  2.2: Photograph of the key elements of the microdialysis technique used in 
these studies. The probe is perfused using a perfusion pump, with a modified 
Ringer’s solution in a syringe. Samples are collected every 20 mins for analysis 
using HPLC / ECD.
2.3.1 Probe design and perfusion solution:
Four main types of microdialysis probes are used: a) linear, b) loop, c) side-by-side and, 
d) concentric (Chaurasia, 1999).
The dialysis membranes of linear probes are formed as cylinders, connected with 
in- and outlet tubes in serial arrangement. The in- and outlet tubes of concentric, loop 
and side-by-side designs, are positioned in parallel requiring only a single point of entry. 
For the present studies the dialysis probe was a single cannula probe and used a 
side-by-side design with the in- and outlet tubes in parallel. Microdialysis probes in this 
thesis were made in-house.
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2.3.1.1 Preparation o f single cannula microdialysis probe:
The essential materials for constructing a microdialysis probe are:
• Small-diameter semi-permeable dialysis tubing
• Stainless steel tubing
• Water-resistant, all purpose epoxy resin
• Silica capillary tubing
1. Two silica capillary tubes cut to a length of 4 cm with a scalpel blade (i.d. 75 pm, 
o.d. 150 pm, Scientific Glass Engineering) are inserted side by side into a 
stainless steel cannula (1.5 cm; i.d. 380 pm, o.d. 500 pm, Goodfellow 
Cambridge Limited), both are secured using quick-set epoxy adhesive (RS).
2. A shorter steel cannula (5 mm) is attached over each silica tube (top end of 
probe) to produce a fork-shaped frame. The silica tubing eventually become the 
inlet and outlet of the probe
3. The silica tubing is inserted into a 5 cm length of polythene tubing (i.d. 0.28 mm, 
o.d. 0.61 mm, Portex). The polythene tubing is then secured to the stainless steel 
cannula using quick-set epoxy adhesive (Araldite).
4. The dialysis membrane is carefully passed over the silica inlet tube at the 
bottom of the probe, which has been trimmed to 1 mm. The membrane is 
trimmed 1 mm past the silica tubing and sealed with quick-set epoxy adhesive 
(RS) to give an active window of 1.5 mm.
5. The dialysis membrane is then trimmed 1 mm from the end of the silica glass 
tubing with a scalpel blade and sealed with quick-set epoxy adhesive (RS). 
Probes are then stored in an airtight container until use (Figure 2.3).
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Figure 2.3: Schematic of the step-by-step process of probe preparation used in these microdialysis studies.
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The probe membrane is a critical component as it forms the interface for the transfer of 
substances between the extracellular fluid and the perfusion medium (Sharp and 
Zetterstrom, 1992). A number of polymeric membranes are used in microdialysis 
sampling. The most common include cuprophan, a regenerated cellulose membrane, 
cellulose acetate and AN-69 copolymer (Stenken, 1999). Each of these different 
polymer membranes has a different molecular weight cut-off. Cut-off is defined as the 
molecular mass of molecules, 90 % of which are rejected by the membrane.
Microdialysis probes perform optimally when perfused at constant, low flow-rates 
generally 1-5 pi / min. Slow flow rates allow more time for analytes to reach 
equilibrium. With high flow rates there is an increased risk of creating a solute void 
around the probe, as solutes are removed rapidly. Therefore, slow flow rates have the 
additional advantage of minimum disturbance to the solute system under study. For 
these experiments a flow-rate of 1.5 pi / min was chosen. The dialysis probe was 
perfused 60 min before experiments were carried out to allow stabilisation of the probe.
2.3.1.2 The perfusion medium
The exact solute content of brain extracellular fluid is unknown. The perfusion medium 
should be physiological, with respect to composition and pH, so that they are isosmotic 
with plasma, and maintain an ionic balance, thereby, minimising osmotic pressure 
effects and loss of fluid from either the perfusion fluid or the tissue interstitial fluid 
(Stenken, 1999; Benveniste and Huttemeier, 1990) and have a stable physiological 
status. A physiological fluid is isotonic with respect to blood serum, i.e. of the same 
osmotic concentration (osmolarity of blood serum = 300 mMol) and also composition. 
Perfusion fluids that are identical to plasma (e.g. Ringer’s solutions) have ion 
concentrations that differ from those of the brain interstitial space (Benveniste and 
Huttemeier, 1990). Artificial cerebrospinal fluid (aCSF) and Ringer’s solution are the 
perfusion media of choice for microdialysis experiments. Ringer’s solution contains 
essential ions to maintain ionic balance, and is buffered by the CSF. aCSF contains 
additional ions and glucose, and, therefore, may introduce ions into the brain which do 
not normally exist for example phosphates.
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Composition o f Ringers:
• KC14 mM
• NaCl 145 mM
• CaCl2 1.3 mM 
Dissolved in distilled water pH 7
2 .4  H ig h  P e r f o r m a n c e  L iq u id  C h r o m a  t o g r a p h y  w it h  E l e c t r o c h e m ic a l  
D e t e c t io n  f o r  a n a l y s is  o f  n o r a d r e n a l in e
2 .4 .1  High Performance Liquid Chromatography
In chromatography, separation is achieved through ‘differential rates of migration’, 
meaning that different solutes move through the system at different velocities. Due to 
the versatility of liquid chromatography, it is the main method of choice employed to 
measure compounds of interest in microdialysates. The liquid chromatography method 
not only provides a degree of selectivity necessary for the analysis of complex mixtures, 
it also enables the microdialysis sampling to determine simultaneously more than one 
substance (see: (Chaurasia, 1999)). Analysis using High Performance Liquid 
Chromatography with Electrochemical Detection (HPLC / ECD) is sufficiently rapid to 
allow perfusates to be analysed continuously as the experiment progresses.
2.4.1.1 Column
The studies in this thesis used reversed-phase ion-pair chromatography which is one of 
the most widely used separation methods for monoamines.
Reversed phase chromatography consists of a nonpolar stationary phase and a polar 
mobile phase. Nonpolar compounds partition between the polar solvent and the 
nonpolar support (Mefford, 1985). Ion-pairing is achieved by addition of an ion-pairing 
reagent to the aqueous organic eluent e.g. a detergent such as octanesulfonic acid (OSA), 
as used within these studies. Silica-based stationary phases are the most common in 
HPLC. The OSA forms a hydrophobic bond with the silica stationary phase. Polar 
amines then form an ion-pair with the OSA. The rate at which solutes move through the
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column is dependent on surface area of the column (related to diameter of the spherical 
packing material), and the type of hydrophobic layer. The type of column used in 
HPLC / ECD depends on the solutes to be separated, the primary requirement being the 
use of polar, primary aqueous solvents containing some ionic species. The columns 
used in this study were octadecylsilane (ODS) columns: the stationary phase consisted 
of silica derivatised with octadecyl groups.
2.4.1.2 High Performance Liquid Chromatography mobile phase
The main role of the mobile phase is to determine the retention time of the solute. If 
solutes elute too quickly, they are not separated from the solvent front. If retention time 
is too long, the peak widens, peak height is reduced, and sensitivity is decreased. The 
retention time of the solute can be altered by modifying the mobile phase in the 
following way:
• An increase in pH of the buffer decreases the retention time of the solute (only if 
pK differs from 7).
• An increase in the concentration of ion-pairing agents e.g. OSA in the buffer 
increases the retention time of monoamines
• An increase in the amount of organic solvent in the buffer decreases the 
retention time of monoamines.
(Sharp and Zetterstrom, 1992)
High Performance Liquid Chromatography mobile phase components:
• 2 mM Octanesulfonic acid (OSA) (98 %, Sigma)
• 1 00 mM NaH2P0 4 (99 %, Fischer)
• 0.67 mM EDTA (99.5 % AnalaR)
• 12 % Methanol (99.8 %, Prolabo)
All dissolved in distilled H20, pH adjusted to 3.75. Under these conditions NA was 
separated out from the solvent front with a retention time of around 8-9 min. The 
mobile phase was degassed by agitation and vacuum filtration using FTK membrane 
filters (Pall Process Filtration). The buffer was recycled for 3-4 months.
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2.4.1.3 Components o f High Performance Liquid Chromatography system:
• Shimadzu LC 6 A isocratic pump ESA 582 delivering mobile phase at a flow rate 
of 1 . 0  ml / min
• Pulse dampener (ESA)
• A 50 pi injection stainless steel loop (Anachem) attached to an injection port: 
Rheodyne 7125
• A guard column: Aquapore G.C. 7 pm, 4.6 x 30 mm, Brownlee, Perkin Elmer
• A column: Hypersil ODS; 5pm packing; 4.6 x 250 mm: Thermo Hypersil Ltd., 
U.K.;
2 .5  E l e c t r o c h e m ic a l  d e t e c t io n  s y s t e m , it s  t h e o r y  a n d  c o m p o n e n t s
The type of analyte as well as sensitivity of the HPLC / ECD system, dictates the choice 
of detector used. The method of detection chosen for these experiments is 
electrochemical detection (ECD), which is well established for amino acids, choline / 
acetylcholine, glucose and amines such as DA, NA and 5-HT (Marsden et al., 1990; 
Ruban, 1993; Cheng & Kuo, 1995). The detector output is integrated and analyzed 
using computer-based (Dell) chromatography hardware / software system 
(TurboChrom). A computer-based system such as this is convenient for data collection, 
analysis, and storage, although slow changes in system sensitivity and baseline noise are 
overlooked more easily through human error than if a chart recorder is used 
(Abercrombie and Finlay, 1991).
2.5.1 Components o f the ECD used in these studies
• Guard cell ESA model 5020 +350 mV
• Electrochemical cell: model 5014B consisting of a porous graphite reference
electrode set at -280 mV and a porous graphite measuring electrode set at
+ 180 mV in series. This cell uses coulometric detection, so that 100 % of the 
analyte is oxidised and recycled in the buffer. This is in contrast to 
amperometric detection, which uses glassy carbon electrodes. Using 
amperometric detection the signal from approximately 95 % of the solute is not 
generated.
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• Coulochem detector ESA model 5100 A
• Integrator: TurboChrom package
The electrochemical detection is a reduction-oxidation reaction and takes place at the 
cell. The negative potential, applied to the first electrode, conditions the mobile phase 
containing the solutes by donating an electron (reduction). Detection occurs at the 
second electrode which is set at a positive potential, and accepts electrons from the 
reduced solute (oxidation). The flow of electrons during the electrochemical reaction 
gives rise to a current measured by the detector. The magnitude of the current generated 
is related to the concentration of the solute being reacted. A standard resistance is found 
through the HPLC / ECD system. According to Ohm’s law, therefore, the current is 
expressed as a peak, measured as (pV) on the chromatogram.
2.5.1.1 Determination o f oxidation potential for Electrochemical Detection
The measuring electrode is fixed at a potential which maximises the signal : noise ratio. 
As mentioned previously, detection takes place in a coulometric cell, which is set at the 
optimum potential. To determine this optimal potential it was necessary to construct a 
current / potential calibration curve for NA. This was achieved by injecting 50 pi NA at 
a concentration of 100 fmol into the HPLC / ECD. The measuring electrode was set at a 
range of potentials from -20 to +380 mV. The voltammogram obtained is shown below 
(Figure 2.4). A plateau is observed from + 200 mV to + 380 mV but from + 200 mV 
to -20 mV the NA peak declines sharply linearly. From these results, it was decided that 
the measuring electrode should be set at +180 mV. The optimal electrode potential 
should be low enough to prevent the oxidation of too many impurities in the samples, as 
this could interfere with the NA peak, but high enough to ensure the electroactive 
species reaching the electrode react.
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F igure 2.4: Voltammogram obtained by oxidation of noradrenaline at electrode 
potentials ranging from -20 to +380 mV.
2.5.1.2 Calibration and determination o f detection limit o f the HPLC /  ECD system
Regular calibration of the HPLC / ECD system was necessary to ensure accurate 
measurement of the NA peak on the chromatogram, as well as determination of the 
detection limit of the system. This was achieved by injecting 50 pi NA at concentrations 
ranging from 2 to 150 fmol with the electrode set at the optimum potential described 
above (180 mV) for the ECD. From 150 fmol / 50 pi down to 2 fmol / 50 pi there is a 
linear relationship between peak height and NA concentration (R2=0.99) (Figure 2.5). 
Since the signal at 4 fmol was more than twice that of the basal noise, it was concluded 
that under these conditions 2-4 fmol was the detection limit for NA.
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F i g u r e  2.5: Calibration curve for the detection of noradrenaline. The height of the 
peak representing oxidation of noradrenaline was plotted (Y-axis) the 
concentration of noradrenaline in the sample (X-axis). The height of the peak 
follows a linear relationship down to 2  fmol noradrenaline.
Calibration of the HPLC / ECD was carried out every day at the start of every 
experiment.
2.6 I n  v iv o  M i c r o d i a l  y s is
2.6.1 Surgical procedure
2.6.1.1 Non-Recovery (continuous anaesthesia) in vivo microdialysis
Induction o f anaesthesia. An oxygen cylinder fitted with a pinindex regulator and flow 
meter was connected to a purpose-built vaporiser to provide smooth delivery of 
inhalational anaesthesia (2.0 % halothane combined with 30 % O2 / 70 % N2 at 2 L / 
min). The halothane was piped into a transparant induction chamber (12.5 cm x 13.5 cm
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x 26.5 cm) enabling observation of the animal during induction of anaesthesia. To 
ensure sufficient depth of anaesthesia the animal’s pedal withdrawal reflex was tested. 
The hindlimb was extended and the skin between digits pinched firmly. The absence of 
a flexor reflex confirmed sufficient anaesthesia to progress with surgery. Whilst 
remaining fully anaesthetised, the mouse was removed from the induction chamber and 
placed in a stereotaxic frame (Kopf), for the duration of the experiment. Anaesthesia 
was mantained by the delivery (via a face-mask) of 1.5-2 % halothane combined with 
30 % O2 / 70 % N2 at 2 L / min.
2.6.1.2 Probe insertion
The flat skull position was obtained using blunt ear bars. An incision was made in the 
midline of the scalp with a scalpel to expose bregma. Forceps were used to withdraw 
the two folds of skin to allow access to the skull which had been cleaned and dried. The 
flat skull position was assumed when ventral coordinates of bregma, and two positions 
±1.0 mm lateral to bregma, were within 0.1 mm. Using a trepanning drill burr, a 1mm 
diameter hole was drilled into the skull where the probe was to be inserted: mm frontal 
cortex: AP +2.1, ML +1, DV -2 according to the mouse atlas of Paxinos and Watson 
(2001). The dura was broken with a needle and a probe, primed with modified Ringer’s 
solution (NaCl 145 mM, KC1 4 mM, CaCL 1.3 mM), placed at the coordinates given 
above. The probe was then slowly lowered vertically into its final position: mm frontal 
cortex: DV -2 mm.
The probe was inserted into the secondary motor (M2) cortical region (Figure 2.6). This 
brain region was chosen based on its topographical relationship with subcortical regions, 
as it most closely resembles that of the FR2 region in the rat brain, which we have 
previously studied (McQuade et al., 1999). In the rat, the FR2 region receives dense 
noradrenergic input from the LC and vice versa (Sara & Herve-Minvielle, 1995).
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Figure 2.6: Coronal schematic of the site of probe insertion in the M2 region of the 
mouse prefrontal cortex. Not drawn to scale.
After probe implantation, the mice were maintained under anaesthesia for the duration 
of the experiment. Vital signs were monitored continually to ensure a respiratory rate of 
100-190 / min (average: 135 ± 20 / min). Core body temperature was maintained at 
38 °C using a warm water-bed. Sterile saline (0.9 %, 0.1 ml) was injected 
subcutaneously, once per hour, to prevent dehydration. Microdialysis probes were 
perfused with modified Ringer’s solution at a rate of 1.5 pi / min and dialysis samples 
collected at 20 min intervals. A drug challenge started after a minimum of three 
consecutive basal samples indicated a stable baseline for spontaneous NA efflux.
2.6.2 Freely-moving in vivo microdialysis
Induction of anaesthesia was as described in Section 2.6.1.1 but using a 95 % O2 and 
5 % CO2 mix at 250 cc / min.
Maintenance o f anaesthesia: Whilst the animal remained fully anaesthetised, it was 
placed in a stereotaxic frame (Kopf) where anaesthesia was mantained by the delivery
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(via a face-mask) of 1.5-2 % halothane combined with 95 % O2 / 5 % CO2 at 250 cc / 
min.
Prior to probe insertion as decribed in section 2.6.1.2 two bone anchor self tapping 
screws (Bioanalytical Systems), were inserted on either side of the skull, at the level of 
the parietal bone to anchor the cyanoacrylate gel that would secure the probes after their 
insertion (Figure 2.7).
Sagitta l  su tu re  B reg m a
F i g u r e  2.7: The dorsal surface of the mouse skull showing placement of the self 
tapping bone screws for securing the dialysis probe in freely-moving mouse 
microdialysis indicated by arrows (Taken from Paxinos and Watson, 2001).
The probe was then secured in place using cyanoacrylate gel glue and activator (RS), 
taking care to avoid the eyes and whiskers of the mouse (Figure 2.8).
F i g u r e  2.8: Photograph of the probe 
secured in place with cyanoacrylate gel glue.
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A collar, made of card, was also attached around the head of the mouse to prevent 
removal of the probe during the night. The mouse was placed in a plastic cage (Harvard 
Apparatus; diameter 8  cm height 21 cm), with free access to wet mash. The plastic cage 
was then placed in an incubator to allow the mouse to recover from anaesthesia. Based 
on histological, functional, metabolic and blood-flow changes caused by the probe 
insertion, it appears that the optimal time for commencing microdialysis is 8-48 h after 
probe implantation (Benveniste and Huttemeier 2003). For the freely-moving mouse 
dialysis, experiments were, therefore, typically carried out 12-24 h after probe 
implantation. The inlet and outlet of the probes were connected, through FEP tubing (i.d: 
0 . 1 2  mm o.d: 0 . 6 8  mm; dead volume: 1 . 2  pi / 1 0  cm), to a low-torque quartz-lined dual 
channel swivel (Instech). Dead volume was kept to the minimum.
2.6.2.1 Drug administration / preparation
For i.p. dosing, the required amount of RX821002 (Sigma,UK) was dissolved in 0.9 % 
saline to give a dosing volume of 10 ml / kg. Fresh solutions were prepared daily. When 
infused locally into the terminal field, via the dialysis probe, desipramine was diluted in 
modified Ringer’s solution.
2.6.2.2 Collection o f dialysates
At 08:00 h on the day after surgery, mice were transferred to the experimental 
laboratory. The cuff was removed and the inlet of the swivel connected via FEP tubing 
(i.d: 0.12 mm o.d: 0.68 mm Royem Scientific Ltd.) to a 1 ml disposable syringe (BD 
Plastipak™) filled with modified Ringer’s solution and perfused using a Kd Scientific 
perfusion pump at 1.5 pi / min. The outlet of the swivel was then connected, using FEP 
tubing, to long-form, tapered polythene tubes (Hughes and Hughes Ltd.) where the 
samples were collected every 20 min. A counterbalanced lever arm (Harvard Apparatus) 
held the swivel (Instech) over the animal container (Harvard Apparatus). The swivel 
was used in order to prevent the tubing from the inlet and outlet of the probe becoming 
entangled.
Samples were analysed immediately after collection using HPLC / ECD as described in 
sections 2.4-5. Probes were always allowed to equilibrate for 60 min before starting
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collection of basal samples. Once a stable baseline had been achieved with three 
successive samples, RX821002 was administered. Depending on experimental design, 
samples were then collected for periods ranging from 120-240 min. The animal was 
then killed using a Schedule 1 method (see Section 2.6.3). Brains were then removed 
from the skull and fixed in 4 % formalin and then stained with cresyl violet for 
confirmation of probe placement (Figure 2.9).
F i g u r e  2.9: Confirmation of probe implantation in the secondary motor (M2) 
region, bregma + 2.1mm. Arrow indicates probe track. Scale bar = 750 pm.
2.6.2.3 Calibration o f the HPLC-ECD system
NA standards of 15, 30 and 60 fmol / 50pl were injected daily. The concentration of the 
test solutes was estimated using a calibration curve of external NA standards.
2.6.3 Schedule 1
After microdialysis experiments, mice were given an overdose of anaesthetic, and a 
sample of NA efflux collected, to confirm NA had been sampled, as NA efflux 
increases substantially during hypoxia. Spinal cords were then severed and their brains 
removed for confirmation of probe placement.
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2.7 B e h a v io u r
2.7.1 Light Dark Exploration Box
We used a light dark-exploration box (LDEB) based on that first described by (Crawley 
& Goodwin, 1980) but with a different protocol.
Mice have an innate aversion to the brightly lit environment, and it is on these factors 
that the LDEB is based (Crawley & Goodwin, 1980). Placement of the animal into a 
novel brightly lit environment applies the mild stressors novelty and light. The conflict 
that arises when an animal is exposed to an unfamiliar environment is between the 
tendency to explore and the initial tendency to avoid the unfamiliar (neophobia). The 
exploratory behaviour is a reflection of a balance of these tendencies in novel situations 
(Hascoet et al., 2001; Bourin & Hascoet, 2003). An advantage of the LDEB, is that it is 
quick and easy to use. No prior training of animals, or food and water deprivation, is 
necessary and only natural stimuli are used (Bourin & Hascoet, 2003).
Typical dimensions of the compartment are one third for the dark compartment and two 
thirds for the light compartment. In this model the safe area is the small dark 
compartment (one third), to which the animals have been allowed to habituate. In the 
studies performed by Crawley and Goodwin, (1980) no habituation took place. The 
aversive area is the large illuminated compartment. The fact that inbred mice show 
substantial differences in their spontaneous behaviour supports the belief that choice of 
strain, is important (Bourin & Hascoet, 2003).
The LDEB, however, can produce false positive results if a drug increases general 
activity. It, therefore, seems reasonable to suggest that preliminary screening of 
locomotor activity (such as open-field or an actimeter test) is advisable before 
conducting the LDEB, as this would eliminate false positives. We have tested the 
animals’ ambulatory activity and found it to be greater in NK1-/-, than NK1+/+ mice 
(Herpfer et al., 2005). NK1-/- mice also demonstrate higher locomotor activity in the 
LDEB (Herpfer et al., 2005).
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2.7.1.1 Apparatus (light/dark exploration box)
All behavioural tests were carried out (13:00-17:30) in a LDEB comprising a light 
compartment serving as the novel ‘test zone’ (30 cm long x 18.8 cm wide x 24 cm high) 
and a dark ‘neutral zone’ (15 cm long x 18.8 cm wide x 24 cm high) (Figure 2.10).
Light zoneNeutral zone
F ig u r e  2.10: Schematic of the LDEB used in these experiments. The LDEB 
comprised of a light novel zone and a dark zone, to which the mice had been 
allowed to habituate. The two compartments are separated by a guillotine style 
door, coloured grey in this schematic.
The walls and floor of the ‘neutral zone’, illuminated at 2 lux, were coloured black. The 
walls and floor of the Tight zone’ illuminated at 10 lux were coloured white. The floor 
of the light arena was divided into 24 squares (4.5 cm ) whereas that of the neutral arena 
was divided into 9 squares (4.5 cm ). The partition between the neutral and light zones 
incorporated a white guillotine style door (30 cm x 7 cm), which could be raised to 
allow the mice to traverse freely between the two compartments.
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2.7.1.2 Behavioural scoring
The following behavioural parameters were measured in both the light and neutral 
arena:
• Number o f lines crossed by the mouse (as an index of locomotor activity), a 
diagonal crossing of the whole body counted as two lines, a vertical or horizontal line 
crossing recorded as one.
• Number of rears (recorded when animal was on hind feet).
• Number and duration o f grooming episodes.
• Risk assessment behaviour; including numer of stretched-attend postures and time 
spent in flat back approach.
Behavioural parameters measured only in the light zone included:
• Latency to leave the light arena following forced entry (Active avoidance)
• Latency to return to the light arena following the first exit (Passive avoidance)
• Number of returns to the light arena
• Total time spent in the light arena. The appearance of all four paws was the 
criterion for re-entry to the light zone, and each Tine-crossing’ had to include both the 
hind paws. Behaviours were scored within 10 minute bins and summary data calculated.
2.7.2 In vivo microdialysis in the light dark exploration box
In vivo microdialysis has previously been used to investigate changes in NA efflux 
caused by novelty as a non-noxious stressor in Maudsley rats (Dailey & Stanford, 1995; 
McQuade et al., 1999). The marked genotype-dependent behavioural differences, 
observed between the NK1+/+ and NK1-/- mice, in response to a novel environment 
have not been investigated using in vivo microdialysis. For this reason, these 
experiments used in vivo microdialysis in the LDEB, to determine whether the 
noradrenergic response to novelty differs between NK1+/+ and NK1-/- mice.
2.7.2.1 Surgical procedure
As described in section 2.6.2
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2.7.2.2 Apparatus
As described in section 2.7
2.7.2.3 Protocol
See Chapter 5.
2 .8  IMMUNOHISTOCHEMISTRY
2.8.1 Background to immunohistochemistry
Immunohistochemistry (IHC) is a method of detecting the presence of specific proteins 
in cells or tissues. The technique consists of a primary antibody binding to a specific 
antigen of interest, the antibody-antigen complex is bound by a secondary antibody 
which is generally biotinylated. The secondary biotinylated antibody binds to the 
antibodies produced by the species in which the primary antibody was raised. 
Application of avidin bound to the fluorescent label or horse-radish peroxidase results 
in the formation of a macromolecular complex around the antigen which is visible under 
the light or fluorescent microscope.
2.8.2 Tissue preparation and fixation
Male NK1+/+ and NK1-/- mice (25-30 g) were deeply anaesthetised with sodium 
pentobarbital (0.2 ml i.p; Merial) and perfused through the left ventricle of the heart 
with heparinised saline, followed by fixative containing 4% paraformaldehyde in 
phosphate buffer (PB) 0.1 M, and distilled water. The brain was removed from each 
animal and post-fixed in the same solution for 2-3 h and then transferred to a solution 
containing 30 % sucrose and 0.02 % azide.
Tissue blocks containing the frontal cortex and LC were mounted onto a freezing 
microtome (SM 2000 R; Leica Microsystems, Milton Keynes, UK) and frozen with dry 
ice. Serial coronal sections 40 pm thick were collected into 5 % sucrose in 0.1 M PB 
and stored at 4°C.
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2.8.2.1 Primary Antibodies
Table 2.1 lists the primary antibodies used in the experiments contained in this thesis. 
The general step-by-step process for the IHC used in these studies is detailed in Figure 
2 . 11.
Antigen Animal 
in which 
raised
Monoclonal
or
polyclonal
(M/P)
Detection
method
Optimal
dilution
Source
Alpha2a Rabbit P TSA 1:50 000 A gift from 
Pete O’Hara 
San
Francisco
Alpha2a Rabbit P DAB
FITC
1 : 1 0 0 0 Affinity
Bioreagents
Alpha2a Goat P DAB
FITC
1 : 1 0 0 0 Santa Cruz
Dopamine-P-
hydroxylase
(DPH)
Rabbit P DAB
FITC
1 : 1 0 0 0 Research
diagnostics
Noradrenaline
transporter
(NAT)
Rabbit P DAB
FITC
1 : 1 0 0 0 Chemicon
NK1 receptor Rabbit P DAB
FITC
1 : 1 0  0 0 0
Tyrosine
hydroxylase
(TH)
Goat P DAB
FITC
1:5000 Calbiochem
T a b l e  2.1: The primary antibodies used in these studies.
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Wash in PB
Wash in PB
Wash in PB
Wash in PB
Wash in PB Wash in PB
Wash in PB
Mount sections; Coverslip with Citifluor Mount sections; Dehydrate; Clear; 
Coverslip with DPX
Incubate in biotinylated 
secondary antibody
Incubate in 
biotinylated 
tyramide (TSA)
Stain with 
chromagen 
(DAB)
Incubate in avidin-conjugated 
FITC
Incubate in primary 
antibody 
4 days at 4°C
Incubate in avidin 
conjugated to horseradish 
peroxidase
Incubate in avidin-conjugated 
FITC
Block:
Serum solution 
For HRP only, to quench 
endogenous peroxidase 
activity
F ig u r e  2.11: Step-by-step schematic of the IHC used in this thesis (Adapted from 
Gadd, 2003).
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2.8.2.2 Primary antibody labelling
The IHC in this thesis used the avidin-biotin complex method. Avidin, a large 
glycoprotein found in egg-white can bind four molecules of the small molecular weight 
vitamin, biotin, with high affinity. The increased sensitivity results from the large 
number of biotin molecules that can be attached to an antibody (Guesdon et al., 1979; 
Hsu & Raine, 1981; Hsu et al., 1981). Because of the large number of biotin molecules 
attached to the antibody, many labelled avidin molecules may be bound at the site of the 
primary antigen-antibody reaction. This enables greater sensitivity to be achieved in 
terms of the amount of label finally bound to the antigenic site (Polak and Noorden, 
1997).
Cy3 and fluorescein isothiocyanate (FITC)
Fluorescence provides a visible label which contrasts well with a dark, non-fluorescent 
background. FITC emits a bright apple-green fluorescence (k 520 nm) at an excitation 
wavelength of 495 nm. Cy3 emits a red fluorescence and belongs to the group of 
CyDyes™, (Amersham International, UK).
Horseradish peroxidase (ABC) method
The instability of immunofluorescence, with time, prompted development of a more 
permanent type of preparation using enzymes as labels. Horseradish peroxidase is an 
enzyme which causes hydrogen peroxide (H2O2) to decompose to water and oxygen. 
When an electron donor is present, this peroxidase activity oxidises the donor. The 
chromagen and electron donor used in these studies was 3 ’3 ’-diaminobenzidine (DAB). 
Degradation of H2O2 results in oxidation of DAB. The reaction product is a brown 
polymer which is insoluble in water or alcohol.
Tyramide Signal Amplification (TSA)
Further amplification can be achieved using TSA. This reaction involves horseradish 
peroxidase catalysing the deposition of biotinylated tyramide onto the complex bound to 
the primary antibody. The numerous biotin molecules deposited by this reaction are 
then visualised indirectly using an avidin-bound label step. Use of TSA allows lower 
concentrations of primary antibody to be used, thereby increasing signal : background 
ratio on tissue sections.
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The method for IHC with chromogenic detection using DAB is found in protocol 2.8.1 
(see Appendix II). Details for conventional fluorescence detection are given in protocol
2.8.2 (see Appendix III), and details for TSA with fluorescent detection is found in 
protocol 2.8.3 (see Appendix IV).
2.8.3 Microscopy and photography
A Leica DMR (Leica Microsystems) or Nikon Eclipse E800 microscope (Nikon, 
Kingston upon Thames, UK) was used to visualise labelled antibody sections. 
Bright-field conditions were used to visualise antigens labelled chromogenically, whilst 
fluorescent dyes were observed under appropriate excitation from a 50 W mercury lamp 
(HBO50; Osram, Munich, Germany). Bright-field digital photography was carried out 
using a JVC colour Video camera (KY-F50; JVC, London, UK) and fluorescent 
photography using a Hamamatsu Chilled CCD camera (C5985; Hamamatsu Photonics, 
Welwyn Garden City, UK) attached to a Macintosh PowerPC G3 computer running 
Vision Explorer VA 1.11 (Graftek Imaging, Austin, USA).
2.8.4 General laboratory solutions 
Phosphate buffer (PB; 0.1M; pH 7.4):
190 mM NaH2P0 4 (BDH, Poole, UK)
810 mM Na2HP04 (BDH, Poole, UK)
Triton Tris buffered Saline (TTBS)
0.05 M Tris saline pH 7.4 
0.3% Triton X-100
0.02 % Azide; Only if diluting antibody, as acts as a preservative of the fluorescence.
Tris buffer (0.15M; pH7.6):
127 mM Tris HC1 (Sigma, Poole, UK)
23 mM Tris base (Sigma)
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Heparinised phosphate-buffered saline (PBS):
Saline (0.9 % NaCl; Baxter, Lessines, Belgium)
5 ml heparin (Monoparin; CP Pharmaceuticals, Wrexham, UK)
~5 mM PB
Normal Goat Serum (NGS) solution:
0.1 MPB
3 % NGS (Vector Laboratories, Burlingame, USA)
0.3 % Triton X-100 (BDH)
0.02%NaN3 (Sigma)
Store at 4 °C
2.9 We s t e r n  b l o t  a n a l  y sis  o f  t h e  n o r a d r e n a l in e  t r a n s p o r t e r  a n d  
CC2tra d r e n o c e p t o r  p r o t e in
Although IHC is a useful method for visualising receptors, transporters or enzymes, 
further quantification using Western blot analysis was required. Western blot analysis 
consists of three main steps: separation of the protein of interest by electrophoresis; 
protein transfer by electroblotting; and immunodetection of the individual proteins.
2.9.1 Tissue preparation
Western blot analysis of (X2a-adrenoceptors was performed on tissue sections from the 
frontal cortex, hippocampus and LC of NK1-/- and NK1+/+ mice. These cortical areas 
were chosen as they receive dense noradrenergic innervation from the LC. The fresh 
brain was quickly dissected, then frozen immediately in liquid nitrogen. Tissue was 
stored at -20°C, until use.
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2.9.2 Method
Tissue samples were rapidly homogenised in 1 ml of RIPA buffer, containing a cocktail 
of proteinase and phosphatase inhibitors (1 % NP40, 20 mM Hepes pH 7.4, 100 mM 
NaCl, 100 mM sodium fluoride (NaF), 1 mM sodium orthovanadate (Na3Vo4), 
l Opg/ ml  leupeptin and pepstatinl pg / ml; Sigma) based on that described by 
Sambrook et al, 1989; Harlow and Lane, 1990). RIPA buffer homogenises the protein 
as well as protecting, linearising and exposing the antigen. The sample is homogenised 
gently until a continuous suspension is generated and then the homogenate is transferred 
to a clean centrifuge tube. Foaming of the sample reflects significant protein denaturing. 
This is avoided by slow homogenisation and taking care not to lift pestle out of the 
solution. The samples are then boiled for 5 min so that proteins are denatured and 
dissolved.
Homogenates were left on ice for 2 h and then centrifuged (12,000 x g, 4°C) for 15 min. 
Centrifugation clears the lysate of insoluble proteins, carbohydrates and lipids. The 
clear supernatant is removed, taking care to avoid the pellet and any lipids that remain 
on the surface, as excess insoluble matter will block the passage of protein during 
SDS-PAGE (polyacrylamide gel electrophoresis). The lysate is stable for several 
months at -20°C.
The protein contents of the supernatant were determined using a BCA kit (Pierce, 
Rockford, IL) using bovine serum albumin (BSA; Pierce, Rockford, IL) as a standard.
All of the samples were mixed 50:50 with Unloading buffer (10 % w/v sodium dodecyl 
sulphate; 50 % v/v glycerol and 0.5 % w/v bromophenol blue; Sigma) and boiled for 
5-10 min to denature proteins. A total of 15 pi (10 pg total protein) of each sample was 
separated on a commercially available 10 % SDS polyacrylamide gel PAGEr (Bio-Rad) 
at 100 V for 90 min. The separated proteins were electrophoretically transferred to a 
hydrophobic polyvinylidene difluoride (PVDF) membrane (Bio-Rad) at 4 °C for 45 min 
at 100 V.
To block non-specific antibody binding, the PVDF membranes were immersed 
overnight at 4 °C in 4 % bovine serum albumin (BSA) and PBS / 1 % Tween. The 
PVDF membranes were then incubated with anti-goat a 2a-adrenoceptor (Santa Cruz
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Biotechnology Inc.) or anti-rabbit noradrenaline transporter (NAT) antibodies 
(Chemicon) at a dilution of 1:1000 in 4 % BSA and PBS / 1 % Tween. All membranes 
were incubated with the primary antibody overnight at room temperature.
The membranes were then washed withTris-buffered saline / 1 % Tween for 2 days, if 
incubated with the ot2a-adrenoceptor antibody, or 1 day if incubated with NAT antibody. 
The secondary antibody which must be against the species in which the primary 
antibody was raised was then applied: 1:2000 made in 4% BSA and PBS / 1% Tween. 
For the a 2a.adrenoceptor the secondary antibody was anti-goat, and for NAT the 
secondary antibody was anti-rabbit. After exposure to the secondary antibody the 
membranes are washed in PBS / Tween (6x5 min washes), and then left for 30 mins in 
PBS / Tween. This is followed by a 1 x 10 min wash in PBS. The protein bands were 
identified by chemiluminescence using the enhanced chemiluminescence (ECL) 
detection system and X-ray film for 1-20 min (Amersham Biosciences Buckinghamshire, 
UK).
To ensure protein was evenly loaded in the gel, the house-keeper protein, GAPDH, was 
used as a control. To identify GAPDH, the membranes received 2 x 10 min washes in 
stripping buffer (1.5 % glycine, 1 % sodium dodecyl sulphate and 1 % Tween) followed 
by 2 x 5 min washes in PBS followed by a block in 4 % BSA for 1 h. Membranes were 
subsequently incubated overnight at room temperature in GAPDH (1:750). This was 
followed by 6  x 5 min washes in PBS / Tween. Membranes were incubated in 1:2000 
diluted horseradish peroxidase-conjugated mouse anti-rabbit IgG (Amersham 
Biosciences Inc., Buckinghamshire, UK).
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2.10 Q u a n t i t a  t i v e  fH]RX821002 a n d  fH ]R A  u w o l s c i n e  a  u t o r a d i o g r a p h y  o f
CLrADRENOCEPTORS
2.10.1 Background
Autoradiography is a process by which the location of radioactive materials in tissue 
sections is detected, by exposure to a photographic emulsion, forming a pattern on the 
film corresponding to the location of the radioactive compounds within or attached to 
the cell. Since the late 1800s dramatic progress in the development of this technique has 
been made (Table 2.2). In 1974 Kuhar and Yamamura combined radioligand binding 
with autoradiography to map the distribution of neurotransmitter receptors (Kuhar and 
Yamamura, 1974). These early studies used in vivo labelling. This involved labelling 
receptors in intact tissues by systemic administration of the radioligand. However, this 
technique is associated with serious limitations for example resolution, sensitivity 
(Stumpf, 2002), lipid solubility and penetration of the blood-brain barrier of the injected 
radioligands and, therefore, was followed by in vitro labelling. This involved incubating 
slide-mounted tissue sections with radioactive ligands, and enabled receptor labelling 
under closely controlled conditions (Young, III & Kuhar, 1979b; Young, III & Kuhar, 
1979a). Adrenoceptors were first identified using light-microscope autoradiography in 
1980 (Young, III & Kuhar, 1980).
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History of autoradiography
1867
Niepce de St. Victor observes blackening of silver iodide and silver 
chloride emulsions by uranium nitrate
1869
Bequerel observes the same darkening with opaque paper placed 
between the uranium nitrate and the emulsions.
1924
The first biological experiment involving autoradiography traces the 
distribution of polonium in biological specimens.
1943
Autoradiographs prepared by exposing lantern slides are used to trace 
13 *1 in thyroid sections.
1946
The resolution of these autoradiographs is improved by painting slide 
emulsion directly onto the tissue sections. This technique would later 
form the basis for modem microradiography.
1950
The stripping of emulsion from slides leads to the development of 
stripping film, which resolves to light microscopic levels.
Late 1950s
1 T I
I-Labeled trifluoroiodomethane is used to measure rat cerebral 
blood flow, despite the high volatility of the tracer compound, and the 
low resolution of the resulting images. When the tracer is replaced 
with 14C-labeled antipyrine, permeability across the blood-brain 
barrier is reduced.
1977
14C-Labeled iodoantipyrine yields accurate measurements of cerebral 
blood flow, and becomes the reference diffusible tracer for this 
experiment.
Late 1970s
Sokoloff et al. use [l4C]deoxyglucose to measure the metabolic rate of 
glucose.
1980s
14C- and 3H-labeled leucine are used to measure rates of amino acid 
incorporation into proteins. The use of autoradiography is also 
proposed for the measurement of ligand binding and drug interaction.
T a b l e  2.2: History of the development of autoradiography.
Radioactive decay results in the emission of subatomic particles capable of ionizing 
matter, p-decay is the most common type of radiation used in autoradiography, p-decay 
occurs when a neutron decomposes into a proton and electron. The most commonly
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used nuclides for autoradiography include 14C and 3H. The half-life of 3H is 12.4 years
■y
better resolution is obtained with H due to low p energies.
2,10.2 General principles of binding
The general procedures of radioligand receptor binding were developed through the use 
of membrane preparations. Radioligands and transmitters possess both hydrophilic and 
hydrophobic portions and, therefore, interact with many sites on the membranes through 
ionic and non-ionic bonds, producing a high degree of non-specific binding (NSB). 
Unless radioligands have a high enough specific activity to permit assay at 
concentrations as low or lower than the dissociation constant, the concentration of 
radioactive ligand which must be added to produce measurable radioactivity in the 
membranes may saturate specific receptors and label primarily non-specific sites 
(Snyder, 1978). Neurotransmitter receptor binding assays have had practical 
ramifications in the design of new drugs (Snyder, 1978).
Using membrane preparations, different types of information have been obtained from 
radioligand binding studies depending on the experimental conditions. Information 
about the affinity of a ligand for a receptor (Ka, equilibrium dissociation constant) and 
the density of binding sites (Bmax) is obtained from saturation binding experiments. 
Tissue sections are incubated in a range of concentrations of radioligand. Total binding 
is assumed from the amount of radioactivity bound. NSB is determined (in parallel) by 
incubating tissue sections in the same conditions but including an excess (i.e. enough to 
saturate specific binding sites) of a suitable cold ligand. NSB is the proportion of 
radioligand binding which is not displaced by drugs specific for the receptor. NSB may 
result from binding to other receptor types, other proteins in the membrane or 
partitioning into lipids. Adrenaline was used as the cold ligand in the present studies: 
this will compete with the radioligand for binding to the a 2-adrenoceptor under 
investigation. Specific binding is then calculated by subtracting NSB (in the presence of 
adrenaline) from total binding.
Competition ligand binding assays provide information about the concentration of 
competing ligand which displaces 50 % of the specific binding of the radioligand ( I C 5 0 ) .  
In this type of assay, a single concentration of radioligand is used. The radioligand is
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used at a low concentration, usually at or below its Kd value. Specific binding of the 
radioligand is then determined in the presence of a range of concentrations of competing 
cold compounds, in order to measure the potency with which they compete for the 
binding of the radioligand. The Kt (a measure of the affinity of the competitor for the 
receptor) is the concentration of competing ligand which roughly occupies 50 % of the 
receptors if no radioligand were present. The IC50 value for a compound can vary 
between experiments depending on radioligand concentration and amount of the target 
binding site etc. The Kt is an absolute value derived from the IC50 using the 
Cheng-Prusoff equation:
Kj  =  ICso
1+( [ L ]/£d)
Where [L] = the concentration of free radioligand used in the assay, and K<i = the 
dissociation rate of the radioligand for the receptor.
Association and dissociation rate constants are determined using association and 
dissociation kinetic experiments for the receptor-ligand complex.
The development of autoradiography in whole brain slices, rather than membranes, has 
offered a useful method to study localization of the receptor of interest. Consequently 
anatomical information is also provided. Another advantage of autoradiography is that 
only small quantities of radiolabelled drug are required, which can be readily and 
accurately measured.
An important consideration when designing radioligand binding experiments is the 
choice of a radiolabelled agonist or antagonist. G protein-coupled receptors, such as 
a- and p-adrenoceptors, form different conformations depending on whether GTP or 
GDP is bound see Section 2.11. Agonists bind to the high affinity conformational states 
of the receptor only. However, if the concentration of the agonist is high enough, they 
will also bind to the low affinity conformational state of the G protein-coupled receptor. 
This leads to different measures of the receptor population. Antagonists will bind to 
both the low affinity and high affinity conformational states of the G protein-coupled
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receptor. Use of a radiolabelled antagonist, therefore, gives a better estimate of the total 
receptor population than a radiolabelled agonist.
2.10.3 The photographic process
Autoradiographic film consists of a flexible base, onto which the photosensitive 
emulsion is coated, and a protective supercoat. The photographic emulsion is composed 
of silver halide grains dispersed within gelatine. The grains are typically > 1 pm in 
diameter; large grains facilitate greater sensitivity, while small grains enable finer 
resolution. The grains consist of silver, bromide, and iodide ions arranged in a crystal 
lattice structure. The labelled sections are apposed to the emulsion. Charged electrons 
and positrons produced by P-decay attract the silver ions of the grains, this reduces the 
atomic silver which forms clumps, called latent image centres. When a threshold 
number of latent image centres is reached within a single silver halide grain, the grain is 
developable. Developable grains form the dark areas of the image when the emulsion is 
developed.
For the autoradiographic studies conducted in this thesis we used a Hyperfilm-3H 
(Amersham Biosciences). This is a speciality, single emulsion coated, film, with no 
anti-scratch layer, for the direct autoradiography of 3H. The anti-scratch layer on most 
films seriously impedes or totally blocks weak p-particles produced by tritium decay. 
As the hyperfilm used in these studies has no anti-scratch layer, these weak particles can 
strike the emulsion directly to form the image decreasing the path length of p particle 
emission (Figure 2.12).
Plastic base 
Emulsion
3H
F i g u r e  2.12: Hyperfilm™ 3H structure.
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2.10.4 Choice o f radiolabel
A number of radioligands are available for labelling a 2-adrenoceptors (Table 2.3)
( X 2 - a d r e n o c e p t o r s c i 2 a - a d r e n o c e p t o r s a 2 c - a d r e n o c e p t o r s
[3H]RX821002‘ 
[3H]RS79948-1972 
[3H]idazoxan3'4 '5 
r3HlUK143045
[3H]RX82100226
[3H]MK9122 
[ H]rauwolscine2'4
Table 2.3: Commercially available radioligands available for autoradiographic
labelling of <X2-adrenoceptors. Compounds underlined are agonists.
^olm berg  et al., 2003), 2(Uhlen et al., 1998), 3(Mallard et al., 1992), 4(Winzer-Serhan 
et al., 1997b), 5(Zilles et al., 1993) 6(Wikberg-Matsson et al., 1995)
[ H]RX821002 was chosen for these studies. Previous studies have demonstrated that it 
labels all a 2-adrenoceptors, with some studies suggesting a preference for the 
a 2a-adrenoceptor subtype (Uhlen et al., 1998). In an attempt to distinguish between the 
different a 2-adrenoceptor subtypes, [ H]rauwolscine was also used, as this compound 
preferentially labels oi2c-adrenoceptors (Uhlen et al., 1998). It was hoped that 
subtraction of the autoradiographic labelling with [3H]rauwolscine from the 
autoradiographic labelling with [3H]RX821002 would provide an estimate of the 
oi2a-adrenoceptor receptor population. Labelling of the (X2b-adrenoceptor was not 
thought necessary as the a 2a and (X2c-adrenoceptors are the major adrenoceptor subtypes 
in the CNS. The a 2b-adrenoceptor is found only in the thalamus (Scheinin et al., 1994) 
an area of the brain not analysed in these studies.
Although the pharmacology and distribution of 012-adrenoceptors is well documented 
within the rat CNS, little is known about the distribution of these receptors in the CNS 
of the mouse. [ H]RX821002 autoradiography was, therefore, used to map the 
localisation and density of ct2-adrenoceptors in relevant brain regions in NK1+/+ and 
NK1-/- mice.
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2.10.5 Methods
2.10.5.1 Drugs and chemicals
[3H]RX821002 (specific activity 41.0 Ci / mmol) used at a concentration of 1.0 nM and 
[3H]rauwolscine (specific activity 66.0 Ci / mmol) used at a concentration of 0.4 nM 
were purchased from Amersham Biosciences. (-)Adrenaline, was obtained from Sigma.
2.10.5.2 Animals and tissue preparation
Receptor autoradiography typically uses fresh-frozen specimens, as ligand binding to 
receptors can be destroyed by chemical fixation due to the cross linking of binding 
proteins. Three mice of each genotype were used. After decapitation, brains were 
rapidly dissected and frozen by immersion into cold isopentane chilled to 45 ± 5 °C on 
dry ice. Brains were than stored at -70 °C until sectioned. Sections (15 pm) were cut on 
a cryostat (Leica) at -22 °C in the horizontal plane. The sections were thaw-mounted 
onto gelatin-coated slides, dried at room temperature for 2  h, and subsequently stored at 
-70 °C with desiccant in sealed containers.
2.10.5.3 Autoradiographic labelling o f a2-adrenoceptors with [3H]RX821002 and 
[3 HJrauwolscine
Slides with brain sections were brought to room temperature over a 15 min period. 
[3H]RX821002 (1.0 nM) and [3H]rauwolscine (0.4 nM) were made in 50-mM potassium 
phosphate buffer, pH 7.4. Tissue sections were incubated with 1 ml of either 
[3H]RX821002 or [3H]rauwolscine at room temperature. In each experiment sections 
from each genotype were processed in parallel. For [ H]RX821002 (1.0 nM) the 
incubation time was 2 0  min, followed by 2  x 2  min washes in the same buffer on ice. 
For [3H]rauwolscine (0.4 nM), the incubation time was 60 min followed by 2 x 30 min 
washes in ice-cold buffer. The slides were than dipped in ice-cold water to remove salts 
and dried under a stream of cold air.
Receptor density was assessed at the approximate K& (single concentration point) of 
[3H]RX821002 (1.0 nM) and [3H]rauwolscine (0.4 nM) for 012-adrenoceptor and
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a 2c-adrenoceptors, respectively. The is the concentration capable of saturating 
approximately half of the a 2-adrenoceptor binding sites in the brain area of interest. The 
use of a single concentration point simplified analysis. Also, saturation analysis cannot 
be reliably performed in brain areas possessing low amounts of the receptors of interest.
NSB of the radioligands was determined by parallel incubation of serial (1:5) sections in 
100 pM cold (-)adrenaline, to block the binding of [3H]RX821002 to a 2-adrenoceptors. 
Radiolabelled, dried tissue sections were apposed to tritium sensitive film (Hyperfilm 
[3H], Amersham Biosciences) along with [3H] microscales (Amersham Biosciences). 
After exposure for 8  weeks the films were manually developed using Kodak D-19 
developer (5min) and Amfix fix (5min).
The identification and nomenclature of brain structures was based on the rat brain atlas 
of Paxinos and Watson (1998).
2.10.5.4 Autoradiographic image analysis
Binding was quantified using image analysis. We used a Microcomputer Imaging 
Device (MCID). Here a video camera captures images from an X-ray film, illuminated 
by a constant light source. A digital image, made up of pixels of the labelled section, is 
produced. Pixels possess both spatial and grey value level characteristics. For the 
autoradiographic studies in this thesis, results were quantified using densitometric 
analysis. The densitometry results are expressed as grey levels (a series of shades 
ranging from black to white) and converted to units of optical density. Optical density 
can be converted to radioactivity per mass area by construction of a calibration curve. 
Grey values of standards of known radioactivity that have been co-exposed with the 
tissue sections during generation of the autoradiogram are used for calibration.
A calibration curve was, therefore, obtained by plotting optical density of [ H] 
calibration standards, co-exposed with tissue sections, against their radioactivity. 
Bilateral measurements were made from sections and averaged. NSB was subtracted 
from total binding. NSB was not above film background, which was, therefore, 
regarded as NSB. The regional amounts of bound radioactivity were converted to 
receptor density (Geary & Wooten, 1985). The results are expressed as finol radioligand
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bound / mg wet tissue. All data reported were from the linear optical density range 
required for densitometric analysis.
2 .11  Q u a n t it a  t iv e  a  u t o r a d io g r a p h y  o f  a d r e n a l in e -s t im u l a  ted
CC2-ADRENOCEPTOR-MEDIA TED f 5S] GTPyS BINDING
[35S]GTPyS autoradiography provides a novel approach to detect functional G protein 
activity of stimulated G protein-coupled receptors (GPCRs) in brain sections. One 
advantage afforded by this approach is that receptor signalling can be studied in 
anatomically defined brain structures. However, a complicating feature is the 
heterogeneously distributed signal in many brain regions under basal assay conditions. 
Endogenous adenosine, acting via Al receptors, to date, is the only identified factor that
1C
may contribute to this. [ S]GTPyS autoradiography predominantly detects signaling of 
receptors that couple to the Gi class of G proteins to which the a,2-adrenoceptors belong. 
The discovery of novel GPCRs in the nervous system e.g. the P2Y12 receptor has been 
facilitated by [ S]GTPyS autoradiography. It is, therefore, becoming increasingly 
evident that, in cryostat brain sections, the integrity of the signaling unit, which for a 
large number of GPCRs resides in specialized membrane microdomains, is better 
preserved compared to bulk membrane preparations, suggesting that constitutive
o r
receptor activity in native brain tissue may be rigorously addressed using [ SJGTPyS 
autoradiography.
2.11.1 Background to the technique
Activation of G protein-coupled receptors increases the rate of binding of [35S]GTPyS to 
G proteins (Lorenzen et al., 1993). When the 012-adrenoceptor is stimulated, GDP is 
released from the Gi/0 protein complex, allowing GTP to bind in its place. This causes 
dissociation of the a  subunit from the py subunits of the heterotrimeric G protein 
complex and the subsequent regulation of signal transduction systems within the cell 
(Figure 2.13). This biochemical step can be quantified by the use of the GTP analogue 
[35S]GTPyS which binds irreversibly to the a-subunit (Hilf et a l , 1989; Lazareno et al., 
1993). The system is normally turned off by the intrinsic GTPase activity of the a  
subunit hydrolysing GTP to GDP, as [35S]GTPyS is a nonhydrolysable GTP analogue 
this is prevented (Figure 2.14). This technique therefore allows the study of
76
Chapter 2: Materials and Methods
a 2-adrenoceptor activation proximal to adenylyl cyclase. As activation of G proteins is a 
functional consequence of G protein-coupled receptor stimulation, this assay provides a 
measure of functional activity.
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1) Resting state 2) Agonist Bound
GTP
3) Activation of effectors4) GTP hydrolysed
Effects:
Inhibition of AC 
XcAM P  
PKA
^ Effects:
I Opening o f Ca2+channels 
^Opening of G protein
t linked inwardly rectifying K+ channels
FIGURE 2.13: Coupling of the a 2 -adrenoceptor to G protein. a 2-Adrenoceptors are G 
protein-coupled receptors. 1) G protein receptors consist of three subunits anchored to the 
membrane through attached lipid residues. 2) Coupling of the a-subunit to a receptor 
occupied by an agonist causes exchange of GDP for intracellular GTP. 3) The a-GTP 
complex dissociates from both the receptor and Py complex to interact with its target, AC. 
The Py complex interacts with ion channels. 4) GTP-ase activity of the a-subunit is 
increased once AC is bound, leading to hydrolysis of GTP to GDP, and re-association of 
the a-subunit with the Py complex. AC; adenylate cyclase, cAMP; cyclic adenosine 
monophosphate, GDP; guanosine diphosphate, GTP; guanosine triphosphate, PKA; 
protein kinase A.
2) Agonist Bound1) Resting state
WWW
i i 5S )G T P y S
3) Activation of effectors
, Inhibition of AC a linked inw ardly rectifying
▼ cAMP I K+channels
|  PKA
FIGURE 2.14: Schematic representation of the use of non-hydrolysable [35S]GTPyS in 
investigating the functional activity of a 2-adrenoceptors. Agonist binding to the receptor, 
stimulates exchange of GDP for [35SlGTPyS, which has been included in the incubating 
medium. In the physiological situation GTP would normally hydrolysed to GDP. As 
GTPyS is a non-hydrolysable form of GTP, it remains permanently bound to the activated 
a-subunit. This allows quantification of the functional activity of the a 2-adrenoceptor, 
through measurement of the radio labelled signal.
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ot2-Adrenoceptors inhibit adenylyl cyclase activity via pertussis toxin-sensitive Gj/0 
proteins (Chabre et al., 1994; Pohjanoksa et al., 1997). Basal [35S]GTPyS binding is 
likely to represent [35S]GTPyS binding to many GTP-binding proteins. However, 
pertussis toxin-sensitive Gi/0 proteins comprise as much as 1 % of total membrane 
protein in the adult CNS and so represent the predominant subtype of GTP-binding 
proteins (Stemweis & Robishaw, 1984; Harmouch et a l , 1997). It is, therefore, more 
likely that the basal binding of GTPyS represents binding to Gi/0 due to the quantity and 
the favourable binding of [35S]GTPyS to Gi/0over Gs.
The [35S]GTPyS assay is well characterised for both the 5-HTia receptor (Sim et al., 
1995; Sim et al., 1997; Waeber & Moskowitz, 1997) (Fabre et al., 2000) and p opioid 
receptors (Sim & Childers, 1997). The autoradiographic distribution of 
a 2-adrenoceptors, however, has been difficult to detect.
2.11.2 Materials
[35S]GTPyS (1000-1500 Ci / mmol; guanosine 5’-(y-thio)triphosphate was purchased 
from Perkin Elmer. Adrenaline bitartrate, dithiothreitol (DTT), 
8-cyclopentyl-l,3,-dipropylxanthine (DPCPX), glycylglycine HC1, guanosine 
5’-0-(3-thiotriphosphate) (GTPyS), and guanosine 5’-diphosphate sodium (GDP), 
ethylene glycol-bis (2-aminoethylether-N,N,N’,N,-tetraacetic acid) (EGTA) were 
purchased from Sigma NaCl, MgCb were research grade.
2.11.2.1 Animals and tissue preparation
Male NK1-/- and NK1+/+ mice (25-30 g) were killed by an overdose of CO2 followed 
by decapitation. Brains were rapidly removed, frozen in isopentane (-40 ± 5 °C) and 
stored wrapped in cling film then foil at -80 °C until use, generally within five days. 
Brain sections (15 pm) were cut in the horizontal or coronal plane on a cryostat (Leica) 
and stored overnight with desiccant at -20 °C. For longer storage periods, sections were 
kept at -80 °C. Sections were brought to room temperature and air dried 30 min prior to 
use.
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Assay buffer for adrenaline-stimulated [35S]GTPyS binding assay
Assay buffer 1:
• 50mM HEPES
• lOOmM NaCl
• 3mM MgCb
• 0.2mM DTT
• 0.2 mM EGTA
Assay buffer 2:
The same as assay buffer 1 but substituted with;
• 2mM GDP
• 10pM DPCPX
Assay buffer 3:
The same as assay buffer 1 and 2 but substituted with;
• 2mM GDP
• 2mM DTT
• O.lnM GTPyS
•y r
Agonist-stimulated [ S]GTPyS binding conditions were based on those previously 
described by (Sim et al., 1995; Sim et al., 1997; Waeber & Moskowitz, 1997; Fabre et 
al., 2000) which we modified to increase signal: noise ratio (Happe et al., 1999; Happe 
et al., 2000; Happe et al., 2001; Happe et al., 2004; Bylund et al., 2001; Bylund et al., 
2001; Froger et al., 2001). The standard assay conditions used in this study were as 
follows:
Brain sections were preincubated at room temperature for an initial 15 min period in 
50mM HEPES sodium salt (4-(2-hydroxyethyl)-l-piperaine ethanesulphonic acid; 
sigma), pH 7.5, supplemented with 100 mM NaCl, 3 mM MgCfe, 0.2 mM EGTA, and 
2mM DTT (assay buffer 1), and then for another 15 min in the same buffer with 2 mM 
GDP dilithium salt (Sigma) and 10 pM DPCPX; an Ai adenosine receptor antagonist to 
decrease background labelling (assay buffer 2). Sections were then incubated for 2 h at 
30 °C in the same buffer with 0.1 nM [35S]GTPyS (1000 Ci / mmol) in either absence
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(basal conditions) or presence (stimulated conditions) of 100 pM adrenaline-bitartrate 
(assay buffer 3). Adrenaline was chosen as an agonist over noradrenaline as previous
• " X  ^studies have shown a 30-40 % lower noradrenaline-stimulated [ S] GTPyS binding in 
the LC compared to adrenaline (Happe et a l , 2000). NSB was determined in the 
presence of 100 juM cold RX821002 to block a,2-adrenoceptors. The use of an
o r
a 2-adrenoceptor antagonist, to block adrenaline-stimulated [ S]GTPyS binding, in this 
study demonstrates specificity of the drug action on a specific receptor type. The 
incubation was stopped by 2 x 2 min washes in ice-cold 50 mM HEPES, pH 7.5, and a 
brief immersion in ice-cold distilled water. Sections were dried under a stream of cold 
air and exposed to Kodak Biomax film for 24-72h. Films were developed by standard 
techniques 5 min in D-19 developer (Kodak, 21 °C), briefly immersed in distilled water 
followed by 5 min in AMFIX black and white fix. Films were analysed using a 
Microcomputer Imaging Device (MCID). When different film exposure times were 
required, film images were normalized using commercial 14C standards (Amersham 
biosciences) calibrated for S.
Results are expressed as mean ± s.e.m. of average measurements from n = 8 different 
mice. Agonist stimulated binding is expressed as percentage increase above baseline 
([stimulated-basal] / basal] x 100) ± s.e.m.) based on that described by (Froger et a l , 
2001).
2.12 A n a l  y s i s  o f  t h e  c o n c e n t r a  t i o n  o f  n o r a d r e n a l i n e  i n  n e u r o n a l  s t o r a  g e  
VESICLES OF NK1+/+ AND NK1-A MOUSE CORTEX
2.12.1 Tissue collection
Male (25-30 g) NK1-/- and NK1+/+ mice were killed by a blow to the head followed by 
cervical dislocation. Brains were removed and the cerebral cortex dissected out on ice.
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2.12.2 Preparation o f brain samples
2.12.2.1 Homogenisation
Cortical tissue was homogenised in 2 ml of a 0.3 M sucrose solution. Homogenate was 
transferred to a centrifuge tube. The homogenising tube was washed a further two times 
in 2 mis of sucrose solution and this solution added to the centrifuge tube.
2.12.2.2 Differential Centrifugation
The cortical homogenate was spun at 500 x g  for 10 min, to remove undisrupted tissue. 
The supernatant (Si) was decanted into clean centrifuge tubes, and temporarily stored 
on ice. To remove large organelles, such as nuclei and mitochondria, which form P2 , the 
Si supernatant (Figure 2.15) was then spun at 10,000 x g  for 25 min. From this, the S2 
supernatant was decanted to a clean centrifuge tube, balanced and temporarily stored on 
ice. The supernatant (S2) was then spun at 100,000 x g for 100 min. The final 
supernatant (S3) contains NA including both soluble, cytoplasmic NA and transmitter 
derived from leaky or disrupted storage vesicles (Von Euler 1967). 2 ml of 0.1 M 
perchloric acid (HCIO4) was added to the P3 pellet, which contains microsomes, 
including storage vesicles (Bisby & Fillenz, 1971), and the majority of NA, and 
homogenised briefly to precipitate the membrane proteins. 1 ml of the homogenate was 
then microfuged for 5 mins to compact the precipitate. The supernatant (S4 ) was 
decanted and stored at -18 °C, before measurement of NA content by HPLC / ECD. 
1 ml of 0.5 M NaOH was added to the remaining pellet and left at room temperature for 
estimation of protein content using the BCA method described in Section 2.9 (Figure 
2.15).
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Homogenate in 0.3 M Sucrose 500 g  10 min
Si 10 000 g 25 min
P2 S2 100 000 g 100 min
P3 S3
Microsomal Pellet 
containing NA storage vesicles
F ig u r e  2.1S: Pattern of differential centrifugation used for isolation of vesicular 
noradrenaline in these studies
2 .1 2 .3  Measurement of noradrenaline
A 1:10 dilution of the supernatant from each sample was made and 50 pi of the 
supernatant introduced to the HPLC microinjector. NA was analysed using HPLC / 
ECD as described in Section 2.4-5.
2 .1 2 .4  Estimation of protein content
This was achieved using BCA as described in Section 2.9.
2 .1 3  S t a t is t ic s
Details of the statistical analysis used for the studies contained in this thesis can be 
found in the protocol section of each chapter.
Discardedr s
Unbroken Cells Pi
& Nuclei
Crude Mitochondrial Pellet 
Containing Synaptosomes
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CHAPTER 3
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NORADRENALINE REUPTAKE INHIBITORS ON 
NORADRENALINE EFFLUX IN ANAESTHETISED NK1-/- AND
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3 EFFECT OF a 2-ADRENOCEPTOR ANTAGONISTS AND 
NORADRENALINE REUPTAKE INHIBITORS ON 
NORADRENALINE EFFLUX IN ANAESTHETISED NK1-/-
AND NK1+/+ MICE
3 .1  I n t r o d u c t io n  a n d  o v e r v ie w
Experiments presented in this chapter were aimed at replicating and extending pilot 
microdialysis studies conducted in this laboratory. These pilot studies, conducted under 
continuous halothane anaesthesia, demonstrated a 2 -fold higher basal noradrenaline 
(NA) efflux in NK1-/- mice compared to their NK1+/+ counterparts. These results could 
be explained in a number of ways, as changes in the concentration of extracellular 
transmitter, found by microdialysis, can be attributed to either an increase in NA release, 
inhibition of reuptake, or both. Microdialysis measures changes in efflux which is 
highly regulated by both ct2-adrenoceptors and the noradrenaline transporter (NAT). 
One way to distinguish between these processes is through application of either a 
noradrenaline reuptake inhibitor, for example desipramine (DMI), or administration of 
an ct2-adrenoceptor antagonist, for example RX821002. Local administration of DMI 
would inhibit clearance of released NA from the synaptic cleft, whereas systemic 
administration of the ct2-adrenoceptor antagonist, RX821002, would block the 
autoreceptor and consequently increase firing-rate of locus coeruleus 
(LC)-noradrenergic neurones and release of NA. Administration of both DMI and 
RX821002 would provide a more realistic indication of the full potential for release and 
were, therefore, used in the experiments described here to investigate the underlying 
mechanisms of increased NA efflux in NK1-/- mice.
3.1.1 Basal noradrenaline efflux in halolhane-anaesthelised NK1-/- mice
3.1.1.1 Effect of ct2-adrenoceptor antagonists
(X2-Adrenoceptors are located on both the cell bodies and terminals of noradrenergic 
neurones where they act to control LC noradrenergic neuronal firing and release of NA, 
respectively (Aghajanian et al., 1977; Cedarbaum & Aghajanian, 1976) (Figure 3.1).
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The hypothesis for the present studies is that the difference in basal NA efflux, between 
the two genotypes, is mainly due to a downregulation or desensitisation of these 
a 2-autoreceptors. To this end, the effect of systemic administration of the 
a 2-adrenoceptor antagonist, RX821002, on NA efflux was compared in the two 
genotypes, to provide a better insight into the function of somatodendritic and 
terminally located 012-adrenoceptors (Figure 3.2; see Section 1.5 for a detailed 
description of why RX821002 was chosen for these studies). If the function of the 
a 2-adrenoceptor is impaired in the NK1-/- mice, we would predict that systemic 
administration of RX821002, which would block the activation of 012-adrenoceptors 
located on both the cell bodies and terminals, would lead to a greater incremental 
increase in NA efflux in NK1+/+ mice (Figure 3.2).
Figure 3.1: 012-Adrenoceptors under 
normal resting conditions. The 
concentration of extracellular 
noradrenaline (NA) depends on a 
balance between activity-dependent 
exocytotic NA release, its reuptake 
•  into nerve endings via the NAT and
tonic activation of autoregulatory a 2-adrenoceptors. ct2-Adrenoceptors exert 
control over release of NA at nerve terminals and neuronal firing-rate at the level 
of cell bodies of the LC.
•  •
•  •
Figure 3.2: Systemic
administration o f RX821002. 
Systemic RX821002 antagonises 
012-adrenoceptors located on the 
cell body and terminals and so 
increases cell firing and release of
NA. However, reuptake of NA by the NAT may mask any differences in release.
• (X2-adrenoceptor
• ot2-adrenoceptor antagonist
& Noradrenaline transporter
Hr Firing-rate
• Noradrenaline
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Herpfer et al., (2005), by infusing RX821002 (1.0 pM and 10 pM) into the frontal 
cortex, investigated terminal control of NA release (Figure 3.3). Following RX821002 
infusion, NA efflux was increased in both genotypes, suggesting that tonic activation of 
(X2-adrenoceptors, located in the terminal field, constrains the spontaneous release of
Figure 3.3: In the studies by 
Herpfer et al., (2005) infusion of 
RX821002 into the frontal cortex 
antagonises a 2-adrenoceptors
located on the terminals, increasing 
release of NA. Any change in 
extracellular efflux of NA would 
provide evidence for the tonic 
inhibitory influence of
<X2-adrenoceptors in the terminal 
field of the two genotypes. However, 
reuptake of NA by the NAT may 
diminish any differences in release.
3.1.1.2 Effect o f noradrenaline reuptake inhibition on noradrenaline efflux in NK1 +/+ 
and NK1-/- mice
Different densities of the NAT are found across different brain areas receiving 
noradrenergic innervation. Autoradiographic studies have shown that the highest 
density of the NAT is found in the LC (Moore & Bloom, 1979; Tejani-Butt, 1992). In 
situ hybridization studies have shown that mRNA for the NAT is found exclusively in 
noradrenergic neurones (Lorang et al., 1994). Selective expression of the NAT on 
noradrenergic neurones, allows spatial and temporal control over the actions of NA 
(Pacholczyk et al., 1991). By controlling the availability of synaptic NA, the NAT 
contributes to the regulation of adrenoceptor signalling; disruption of the NAT gene 
results in perturbations in NA homeostasis (Xu et al., 2000). DMI is a well known 
tricyclic antidepressant, which inhibits the Na+/ Cl' dependent NAT. DMI is commonly 
used in microdialysis studies and has generally been shown to increase NA efflux 
(Mateo et al., 1998; Sacchetti et al., 2001; Beyer et al., 2002; Garcia et al., 2004;
NA in both NK1+/+ and NK1-/- mice.
•  •
•  •
• a 2-adrenoceptor
) ct2-adrenoceptor antagonist
Noradrenaline transporter
Firing-rate
• Noradrenaline
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Femandez-Pastor et al., 2005). Since the DMI-induced increase in NA efflux is 
constrained by both somatodendritic and terminally located autoregulatory 
a 2 -adrenoceptors, acting to control release of NA or firing-rate of LC neurones (Mateo 
et al., 1998; Dennis et al., 1987), the increase in NA efflux will depend on the tonic rate 
of NA release.
Herpfer et al, (2005), using systemic DMI (10 mg / kg i.p.), showed the same 
incremental increase in NA efflux in NK1+/+ and NK1-/- mice (Figure 3.4; (Herpfer et 
al., 2005)). This suggests that the amount of NA cleared by the NAT is the same in both 
genotypes. However, since systemic DMI inhibits both somatodendritically and 
terminally located NATs, systemic DMI does not distinguish the function of the NAT at 
these separate areas. Local infusion of DMI into either the frontal cortex or LC would 
help to elucidate the function of the NAT located at these areas. Therefore, these current 
studies infused DMI (5 pM followed by 50 pM) into the terminal field (Figure 3.5).
Figure 3.4: Systemic administration 
o f DMI inhibits the NAT on the cell 
body and terminals. Consequently 
both <X2-adrenoceptors located on 
the cell bodies and terminals are 
activated preventing a further rise 
in extracellular NA. Systemic DMI 
increases NA efflux to the same
extent in both NK1+/+ and NK1-/- mice (Herpfer et a l 2005)
a 2-adrenoceptor
•  •
Noradrenaline transporter 
*  Noradrenaline transporter inhibitor
Firing-rate 
•  Noradrenaline
Figure 3.5: Infusion o f DMI into 
the frontal cortex inhibits the NAT 
on noradrenergic terminals. This 
would increase extracellular NA in 
the terminal field. However, 
<X2-adrenoceptors on the terminals 
would constrain this release.
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The rise in terminal NA following local DMI infusion will activate terminal 
(X2-adrenoceptors constraining further release of NA. However, somatodendritic 
(X2-adrenoceptors are unlikely to be affected leaving firing-rate unchanged (Figure 3.5). 
Systemic administration of DMI, alone, is likely to produce an increase in NA at the 
level of both the cell bodies and terminal regions, consequently activation of 
ot2-adrenoceptors, located somatodendritically and at terminal regions, will suppress 
both firing-rate of LC neurones and release of NA, preventing a further increase in NA 
efflux and possibly even leading to a decrease in NA efflux (Figure 3.4). It is, therefore, 
possible that local cortical infusion of DMI may result in a larger increase in NA efflux, 
compared to systemic administration of DMI.
Since local DMI would block the uptake of released NA in the terminal field, only, we 
would expect to see an increase in NA efflux in both NK1+/+ and NK1-/- mice. This 
increase in NA efflux may be constrained by the terminal autoregulatory 
012-adrenoceptors in NK1+/+ mice (Figure 3.5). As we believe the ot2-adrenoceptors to 
be less efficient in NK1-/- mice, it is possible that DMI infusion into the cortex may 
result in a greater incremental increase in these animals due to impaired negative 
feedback on NA release, exerted by a 2-adrenoceptors.
Furthermore, an increase in NA efflux in NK1+/+ or NK1-/- mice following systemic 
administration of an 012-adrenoceptor antagonist may be masked by sequestration of NA 
through the NAT. Comparison of the results from local infusion of DMI, with those 
produced by systemic administration of RX821002, alone, should determine the extent 
to which the terminal NAT, masks an increase in NA release. Because microdialysis 
probes usually have an efficiency of 10 %, and concentrations of perfusates decrease 
with increasing distance from the probe, despite infusing DMI at a concentration of 5 
and 50 pM, the NAT in the terminal field will see only a fraction of this concentration. 
However, at concentrations of 5 and 50 pM the K\ for the rat NAT (7.36 nM) is likely to 
be reached.
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3.1.1.3 Combining systemic a2~adrenoceptor antagonists and local noradrenaline 
reuptake inhibition in NK1+/+ and NK1-/- mice
Combining (X2-adrenoceptor antagonists with noradrenaline reuptake inhibitors, and 
altering their routes of administration (systemic versus cortical infusion), enables a 
clearer insight into differences in the rate of release between NK1+/+ and NK1-/- mice. 
Blockade of the NAT means that possible differences in the rate of release of NA are no 
longer masked by clearance through the NAT. Invemizzi & Garattini, (2004) and Nutt 
et al., (1997) combined systemic administration of a noradrenaline reuptake inhibitor, 
e.g. DMI, with systemic administration of an a,2-adrenoceptor antagonist e.g. RX821002 
and demonstrated a marked enhancement of the increase in extracellular NA induced by 
the noradrenaline reuptake inhibitor. However, these experiments give no indication of 
whether the potentiation of NA efflux is through blockade of somatodendritic 
a 2-adrenoceptors, located on noradrenergic neurones in the LC and / or terminal 
a 2 -adrenoceptors. In the studies performed by Herpfer et al., (2005) infusion of 
RX821002 (0.1 and 1.0 pM) via retro-dialysis, into the frontal cortex, increased NA 
efflux to a greater extent in DMI-pre-treated NK1+/+ mice, than in N K 1-/- mice. DMI 
pre-treatment did not augment the increase in NA induced by RX821002 infusion in 
NK1-/- mice. These findings suggest that terminal ot2-adrenoceptors are functioning 
differently in NK1+/+ and NK1-/- mice.
90
Chapter 3: Microdialvsis in anaesthetised NK1 +/+ and NK1-/- mice
If a 2-adrenoceptors are downregulated or desensitised in NK1-/- mice, then combining 
systemic administration of an ci2-adrenoceptor antagonist should have little, or no effect, 
on the incremental increase in NA efflux following cortical infusion of DMI. In 
contrast, in NK1+/+ mice a 2-adrenoceptors should constrain any increase in NA efflux 
following DMI infusion. As a consequence combining an 012-adrenoceptor antagonist 
systemically with local DMI should result in a greater incremental increase in NA efflux 
in NK1+/+ mice, compared with NK1-/- mice (Figure 3.6) as seen previously (Herpfer 
et al., 2005).
Figure 3.6: Systemic administration o f 
RX821002 in combination with DMI 
infused into the frontal cortex. 
RX821002 antagonises
<X2 -adrenoceptors located on the cell 
•  •  •  •  body and terminals, increasing cell
firing and release o f NA. A difference 
in the rate of release should no longer be masked by reuptake in the frontal cortex 
and cause a marked enhancement of NA efflux.
a 2-adrenoceptor 
012-adrenoceptor antagonist 
Noradrenaline transporter 
♦  Noradrenaline transporter inhibitor
Firing-rate 
# Noradrenaline
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3.1.2 Aims
The experiments described in this chapter were designed to complement those
performed by (Herpfer et al., 2005). The main aim was to provide evidence that the
(X2-adrenoceptor mediated regulation of NA release is impaired in NK1-/- mice.
The objectives were to:
1. Confirm the preliminary findings, in anaesthetised mice, that NK1-/- mice 
display higher basal efflux o f NA in the frontal cortex when compared with their 
wildtype counterparts (Fisher et al., 2003.,2004; Stewart et al., 2004;(Herpfer et 
al., 2005)).
2. Explore whether the difference in basal NA efflux, in NK1+/+ and NKl-/~ mice 
could be attributed to impairment in the function o f a2-adrenoceptors, and 
whether an increase in NA release is masked by clearance through terminally 
located noradrenaline transporters.
This involved determining the effect of systemic administration of RX821002, alone, on 
NA efflux in NK1+/+ and NKl-/-mice. Systemic administration of RX821002 would 
inhibit both somatodendritic 012-adrenoceptors which govern cell firing, and terminal 
ct2-adrenoceptors, which govern release. However, reuptake of NA by the NAT in the 
terminal field could mask increased release of NA, following antagonism of the 
a 2-adrenoceptors, alone. To determine the contribution made by the terminal NAT to 
clearance of NA, NA efflux, following local infusion of DMI into the frontal cortex, 
was monitored in both NK1+/+ and NK1-/- mice. By combining systemic 
administration of RX821002, with local infusion of DMI into the terminal field, thereby 
excluding the influence of clearance through the NAT, we were further able to 
determine the full potential for NA release governed by ct2-adrenoceptors.
92
Chapter 3: Microdialvsis in anaesthetised NK1+/+ and NK1-/- mice
3 .2  P r o t o c o l s
All procedures complied with the Animals (Scientific Procedures) Act 1986. Adult (6-8 
weeks, 25-30g) male NK1-/- and NK1+/+ mice (n=4) for experiment 1 and (n=9) for 
experiment 2 were used. Probes were implanted as described in Section 2.6.1. 
Experiments started at 08:00 a.m. every day.
3.2.1 Experiment 1: Systemic administration of RX821002 alone
NK1+/+ and NK1-/- mice were divided randomly into groups destined for either saline 
or RX821002 treatment. Once a stable baseline had been achieved, RX821002 
(0.3 mg / kg i.p.) or saline was administered, and sampling continued for a further 240 
min. [This dose was chosen based on preliminary pilot studies. At the 10-fold higher 
dose of 3 mg / kg i.p. the mortality rate in NK1-/-, but not NK1+/+ mice, was 
unacceptable].
3.2.2 Experiment 2: Systemic RX821002 in combination with intracortical DMI 
infusion
NK1+/+ and NK1-/- mice were divided randomly into two groups and given one of the 
following treatments:
• Systemic administration of saline followed by cortical DMI infusion at 5 pM 
and 50 pM.
• Systemic administration of RX821002 (0.3 mg / kg i.p.) followed by cortical 
infusion of DMI at 5 pM and 50 pM.
Three basal samples were collected to ensure a stable baseline, RX821002 
(0.3 mg / kg i.p.) was administered and a further 2 x 20-min samples were collected. 
Ringer’s solutions containing 5 pM and 50 pM of DMI were then infused, via 
retro-dialysis, 40 min after injection of RX821002, at which time the NA efflux 
response to RX821002 had stabilised (see experiment 1). 3 x 20-min dialysis samples 
were collected, at each concentration (Figure 3.7).
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‘Binl’ ‘Bin2’ ‘Bin3’
T ^ o  T - 2o T o  T 2 0  T 4 0  T o o  T s o  T 100  T 1 2 0  T 1 4 0  T 1 6 0
5 pM DMI 50 pM DMI
RX821002 / Saline
Figure 3.7: Schematic of the dosing protocol and the definition of the 'bins' used in 
analysis of the data.
The concentration of NA in the dialysate samples was determined using HPLC / ECD 
as described in Sections 2.4-2.5. Data are expressed as mean ± s.e.m. fmol / 20 min 
noradrenaline concentration, without correction for probe recovery.
3.2.3 Data Analysis
Statistical analysis was performed on both raw and net changes in efflux. Net values 
were calculated by subtracting the mean of three consecutive ‘basal’ samples from all 
the dialysis samples of an individual animal see: (Dailey et al., 1996). When comparing 
drug-induced changes and basals, statistical analysis of the raw data was carried out. All 
microdialysis data were analysed using 3-way repeated measures ANOVA in SPSS PC+. 
‘Time’ was considered a ‘within subjects’ factor. When looking for genotype dependent 
effects of drug, ‘drug treatment’ and ‘genotype’ were the between subjects factors. If an 
overall effect of ‘time’, ‘drug treatment’, ‘genotype’, or an interaction between them, 
was found, using multifactorial ANOVA, data for a single factor were further 
investigated using least significant difference (LSD) multiple comparisons post-hoc 
analysis. This allowed us to identify differences between the different groups. When 
efflux was compared with basal levels, the analysis was carried out in bins of three 
consecutive samples.
For these studies:
• ‘binl ’ = Basal samples ( T . 40 - T 0 )
• ‘bin2’ = 5 pM DMI (T60-Tioo)
• ’bin3’ = 50 pM DMI (Ti2o-T16o)
See Figure 3.7 for the schematic of the ‘bins’ used in these studies.
94
Chapter 3: Microdialvsis in anaesthetised NK1+/+ andNKl-/- mice
If data violated the Mauchley’s test for sphericity, then the Greenhouse-Geisser ‘s ’ 
correction was used. A value of P < 0.05 was required for statistical significance.
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3 .3  R e s u l t s
3.3.1 Experiment one: Effect of systemic RX821002 on noradrenaline efflux
Between T0-T120 following either RX821002 (0.3 mg / kg i.p.) or saline (10 ml / kg i.p.) 
there was a main effect o f ‘genotype’ (Fi,i2 = 16.52; P = 0.002; T20-T120; Figure 3.8a-b) 
and a ‘genotype x drug’ interaction (Fi,i2 = 6.04; P = 0.03; T20-T120), demonstrating a 
drug dependent change in NA efflux, which was different between genotypes. For 
180-min after systemic administration of either RX821002 (0.3 mg / kg i.p.) or saline 
(10 ml / kg i.p.) a main effect of ‘genotype’ (Fi,i2 = 13.57; P = 0.003; T20-T180) was still 
observed but the ‘drug x genotype’ interaction just failed to match the criterion for 
significance (Fi,i2 = 4.67; P = 0.052).
3.3.1.1 Basal efflux differed between NK1-/- and NK1 +/+ mice
Mean basal efflux in the frontal cortex of NK1-/- mice was 8.99 ± 2.2 fmol / 20 min. 
This was higher than basal efflux (1.73 ± 0.23 fmol / 20 min) in the NK1+/+ mice 
(FU5 = 19.69; P = 0.001) (Figure 3.8a-b).
3.3.1.2 Effect o f saline injection on NK1+/+ and NK1-/- mice
Systemic administration of 0.9 % saline (10ml / kg i.p.), at To, had no effect on NA 
efflux in either NK1-/- (F2,6 = 1.56; P = 0.29) or NK1+/+ ( F 1,3 = 2.99; P = 0.19) mice, 
over the 240 min of the experiment (Figure 3.8a). Although, in NK1-/- mice, there was 
an apparent increase in NA efflux after the injection of saline, this did not differ from 
baseline. The higher NA efflux in NK1-/- mice, compared to NK1+/+ mice, was 
maintained throughout the experiment (Fi,6 = 19.84; P = 0.007; T0-T240; ‘genotype’; 
Figure 3.8a).
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3.3.1.3 RX821002 (0.3 mg /  kg i.p.) increased noradrenaline efflux in NK1+/+ mice 
only
Post-hoc analysis was performed over the T0-T120 min post-injection of RX821002. This 
revealed that RX821002 increased NA efflux in the frontal cortex of NK1+/+ only, 
compared to basals, and abolished the difference in NA efflux in NK1+/+ and NK1-/- 
mice (Figure 3.8b). After treatment with RX821002, the NA efflux in NK1+/+ mice, 
was not different from that in NK1-/- mice treated with RX821002 (P = 0.278; Figure 
3.8b). NA efflux in NK1+/+ mice after RX821002 (0.3 mg /kg i.p.), was greater than 
NK1+/+ mice treated with saline (P = 0.024; Figure 3.8d) but not different from NK1-/- 
mice treated with saline (P = 0.064). RX821002 had no effect on NA efflux in NK1-/- 
mice (Figure 3.8c).
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FIGURE 3.8a-d: Effect of RX821002 (0.3 mg / kg i.p.) on noradrenaline 
efflux in halothane-anaesthetised NK1+/+ and NK1-/- mice. RX821002 
increased noradrenaline efflux in NK1+/+ mice, only. This increase 
abolished the genotype dependent difference in cortical noradrenaline 
efflux. Values are expressed as mean ± s.e.m. n = 4. * = P  ^0.05; ** = P ^ 
0.001.
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3.3.2 Experiment two: Effect of intracortical infusion o f desipramine on RX821002 
induced increase in noradrenaline efflux
This experiment examined NA efflux in four groups:
• Groups 1 and 2: Systemic administration of saline followed by cortical DMI 
infusion at 5 pM and 50 pM in both NK1+/+ and NK1-/- mice.
• Groups 3 and 4: Systemic administration of RX821002 (0.3 mg / kg i.p.) 
followed by cortical infusion of DMI at 5 pM and 50 pM in both NK1+/+ and 
NK1-/- mice.
The results describe, first, whether RX821002 increases NA efflux over the 40 min 
pre-treatment time. Groups 1 and 2 are then analysed to determine the effect of DMI 
infusion, alone, on NA efflux in NK1+/+ and NK1-/- mice. The results then describe the 
comparison between all four groups to determine if pre-treatment with RX821002 
potentiates the DMI induced increase in NA efflux. The following results are from one 
fully randomised experiment.
3.3.2.1 Effect o f genotype on basal noradrenaline efflux
As with experiment 1 (Figure 3.8), there was a marked difference in basal NA efflux in 
NK1+/+ and NK1-/- mice. Mean basal efflux in the frontal cortex of NK1-/- was 6 ± 1.5 
fmol / 20 min and this was higher than the mean basal efflux of 2 ± 1 fmol / 20 min in 
the NK1+/+ mice (Fi,28 = 6.06; P = 0.02 ‘genotype’; Figure 3.9a-b).
Over the 40 min post injection of RX821002, analysis of the raw data showed that NA 
efflux differed with genotype (‘time x genotype’ interaction; F3J 6 = 3.03 P = 0.036; 
T0-T40; Figure 3.9b-c), and that the increase in NA efflux was dependent on the drug 
(‘time x drug’ interaction; F3 76 = 4.18; P = 0.009) in both genotypes. Analysis of the net 
change in NA efflux from T0-T40 post-injection of RX821002 at To, revealed a 
‘genotype x drug’ interaction (Fi,27 = 7.3; P = 0.012 T0-T40; Figure 3.10b-c), 
demonstrating an effect of RX821002 on NA efflux which differed between genotypes.
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3.3.2.2 RX821002 pre-treatment increases cortical noradrenaline in NK1+/+ mice, 
only
LSD post-hoc analysis showed that RX821002 increased the net efflux of NA in 
NK1+/+ mice, only (Figure 3.10b-c). The net increase in NA efflux in NK1+/+ mice 
was greater than that in NK1-/- mice (P = 0.001) following treatment with RX821002, 
and, greater than that in saline treated NK1+/+ (P = 0.006) and NK1-/- (P = 0.005) mice. 
No difference between individual groups was revealed by LSD post-hoc analysis of raw 
data (Figure 3.9b-c).
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FIGURE 3.9a-d: Raw data. Effect of DMI infused into the frontal cortex 
alone, and combined with RX821002 pre-treatment in NK1+/+ and 
NK1-/- mice. RX82I002 (0.3 mg / kg i.p.) increased noradrenaline 
concentration in NK1+/+ mice, only. DMI increased noradrenaline 
efflux at a concentration of 50pM only, and only in NK1+/+ mice. Pre­
treatment with RX821002 did not potentiate the increase in 
noradrenaline efflux in either genotype.Values are mean ± s.e.m. $ = P  ^
0.05 c.f NK1-/-; **=P<, 0.05 c.f. basal; # = P <> 0.05 c.f. 5 pM; n = 9.
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FIGURE 3.10a-d: Net noradrenaline efflux. Effect of DMI infused into 
the frontal cortex alone and combined with RX821002 pre-treatment in 
NK1+/+ and NK1-/- mice. RX821002 (0.3 mg / kg i.p.) increased 
noradrenaline concentration in NK1+/+ mice, only. DMI increased 
noradrenaline efflux at a concentration of 50pM only, and only in 
NK1+/+ mice. Pre-treatment with RX821002 did not potentiate the 
increase in noradrenaline efflux in either genotype.Values are mean ± 
s.e.m. * = P  ^ 0.05 c.f. basal; # = P   ^ 0.05 c.f. 5 pM; $ = P   ^ 0.05 c.f. 
NK1-/-; o = P ^ 0.05 c.f. saline treatment; n = 9.
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3.3.2.3 Intracortical infusion o f DMI increases noradrenaline efflux in NK1+/+ mice, 
only
To determine the effect of intracortical infusion of DMI alone, on NA efflux, only saline 
pre-treated NK1+/+ and NK1-/- mice were included for this analysis.
In saline pre-treated mice, DMI increased NA efflux ^ 3,29 = 3.04; P = 0.041; T.40-T16O; 
‘time’), but this differed across genotypes (F3.27,29.4 6 = 2.91; P = 0.047; T-40-T160; ‘time x 
genotype’ interaction). Infusion of 5 pM DMI had no effect in either genotype (Figure 
3.9 and 3.10). However, in NK1+/+ mice only, NA efflux was increased by 50 pM DMI 
compared to both basals and 5 pM DMI (Figure 3.9 and Figure 3.10). See footnote1 for 
statistics used to support this conclusion.
LSD post-hoc analysis did not reveal a difference between the groups. However, 
analysis of saline pre-treated NK1+/+ mice, only, showed that 50 pM DMI ‘bin3’, 
increased NA efflux compared to basals ‘binl’ (Fij = 20.97; P = 0.003) and 5 pM DMI 
‘bin2’ (Fi 6 = 18.05; P = 0.005). There was no effect of DMI at any concentration in 
saline pre-treated NK1-/- mice.
1 Raw data:
‘Binl’ (basals; T-40-T0) versus ‘bin3’ (50 pM DMI; T120-T160): F^n = 5.91; P = 0.033. 
‘Bin x genotype’ interaction: Fi.n = 7.09; P = 0.022.
LSD post-hoc analysis did not reveal a difference between groups.
‘Bin2’ (5 pM DMI, T60-T100) versus ‘bin3’ (50 pM DMI, T120-T160): Fi,io = 5.64; 
P = 0.039.
‘Bin x genotype’ interaction: Fijo =10.47; P = 0.009.
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3.3.2.4 Systemic administration o f RX821002 followed by cortical infusion o f DMI 
does not potentiate noradrenaline efflux in either genotype
To determine if pre-treatment with RX821002, potentiated the DMI induced increase in 
NA efflux compared with saline pre-treatment, all treatment groups were included in 
this analysis.
Analysis of the raw data showed that NA efflux increased with time across all groups: 
main effect of ‘time’ (1*3,5 5 = 5.59; P = 0.002; T60-T160; Figure 3.9a-d). Analysis of the 
net increase in NA efflux, showed that this increase in NA efflux was different between 
genotypes (F4/71 = 2.6; P = 0.043; T60-T160; ‘time x genotype’; Figure 3.10a-d).
Analysis of the raw data showed that infusion of 50 pM DMI increased NA efflux 
compared to 5 pM DMI: ‘bin2’ (5pM DMI, T60-T100) versus ‘bin3’ (50pM DMI, 
T120-T160)' F 1,19 = 7.24; P = 0.014; main effect of ‘bin’. This main effect of ‘bin’ was 
different between NK1+/+ and NK1-/- mice (‘bin x genotype’ interaction: Fi,i9 = 6.11; 
P = 0.023). However, no difference between groups was found using LSD post-hoc 
analysis.
Analysis of the net data also showed a main effect of ‘bin’ (Fi i9 = 7.24; P = 0.014) and 
an overall ‘bin x genotype’ interaction (F 1,19 = 6.11; P = 0.023). LSD post-hoc analysis 
showed no increase in NA efflux in NK1-/- mice pre-treated with either saline or 
RX821002 over the entire experiment. LSD post-hoc analysis revealed the net increase 
in NA efflux caused by 50 pM DMI in RX821002 pre-treated NK1+/+ mice was greater 
than both saline (.P = 0.001) and RX821002 (P = 0.049) pre-treated NK1-/- mice. Net 
NA efflux induced by 50 pM DMI was not different between RX821002 and saline 
pre-treated NK1+/+ mice, showing that pre-treatment with RX821002 did not potentiate 
the increase in NA efflux when DMI was infused into the frontal cortex, suggesting 
release rate was maximal already.
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3 .4  D is c u s s io n
3.4.1 Main findings from these studies
3.4.1.1 Genetic disruption of the NK1 receptor increases noradrenaline efflux in 
halothane-anaesthetised NK1-/- mice
Basal NA efflux in anaesthetised NK1-/- mice was 4-5 fold higher than the NK1+/+ 
counterparts, supporting previous studies in this laboratory (Fisher et al., 2003; Stewart 
et al., 2004; Herpfer et al, 2005).
3.4.1.2 Systemic RX821002 increases noradrenaline efflux in NK1+/+ mice, only
Systemic administration of the a 2-adrenoceptor antagonist, RX821002 (0.3 mg / kg i.p.), 
increased NA efflux in the frontal cortex of halothane-anaesthetised NK1+/+ mice, only, 
and the genotype-dependent difference in NA efflux was abolished. Systemic 
administration of RX821002 would antagonise a 2-adrenoceptors at the level of cell 
bodies in the LC and on terminals. A reduction in ct2-adrenoceptor inhibitory function 
would be expected to increase NA release and blunt the response to drugs acting at 
these receptors in NK1-/- mice. Therefore, the lack of effect of RX821002 in NK1-/- 
mice can be attributed to an impaired function of either somatodendritically or 
terminally located ot2-adrenoceptors. The RX821002-induced increase in NA efflux in 
NK1+/+ mice is in agreement with studies in rats (Meana et al., 1997; Hudson et al., 
1999). The increase in NA efflux in NK1+/+ mice, only, following systemic RX821002, 
suggests that reuptake through the terminal NAT, does not conceal a genotype 
dependent difference in the release rate of NA.
It has been suggested that NK1 antagonists attenuate the responsiveness of 
a 2-adrenoceptors, to systemic injection of the a 2-adrenoceptor agonist clonidine 
(Haddjeri & Blier, 2000). This attenuated response to clonidine after administration of 
an NK1 receptor antagonist may generalise to an attenuated response of 
a 2-adrenoceptors to the endogenous agonist NA in NK1-/- mice, and hence an increase 
in basal NA efflux. Attenuation of the negative feedback role exerted by
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a 2-adrenoceptors in NK1-/- mice would tend to increase NA, as well as decreasing the 
response to systemic administration of ot2-adrenoceptor antagonists such as RX821002.
3.4.1.3 Cortical infusion of desipramine increases noradrenaline efflux in NK1+/+ mice, only
The results presented here show that a 5 pM DMI infusion does not increase NA efflux 
in either NK1+/+ or NK1-/- mice. Infusion of 50 pM DMI increased NA efflux 
compared to basal, but only in NK1+/+ mice, confirming regulation of NA release 
differs between the two genotypes. This suggests that although reuptake through the 
NAT does not mask a difference in NA release, between NK1+/+ and NK1-/- mice 
following systemic RX821002, some of the released NA is normally cleared by 
reuptake through the NAT in NK1+/+ mice, only.
The lack of effect of local cortical infusion of DMI on NA efflux in NK1-/- mice is 
intriguing. If the autoregulatory (X2-adrenoceptors are desensitised in NK1-/- mice, a 
substantial increase in NA efflux would be expected following infusion of DMI. As 
Stewart et al., (2004) have demonstrated an increase in NA efflux when 5 pM DMI was 
infused into the frontal cortex, the lack of effect of DMI on NA efflux in NK1-/- mice 
cannot be explained by a fault with the terminal NAT.
The extracellular concentration of DMI when it is infused through the microdialysis 
probe is not possible to determine. This is because the drug concentration will form a 
gradient which decreases with increasing distance from the probe. Assuming a probe 
efficiency of 10 %, the concentration of DMI surrounding the probe will be well within 
the range of the K\ (7.36 nM; Table 3.1) for the NAT. Therefore, the lack of effect of 
DMI, on NA efflux in NK1-/- mice, is unlikely to be due to infusion of a concentration 
unable to block the NAT fully.
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p/fi Value ± s.e.m. (A values in parentheses)
Rat NAT Human NAT Bovine NAT
Compound
(-)-Adrenaline 5.187±0.040 
(6.50 pM)
5.435 10.034 
(3.68 pM)
5.301 10.033 
(5.00 pM)
Desipramine 8.1310.091 
(7.36 nM)
8.0691 0.046 
(8.54 nM)
8.052 1 0.023 
(8.88 nM)
T a b l e  3.1: pAj and K\ values for adrenaline and DMI inhibition of noradrenaline 
uptake in COS-7 cells expressing the rat, human, or bovine NAT. IC5 0 values were 
calculated from percent inhibition of specific uptake of [3H]noradrenaline (lOnM). 
Each ICso value was converted into a K\ value according to Cheng and Prussoff 
method assuming competitive inhibition. Adapted from (Paczkowski et al., 1999).
Using the isolated perfused rat heart two distinct mechanisms of uptake of NA have 
been identified (Iversen, 1965), each having characteristics of a saturable active 
transport system, and possess strikingly different drug sensitivities. The two distinct 
mechanisms are identified as uptake 1 and uptake 2 corresponding to neuronal and 
extraneuronal uptake, respectively. The DMI-sensitive NAT mediates the high affinity 
uptake 1 of NA, with a low maximum rate of uptake. Uptake 2 has a low affinity and 
transports adrenaline, isoprenaline, and NA at a much higher maximum rate.
It is possible that NA clearance, through uptake 1 in NK1-/- mice, is constrained by a 
‘ceiling’ effect, due to the low maximum rate of uptake of this transporter and the 
higher basal efflux of NA in NK1-/- mice. For this reason, inhibition of the NAT in 
NK1-/- mice may not result in an increase in NA, since the NAT is not removing a 
substantial amount of NA from the synaptic cleft. Competition between DMI and the 
high NA efflux in NK1-/- mice, for the binding site on the NAT, may also result in an 
increase in the I C 5 0  of DMI required to inhibit the NAT in these animals.
Another reasonable explanation, for the lack of effect of DMI in NK1-/- mice, is that the 
higher basal NA efflux in anaesthetised NK1-/- mice means that these animals are 
primed for removal of NA from the extracellular space, in order to maintain a 
homeostatic concentration of NA. It is possible that, in NK1-/- mice, reuptake through
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alternative transporters for example the dopamine (DA) or even (but less likely) the 
serotonin (5-HT) transporters, which belong to the same subfamily of 
Na+/Cl -dependent transporters as the NAT, masks the increase in NA efflux following 
local infusion of DMI. Although the DA (Giros et al., 1994) and 5-HT (Pacholczyk et 
al, 1991) transporters are not very efficient at removing NA (Kx 10 000 nM), a role for 
these low affinity transporters could be important in situations where there are high 
amounts of NA. It is possible that a developmental consequence of disruption of the 
NK1 receptor, and the need to remove higher amounts of NA, has meant that they have 
become more efficient at removing NA or are even upregulated in NK1-/- mice.
Alternatively, the extracellular NA in NK1-/- mice may be taken up through a DMI 
insensitive, apparently fluoxetine sensitive transporter, located at non-noradrenergic 
sites. Available evidence suggests that fluoxetine inhibits NA reuptake through one or 
more non-noradrenergic sites, possibly a transporter on dopaminergic neurones (Hughes 
& Stanford, 1998; Hughes & Stanford, 1996). Such a transporter could explain why 
DMI had no effect on NA efflux in NK1-/- mice in these current studies. It is possible 
that this non-noradrenergic transporter has been upregulated in NK1-/- mice, to 
compensate for the higher basal NA efflux observed during halothane anaesthesia. 
Following infusion of DMI, increased efflux in NA could be taken up through this 
transporter in NK1-/- mice, preventing an observable increase in NA efflux.
The cloning of the human extraneuronal transporter by Schomig and colleagues 
(Schomig et al, 1998), marked the discovery of the second transporter responsible for 
uptake 2, which is inhibited by steroids. In humans, uptake 2 is mediated via the 
extraneuronal transporter for monoamine transmitters (Grundemann et a l, 1998), and in 
the rat through the organic cation transporter (OCT3) (Wu et al, 1998). This transporter 
is effective at removing adrenaline and NA, when catecholamine concentration 
increases above a critical threshold (Iversen, 1967), and binds the rodent stress hormone 
corticosterone with high affinity (Iversen & Salt, 1970; Grundemann et a l, 1998). In 
spite of the fact that these transporters have been well characterized in vitro, their in 
vivo roles remain elusive. mRNA for OCT3 has been found in neural cell populations of 
the rat cerebellum, hippocampus and cerebral cortex (Wu et al., 1998). This could 
indicate that in these brain regions, OCT3 acts to inactivate the fraction of released NA 
that escapes uptake 1 through the DMI sensitive NAT, and may explain why these
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studies failed to see an increase in NA efflux, following infusion of DMI in NK1-/- 
mice.
Alternatively, the higher basal NA efflux observed in NK1-/- mice could result in an 
upregulation of the NAT. To maintain homeostatic NA signalling, NAT levels would be 
expected to decrease when synaptic NA levels are low and increase when synaptic NA 
levels are high, and loss of the NAT or NA clearance has been associated with 
depression (Klimek et al., 1997). Depletion of NA, with reserpine, decreases NAT 
levels (Lee et al., 1983), whereas increasing the concentration of NA with monoamine 
oxidase inhibitors, increases the number of NATs (Lee et al., 1983). Although NA is 
not required for a downregulation of the NAT (Weinshenker et al., 2002), regulation of 
the NAT may be more sensitive to changes in NA in younger mice (Weinshenker et al., 
2002). This suggests that the impact of genetic disruption of the NK1 receptor, on the 
noradrenergic system at early developmental stages, could result in profound changes in 
the regulation of the NAT in these animals.
DMI may also act on receptors non-specifically in NK1-/- and not NK1+/+ mice. DMI 
is an ai-adrenoceptor antagonist, ai-Adrenoceptor antagonists e.g. prazosin suppress 
the excitatory influence of the ai-adrenoceptor on serotonergic DR neurones, 
decreasing 5-HT efflux in the DR (Bortolozzi & Artigas, 2003). This would lead to a 
decrease in the inhibitory input of the DR to the LC, which would be predicted to lead 
to an increase in NA efflux in NK1+/+ and NK1-/- mice. However, ai-adrenoceptor 
antagonists also depress noradrenergic function (Marek & Aghajanian, 1999) and 
decrease both 5-HT and NA efflux in the hippocampus (Weikop et al., 2004), so it may 
be that in NK1-/- mice ai-adrenoceptors are more sensitive to the antagonising effects 
of DMI, thereby preventing an increase in NA efflux (also: Herpfer et al., 2005). DMI 
also antagonises histamine receptors. Administration of the Hi antagonist 
clorpheniramine decreases extracellular NA in the paraventricular nucleus / anterior 
hypothalamic region of the rat (Bealer, 1993), so we cannot exclude the possibility that 
in NK1-/- mice, but not NK1+/+ mice the antagonistic actions of DMI at Hi receptors is 
acting to constrain the release of NA (see: (Herpfer et al., 2005). DMI also antagonises 
muscarinic receptors. Muscarinic receptors generally inhibit NA release, and so this 
action is unlikely to contribute to the lack of effect of DMI in NK1-/- mice reported here.
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3.4.1.4 Systemic RX821002 does not potentiate noradrenaline efflux following cortical 
desipramine infusion
As seen with the previous experiment, systemic RX821002 increased NA efflux in 
NK1+/+ mice, only. When DMI was infused through the probe a further increase was 
observed with 50 pM DMI, only. This increase evoked by DMI was not augmented by 
pre-treatment with RX821002 in either genotype.
The lack of potentiation on NA release suggests that in NK1+/+ mice, release rate is 
maximal following systemic pre-treatment with RX821002. This increase in release 
could overwhelm the NAT, so that reuptake through the NAT does not mask a 
difference in the release of NA, between NK1+/+ and NK1-/- mice. Therefore, although 
cortical infusion of DMI, alone, results in an increase in NA efflux in NK1+/+ mice, 
only, demonstrating that some released NA is normally cleared by the NAT. This 
clearance does not mask a difference in the rate of release, between NK1+/+ and NK1-/- 
mice, attributable to a difference in the ct2-adrenoceptor.
Although no potentiation on NA efflux in either genotype was observed by combining 
systemic 012-adrenoceptor antagonism with cortical infusion of a noradrenaline reuptake 
inhibitor, both DMI and RX821002 were effective at increasing NA efflux in NK1+/+ 
mice, only. The lack of effect of RX821002 in NK1-/- mice supports the notion that 
012-adrenoceptors in these animals are not functioning efficiently. The lack of effect of 
DMI in NK1-/- mice may be attributed to re-uptake through alternative transporters, as 
described in the previous section. The lack of effect of combining systemic RX821002 
and local infusion of DMI, in NK1-/- mice, may result from a combination of these 
factors.
3.4.2 Comparison of current findings and previous studies
Since these studies were run in parallel with those performed by Herpfer et al., (2005), 
Table 3.2 presents a summary of the results found with these current studies in 
comparison with those found by Herpfer et al., (2005).
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Herpfer et al, 
(2005)
NK1
+/+
NK1
-/-
Current studies
NK1
+/+
NK1
-/-
Effect on noradrenaline efflux
Systemic DMI
(10 mg / kg i.p.) 
alone
f t Systemic RX821002 (0.3 mg / kg i.p.) 
alone
f
Infusion of 
11X821002 (1.0 
and 10.0 pM) 
into the frontal 
cortex alone.
t f Infusion of DMI (50pM) into the frontal 
cortex alone.
t
Infusion of 
RX821002 (0.1 
and 1.0 pM) into 
the frontal cortex 
combined with 
systemic
administration of 
DMI (10 mg / kg 
i.p.).
tt t Infusion of DMI (5pM and 50 pM) into 
the frontal cortex 
combined with 
systemic
administration of 
RX821002 (0.3 mg / 
kg i.p.).
f
T a b l e  3.2: Summary of the results found by Herpfer et al., (2005) and results 
found in these current studies.
Although in these current studies cortical infusion of DMI, did not increase NA efflux 
in NK1-/- mice, systemic administration of DMI (10 mg / kg i.p.), does produce the 
same incremental increase in NA efflux, in both NK1-/- and NK1+/+ mice (Herpfer et 
al., 2005).
In contrast to the results presented herein, demonstrating that systemic administration of 
RX821002 increases NA efflux in NK1+/+ mice, only, Herpfer et al, (2005) showed 
that local infusion of RX821002 into the terminal field, increases NA release to the 
same extent in both NK1+/+ and NK1-/- mice (Herpfer et al, 2005). However, cortical 
infusion of RX821002, increases NA efflux to a greater extent in NK1+/+ mice only,
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following pre-treatment with systemic DMI (Herpfer et al, 2005), whereas systemic 
RX821002 followed by local infusion of DMI has no potentiating effect on NA efflux. 
The lack of a potentiating effect on NA efflux, produced by pre-treatment with 
RX821002, is also in contrast to a number of reports demonstrating that antagonism of 
a 2 -adrenoceptors augments the increase in NA caused by a noradrenaline reuptake 
inhibitor or dual 5-HT / NA reuptake inhibitors (Dennis et al., 1987; Wortley et al., 
1999a; Wortley et al., 1999b; Geranton et al., 2003).
3.4.3 Interpretation o f these current findings in light ofprevious findings
By combining systemic administration of DMI with cortical infusion of RX821002, the 
studies performed by Herpfer et al., (2005), focused on the terminal control of NA 
release. By combining systemic RX821002 with cortical infusion of DMI, the studies 
contained herein provide further information on the activity of both somatodendritic and 
terminal a,2-adrenoceptors.
Noradrenaline reuptake inhibitors, including DMI, inhibit the firing-rate of LC 
noradrenergic neurones by increasing the endogenous noradrenergic tone on 
somatodendritic a 2-adrenoceptors (Mateo et al., 1998; Meana et al., 1992; Palij & 
Stamford, 1994; Svensson & Usdin, 1978; Szabo & Blier, 2001). Therefore, it is likely 
that in the studies of Herpfer et al., (2005), systemic DMI would limit firing-dependent 
NA release in the frontal cortex of NK1+/+ mice, due to increased activity at 
somatodendritic ct2-adrenoceptors, which decrease firing-rate (Figure 3.11).
#  F i g u r e  3.11: Systemic administration
# of DMI inhibits the NAT on the cell
' 9 body and terminals. As a consequence
•  both <X2-adrenoceptors located on cell 
bodies and terminals are activated 
preventing a further rise in 
extracellular NA.
ct2-adrenoceptor
Noradrenaline transporter
Noradrenaline transporter inhibitor 
■4“ Firing-rate 
•  Noradrenaline
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S i n c e  i t  i s  h y p o t h e s i s e d  t h a t  t h e  e f f i c i e n c y  o f  s o m a t o d e n d r i t i c  012- a d r e n o c e p t o r s  i s  
d e c r e a s e d  i n  N K 1 - / -  m i c e ,  D M I  i s  u n l i k e l y  t o  a l t e r  t h e  f i r i n g - r a t e  o f  L C - n o r a d r e n e r g i c  
n e u r o n e s  i n  t h e s e  a n i m a l s .  T h e  p o t e n t i a t e d  e f f e c t  o n  N A  e f f l u x ,  b y  c o m b i n i n g  s y s t e m i c  
D M I  f o l l o w e d  b y  i n t r a c o r t i c a l  R X 8 2 1 0 0 2 ,  o b s e r v e d  i n  N K 1 + / +  m i c e  o n l y ,  s u g g e s t s  t h a t  
t h e  i n f l u e n c e  o f  t h e  N K 1  r e c e p t o r  o n  N A  r e l e a s e ,  c o n t r o l l e d  b y  t e r m i n a l  
o t 2 - a d r e n o c e p t o r s ,  i s  r e v e a l e d  o n l y  a t  l o w  r a t e s  o f  N A  r e l e a s e  a n d  l o w  f i r i n g - r a t e s  
( H e r p f e r  et al., 2 0 0 5 ) .  T h i s  i s  f u r t h e r  s u p p o r t e d  b y  t h e  l a c k  o f  a u g m e n t a t i o n  o n  N A  
e f f l u x ,  o b s e r v e d  w h e n  s y s t e m i c  R X 8 2 1 0 0 2 ,  w h i c h  w o u l d  i n c r e a s e  f i r i n g - r a t e  a n d  
r e l e a s e  o f  N A ,  i s  c o m b i n e d  w i t h  l o c a l  i n f u s i o n  o f  D M I  i n  t h e s e  c u r r e n t  s t u d i e s .
F u r t h e r m o r e ,  i t  i s  l i k e l y  t h a t  l o c a l  c o r t i c a l  i n f u s i o n  o f  D M I  w i l l  h a v e  n o  e f f e c t  o n  
f i r i n g - r a t e  o f  L C - n o r a d r e n e r g i c  n e u r o n e s ,  a n d ,  t h e r e f o r e ,  w i l l  n o t  b l u n t  t h e  i n c r e a s e  i n  
N A  e f f l u x  i n  e i t h e r  N K 1 + / +  o r  N K 1 - / -  m i c e .  I t  i s  p o s s i b l e ,  t h e r e f o r e ,  t h a t  t h e  l a c k  o f  
e f f e c t  o f  c o r t i c a l  D M I  i n  N K 1 - / -  m i c e ,  c o u l d  b e  d u e  t o  t h e s e  a n i m a l s  a t t e m p t i n g  t o  
m a i n t a i n  h o m e o s t a t i c  s i g n a l l i n g ,  w h i c h  i s  a t  a  h i g h e r  l e v e l ,  b y  r e m o v i n g  e x c e s s  N A  
t h r o u g h  a l t e r n a t i v e  t r a n s p o r t e r s  f o r  e x a m p l e  t h e  l o w  a f f i n i t y  D A ,  5 - H T  o r  O C T  
t r a n s p o r t e r s  d e s c r i b e d  p r e v i o u s l y .
T h e  s a m e  i n c r e m e n t a l  i n c r e a s e  i n  N A  e f f l u x  i n  b o t h  N K 1 + / +  a n d  N K 1 - / -  m i c e  
f o l l o w i n g  c o r t i c a l  i n f u s i o n  o f  R X 8 2 1 0 0 2  ( H e r p f e r  et al., 2005) d e m o n s t r a t e s  t h a t  
t e r m i n a l  c t 2 - a d r e n o c e p t o r s  t o n i c a l l y  c o n s t r a i n  e f f l u x  o f  N A  i n  b o t h  g e n o t y p e s .  T h e  
r e s u l t s  a l s o  s u g g e s t  t h a t  c l e a r a n c e  t h r o u g h  t h e  t e r m i n a l  N A T  m a s k s  a  d i f f e r e n c e  i n  
r e l e a s e  o f  N A ,  s i n c e  s y s t e m i c  D M I ,  f o l l o w e d  b y  c o r t i c a l  i n f u s i o n  o f  R X 8 2 1 0 0 2 ,  r e v e a l s  
a  p o t e n t i a t e d  r e s p o n s e  i n  N A  r e l e a s e  i n  o n l y  N K 1 + / +  m i c e .
S y s t e m i c  R X 8 2 1 0 0 2 ,  w h i c h  i n c r e a s e s  N A  e f f l u x  i n  N K 1 + / +  m i c e  o n l y ,  w o u l d  
a n t a g o n i s e  b o t h  t e r m i n a l  a n d  s o m a t o d e n d r i t i c  a 2 - a d r e n o c e p t o r s .  S i n c e  t e r m i n a l  
a n t a g o n i s m  o f  a 2 - a d r e n o c e p t o r s  r e s u l t s  i n  t h e  s a m e  i n c r e m e n t a l  i n c r e a s e  i n  N A  e f f l u x  i n  
b o t h  g e n o t y p e s  i t  i s ,  t h e r e f o r e ,  l i k e l y  t h a t  t h e  d e c r e a s e d  t o n i c  c o n s t r a i n t  o f  
012- a d r e n o c e p t o r s  i n  N K 1 - / -  m i c e ,  l i e s  a t  t h e  l e v e l  o f  L C  c e l l  b o d i e s .  M o r e o v e r ,  i t  
s u g g e s t s  t h a t  t h e  d i f f e r e n c e  i n  a c t i v i t y  o f  s o m a t o d e n d r i t i c  002- a d r e n o c e p t o r s ,  b e t w e e n  t h e  
t w o  g e n o t y p e s ,  b e c o m e s  a p p a r e n t  a t  h i g h e r  f i r i n g - r a t e s  a n d  r a t e s  o f  r e l e a s e ,  a n d  i s  n o t  
m a s k e d  b y  r e u p t a k e  t h r o u g h  t h e  N A T .  I n  t h i s  s i t u a t i o n  t h e r e  i s  n o  a u g m e n t a t i o n  o f  N A
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efflux in NK1+/+ mice, following cortical infusion of DMI, suggesting a ‘ceiling’ effect 
on NA release.
Taken together these findings strongly indicate that the regulatory influence of both the 
(X2-adrenoceptor and NK1 receptor on noradrenergic neurones is revealed during 
different rates of LC-noradrenergic cell firing and release of NA. Potentiation of NA 
efflux, produced by systemic DMI and local 012-adrenoceptor antagonism, is observed 
only during low firing-rates and low rates of NA release, and, only in NK1+/+ mice. 
This would suggest that the different activity of terminal 012-adrenoceptors, between the 
two genotypes, becomes apparent at lower firing-rates. Conversely, at higher 
firing-rates, as would occur following systemic RX821002, NA efflux is increased in 
NK1+/+ mice only, and the genotype dependent difference in NA efflux is abolished. If 
RX821002 has no effect on somatodendritic 012-adrenoceptors in NK1-/- mice, because 
they are desensitised, firing-rate in these animals will be unaffected. However, systemic 
RX821002 is likely to increase the firing-rate in NK1+/+ mice and this situation reveals 
the difference in activity of somatodendritic (X2-adrenoceptors between the genotypes. 
This may explain why local cortical infusion of RX821002, which would have little or 
no effect on firing-rate, results in the same incremental increase in NA efflux in both 
genotypes (Herpfer et al., 2005).
This interpretation is further supported by a study revealing that stress-induced 
activation of c-fos, in the rat LC, is enhanced by NK1 receptor antagonism (Hahn & 
Bannon, 1998). Systemic administration of NK1 receptor antagonists alone, does not 
result in substantial LC c-fos expression (Hahn & Bannon, 1998). This suggests that the 
excitatory effect of NK1 receptor antagonism on LC neurones becomes apparent during 
situations which are likely to increase the firing-rate of LC-noradrenergic neurones. 
Furthermore, it suggests that the effect of genetic disruption of the NK1 receptor on the 
noradrenergic system, particularly the 012-adrenoceptor, may also become more apparent 
during situations where the firing-rate of the LC has been artificially manipulated by 
drugs, as seen here, or during stressful stimuli.
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3.4.4 Halothane anaesthesia as a confounding factor
Noradrenergic projections of the central nervous system (CNS) are known to be 
important targets in general anaesthesia (Angel, 1993). It has also been suggested that 
noradrenergic neurones in the LC are important targets in mediating the hypnotic 
actions of ct2-adrenoceptor agonists such as clonidine (De Sarro et al., 1987; Scheinin & 
Schwinn, 1992). Anaesthetics such as sodium pentobarbitone decrease NA efflux in the 
frontal cortex of rats by 92 % (Dailey et a l , 1998). Halothane is a volatile anaesthetic. 
Volatile anaesthetics can also reduce NA release in the CNS and alter neuronal 
excitability in a non-specific way (Mizuno et al., 1994).
During halothane anaesthesia, LC neurones fire in a spontaneous, slow and regular 
pattern. The reduction in LC firing induced by halothane may be due to a halothane 
induced membrane hyperpolarisation, leading to a decrease in cell firing (Nicoll & 
Madison, 1982). Withdrawal from halothane anaesthesia, results in an increase in LC 
neuronal firing (Saunier et al., 1993) NA efflux (Chave et a l , 1996) and a 5-fold 
increase in the ED50 of intravenous clonidine (Saunier et a l , 1993). The increase in the 
effectiveness of clonidine as a sedative during halothane anaesthesia, suggests an 
increase in the sensitivity of a 2-adrenoceptors. Furthermore, acutely administered 
clonidine reduces the halothane anaesthetic requirement in dogs by a maximum of 48 % 
(Bloor & Flacke, 1982). This is consistent with a synergism between halothane and 
012-adrenoceptors on LC neuronal firing (Saunier et a l , 1993), or an increased 
sensitivity of a 2-adrenoceptors during halothane anaesthesia (Saunier et a l, 1993). The 
variable effects of anaesthetics makes it difficult to draw direct links to their mode of 
action in NK1+/+ and NK1-/- mice. Nevertheless, halothane anaesthesia exposes 
differences in basal NA efflux, between NK1+/+ and NK1-/- mice, which is not 
apparent during freely-moving microdialysis (Chapter 4).
Studies carried out in our laboratory also demonstrate that when freely-moving mice are 
placed under halothane anaesthesia, NA efflux is decreased in both genotypes. However, 
the net decrease in NA efflux is greater in NK1+/+ mice (Yan, unpublished 
observations). This suggests that halothane anaesthesia decreases NA efflux to a greater 
extent in NK1+/+ mice compared with NK1-/- mice. This may be attributed to a 
decrease in the activity of a,2-adrenoceptors in NK1-/- mice, thereby attenuating the
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decrease in NA efflux, and further supports a difference in the activity of these receptors 
between these two genotypes.
3.4.5 Summary
In halothane-anaesthetised NK1-/- mice, systemic RX821002 and local infusion of DMI 
have no effect on NA efflux. However, in NK1+/+ mice, both RX821002 and DMI 
increase NA efflux. The lack of effect of RX821002 in NK1-/- mice could be the result 
of either a downregulation and / or desensitisation of the autoregulatory 012-adrenoceptor. 
This downregulation and / or desensitisation of the autoregulatory adrenoceptor could 
be a cause or consequence of the 4-5 fold increase in basal NA efflux in NK1-/- mice.
3.4.6 Conclusions
• There is a difference in the regulation of NA efflux between NK1+/+ and 
NK1-/- mice
• This difference in the release regulating mechanism could involve a 
downregulation / desensitisation of autoregulatory 012-adrencoptors. However, 
alterations in alternative transporters, for example the OCT, can not, as yet, be 
ruled out.
The following chapters compare the effect of RX821002 on freely-moving NK1+/+ and 
NK1-/- mice and investigate whether there is further evidence that ct2-adrenoceptors are 
downregulated or desensitised.
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CHAPTER 4
EFFECT OFANTAGONSIM OF ar ADRENOCEPTORS ON 
NORADRENALINE EFFLUX IN THE FRONTAL CORTEX OF 
FREELY-MOVING NK1+/+ AND NK1-A MICE
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4 EFFECT OF ANTAGONISM OF a 2-ADRENOCEPTORS ON 
NORADRENALINE EFFLUX IN THE FRONTAL CORTEX OF 
FREELY-MOVING NK1+/+ AND NK1 -/- MICE
4.1 I n t r o d u c t io n
In Chapter 3, it was demonstrated that the selective 012-adrenoceptor antagonist, 
RX821002 (0.3 mg / kg i.p.), increased noradrenaline (NA) efflux in the frontal cortex 
of halothane-anaesthetised NK1+/+ mice, only, and abolished the 4-5-fold difference in 
basal NA efflux.
The current study was aimed at investigating the effect of antagonism of the 
ot2-adrenoceptor, using RX821002, on NA efflux in freely-moving NK1+/+ and NK1-/- 
mice. A difference in noradrenergic efflux between NK1+/+ and NK1-/- mice, in 
response to RX821002, would further support the hypothesis that 012-adrenoceptors in 
NK1-/- mice are impaired in some way. Freely-moving in vivo microdialysis is 
preferred, as animals are free of halothane anaesthesia. Further, probes have been 
implanted 24 h prior to the experiment and mice have been allowed to remain in the 
home cage in which the experiment is conducted.
4.1.1 Background
Extensive investigations into the modulation of NA release in the cerebral cortex, with 
particular focus on the role of terminal 012-adrenoceptors, have been carried out in the 
freely-moving rat, in this laboratory as well as others. Mateo et al., found that, in the rat, 
NA release in cortical terminal fields is under tonic modulation by somatodendritic 
oi2a-adrenoceptors located on LC neurones (Mateo et al., 1998; Mateo & Meana, 1999). 
This was achieved using RX821002 and the selective ot2a-adrenoceptor antagonist 
BRL44408 which were infused, via retrodialysis, into the locus coeruleus (LC). The 
study performed by Mateo et al., (1998), found that basal NA efflux in the LC and the 
frontal cortex were elevated (30 %) by the local infusion of RX821002 in the LC. 
Additionally, at a dose of 2 mg / kg i.p. RX821002 produced a modest increase in the 
firing-rate of LC neurones (Mateo et al., 1998) and completely reversed the inhibitory
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effect of a low dose of DMI (1 mg / kg i.p.) on the firing-rate of noradrenergic neurones. 
RX821002 has also been shown to produce an increase in NA efflux in the bed nucleus 
stria terminalis (BNST) when perfused into this brain area (Forray et al., 1997; Forray 
et al., 1999), in the cingulate cortex when perfused into the LC (Mateo et al., 1998; 
Femandez-Pastor & Meana, 2002) and in the frontal cortex following systemic 
administration (Wortley et al., 1999a). All this evidence suggests that there is tonic 
inhibitory modulation of cortical NA release by a 2-adrenoceptors located either 
somatodendritically, or, on neuronal terminals (Cedarbaum & Aghajanian, 1976; 
Aghajanian et al., 1977) (Figure 4.1). Furthermore, these studies demonstrate the ability 
of RX821002, administered directly via retrodialysis, or systemically, to increase NA 
efflux in a number of brain regions in rats.
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R ecurrent collateral inhibition: NA
released from a collateral activates 
somatodendritic a 2a-adrenoceptor and
initiates inhibition of neuronal cell firing
in the locus coeruleus.
Som atodendritic
a 2a-adrenoceptor
Feedback inhibition o f  NA release: Activation of 
terminal a 2a-AR triggers negative feedback, blunts 
release of NA, ensures transmitter stores are 
conserved and prevents excessive stimulation of post- 
synaptic cells.
Post-synaptic a 2a-adrenoceptor located on either 
noradrenergic neurones or other neurons.
^  Noradrenaline transporter 
□  (X2c-A R
Q  cx2a-AR 
NA- Noradrenaline
F igure 4.1: Regulation of noradrenaline release by the autoregulatory a 2 -adrenoceptor, located on cell bodies of LC neurones 
noradrenergic terminals, and on non-noradrenergic neurones.
120
Chapter 4: Microdialvsis in freelv-movine NK1 +/+ and NK1-/- mice
However, there are no published reports investigating the electrophysiological or release 
of NA, in response to RX821002, in the frontal cortex of freely-moving mice. Based on 
the results in Chapter 3, systemic administration of RX821002 is expected to produce a 
dose-dependent increase in NA efflux in the frontal cortex of NK1+/+ mice, only. 
However, the absence of halothane anaesthesia could influence basal NA efflux in both 
genotypes and expose a difference in the response to RX821002.
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4.2 P r o t o c o l s
Probes were implanted as described in Section 2.6.2. On the day after surgery, the 
microdialysis experiment started at 08:00 a.m.
NK1+/+ and NK1-/- mice were divided randomly into 4 groups and given one of the 
following treatments:
• Saline 10 ml / kg i.p.
• RX821002 0.3 mg / kg i.p.
• RX821002 1 mg/kg i.p.
• RX821002 3 mg / kg i.p.
In each case NA efflux was monitored for 3 h following systemic administration of 
RX821002.
122
Chapter 4: Microdialvsis in freelv-movinz NK1+/+ and NK1-/- mice
4.3 R e s u l t s
4.3.1 Effect o f genotype on basal noradrenaline efflux
There was no difference in basal NA efflux pooled across the groups in NK1+/+ (4.72 ±
0.34 fmol / 60 min from T-40-T0) and NK1-/- mice (5.22 ± 0.36 fmol / 60 min from 
T_4o-To).: main effect of ‘genotype’, (Fi,65 = 1-13; P = 0.29; T_4o-To; Figure 4.2a-c). 
There was no difference between groups of animals destined for different drug 
treatments (Figure 4.2a-c).
4.3.2 Effect of intraperitoneal injections of saline or RX821002 on noradrenaline 
efflux in the frontal cortex
4.3.2.1 Injection o f saline 10 ml/kg i.p.
A transient increase in NA efflux was apparent after administration of saline 10 ml / kg
1.p. in both genotypes. However, this increase was not maintained after the first 20 min 
post injection and was not different from basal NA efflux (Figure 4.2a-c).
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a) Effect of RX821002 (0.3 mg/kg i.p.) on 
cortical noradrenaline efflux in freely-moving
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NK1+/+ and NK1-/- mice
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Time (min)
Effect of RX821002 (1 mg/kg i.p.) on cortical 
noradrenaline efflux in freely-moving 
NK1+/+ and NK1-/- mice
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c)
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Effect of RX821002 (3 mg/kg i.p.) on cortical 
noradrenaline efflux in freely-moving 
NK1+/+ and NK1-/- mice
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NK1-/- Saline 
NK1+/+ RX821002 
NK1-/- RX821002
FIGURE 4.2a-c: Raw data. Effect of RX821002 on noradrenaline efflux. 
RX821002 (0.3 mg / kg i.p.) did not increase noradrenaline efflux in either 
genotype. At 1 mg / kg i.p. RX821002 increased noradrenaline efflux in 
NK1+/+ mice, only. At a dose of 3 mg / kg i.p. RX821002 began to produce 
effects in both genotypes. Values are mean noradrenaline efflux ± s.e.m. n = 9; 
*P = £ 0.05.
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a) Effect of RX821002 (0.3mg/kg i.p.) on cortical 
noradrenaline efflux in freely-moving
NK1+/+ and NK1 -/- mice.
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FIGURE 4.3a-c: Effect of RX821002 on net noradrenaline efflux in freely- 
moving mice. RX821002 (0.3 mg / kg i.p.) did not increase noradrenaline efflux 
in either genotype. At 1 mg / kg i.p. RX821002 increased noradrenaline efflux 
in NK1+/+ mice, only. At a dose of 3 mg / kg i.p. RX821002 began to produce 
effects in both genotypes. Values are mean net noradrenaline efflux ± s.e.m. n = 
9; * P = £0.05.
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4.3.2.2 Injection o f RX821002 0.3, 1.0 and 3.0 mg /  kg i.p.
Analysis o f raw data: Comparison of saline and 0.3 mg / kg i.p. treatment groups 
revealed a main effect of ‘drug’ (Fu 6 = 7.03; P = 0.017; To-Tigo; Figure 4.2a). Post-hoc 
analysis showed that RX821002, in NK1+/+ mice, increased NA efflux compared to 
saline treatment (P = 0.003). However, this increase was not different from NK1-/- mice 
treated with RX821002 (0.3 mg / kg i.p; P = 0.24).
Comparison of saline and 1.0 mg / kg i.p. treatment groups revealed a main effect of 
‘drug’ (F 1,13 = 6 .6 8 ; P = 0.023, To-Tigo) and a ‘drug x genotype’ interaction (Fij3 = 5.17; 
P = 0.041; Figure 4.2b). From T100-T140 a main effect of ‘drug’ was also found 
(F1 2 3 = 8.99; P = 0.006) along with a ‘drug x genotype’ interaction (Fi,23 = 7.26; 
P = 0.013). Over these three time points RX821002 (1.0 mg / kg i.p.) increased NA 
efflux in NK1+/+ mice to a greater extent then NK1-/- mice treated with RX821002 (1.0 
mg / kg i.p; P = 0.012). The RX821002 induced increase in NA efflux was also higher 
than that observed in saline treated NK1+/+ (P = 0.001) and NK1-/- (P = 0.007) mice.
Comparison of saline and 3.0 mg / kg i.p. treatment groups revealed a main effect of 
‘drug’ (F1516 = 9.06; P = 0.008, To-Tigo; Figure 4.2c). However, no ‘drug x genotype’ 
interaction was found, suggesting non-specific effects occurring at this higher dose or 
desensitised 012-adrenoceptors.
Analysis of net data, revealed the same pattern of results as analysis of raw data (Figure 
4.3a-c).
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4.4 D i s c u s s i o n
RX821002 crosses the blood-brain barrier (Millan, 1992). Therefore, following 
systemic administration, the a 2-adrenoceptor antagonist should increase firing-rate of 
LC noradrenergic neurones (Mateo et al., 1998; Ugedo et al., 1998). It should also 
block autoreceptors located on noradrenergic nerve terminals and so enhance NA 
release in terminal projection areas. The increase in NA efflux induced by RX821002 
found in these experiments supports this. The 1.5-fold increase above basal levels in NA 
efflux, seen with RX821002 (1 mg / kg i.p.) in NK1+/+ mice only, is also similar to that 
observed by (Meana et al., 1997).
4.4.1 Basal noradrenaline efflux is not different in freely-moving NK1+/+ and 
NK1-/- mice
In contrast to the results presented in Chapter 3 there was no difference in NA efflux 
between freely-moving NK1+/+ and NK1-/- mice. When mice were placed under 
halothane-anaesthesia as in Chapter 3, a significant 4-5-fold difference in basal NA 
efflux was observed between the two genotypes.
It is interesting to note that the average basal NA efflux of NK1+/+ freely-moving mice 
was higher than halothane-anaesthetised NK1+/+ mice in Chapter 3. These two studies 
were not randomised together and so direct comparisons are strictly not valid. This is, 
however, in agreement with studies showing that halothane blocks the response of 
mesencephalic reticular neurones in the cat (Shimoji et al., 1977). Under halothane 
anaesthesia LC neurones fire in a slow and regular pattern in the rat (Saunier et al., 
1993). Withdrawal from halothane anaesthesia increases the average firing-rate of LC 
neurones, although NA is normally released during burst-firing. Anaesthetics, such as 
chloral hydrate and pentobarbital, selectively suppress release, reuptake and metabolism 
of NA, but have no effect on the basal extracellular concentrations of NA in the medial 
preffontal cortex of rats (Pan & Lai, 1995). It was, therefore, predicted that removal of 
halothane anaesthesia would result in an increase in basal NA efflux in both genotypes.
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However, in contrast to NK1+/+ mice, NK1-/- mice demonstrated a reduction in basal 
NA efflux in the freely-moving situation compared to halothane anaesthesia, suggesting 
that in NK1-/- mice halothane has an excitatory effect in these experiments.
4.4.2 Effect of RX821002 (0.3 mg/kg) on noradrenaline efflux
In both freely-moving NK1+/+ and NK1-/- mice, 0.3 mg / kg RX821002 did not affect 
NA efflux. However, under halothane anaesthesia (Chapter 3) a dose o f 0.3 mg / kg i.p 
of RX821002 increased NA efflux approximately 4-fold above basal in NK1+/+ mice, 
only. Therefore, although there is probably a lower noradrenergic tone at 
a 2 -adrenoceptors under halothane anaesthesia, compared to the freely-moving situation, 
a lower dose of the (X2 -adrenoceptor antagonist produces an increase in NA efflux that is 
not observed in the freely-moving situation. This could be due to the fact that halothane 
anaesthesia increases the sensitivity of ct2 -adrenoceptors or has a synergistic interaction 
with ct2 -adrenoceptors (Saunier et al., 1993).
4.4.3 NK1-/- mice do not respond to RX821002
In freely-moving NK1-/- mice, NA efflux was unaffected by RX821002 at 0.3 and
1.0 mg / kg i.p., suggesting that the a 2 -adrenoceptors in these animals are not 
functioning efficiently. In contrast, in freely-moving NK1+/+ mice a dose o f 1 mg /kg
i.p. did increase NA efflux compared to NK1-/- mice. The higher dose o f 3 mg / kg i.p. 
increased NA efflux in both genotypes, perhaps due to non-specific effects, or a lower 
affinity of (X2 -adrenoceptors in NK1-/- mice, perhaps as a result of desensitisation.
4.4.4 Summary and conclusions
An increase in NA efflux in NK1+/+ mice, compared to NK-/- mice, was found with a 
dose of 1 mg / kg i.p. Freely-moving NK1-/- mice do not respond to RX821002 (0.3 and
1.0 mg / kg i.p.). At the higher dose o f 3 mg / kg i.p. the ‘drug x genotype’ was no 
longer found suggesting an effect on NA efflux in both genotypes at this dose. Based on 
the results from this dose-response experiment a dose of 1 mg / kg was chosen for 
microdialysis studies using the light / dark exploration box (see Chapter 5).
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The following chapter describes two complimentary experiments that investigate the 
behavioural and NA response of NK1+/+ and NK1-/- mice to the non-noxious stressor, 
novelty. To determine whether any genotype dependent differences in behaviour or NA 
efflux could be attributed to differences in the 012-adrenoceptor, NA efflux and 
behavioural reactions to novelty were monitored following systemic administration of 
the ct2-adrenoceptor antagonist RX821002 (1 mg/kg i.p.).
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5 EFFECT OF NOVELTY ON BEHAVIOUR AND NORADRENALINE 
EFFLUX IN NK1+/+ AND NK1-/- MICE
5.1 I n t r o d u c t io n
This chapter presents results from an experiment used to determine the behavioural 
response of NK1+/+ and NK1-/- mice to a non-noxious naturalistic novel environment, 
the light dark exploration box (LDEB). In vivo microdialysis was also used to determine 
parallel effects on NA efflux in the preffontal cortex of NK1+/+ and NK1-/- mice in the 
same novel environment.
5.1 .1  Why use naturalistic behavioural tests?
Physical, aversive stimuli such as restraint (Abercrombie & Jacobs, 1987; Yokoo et al., 
1990a; Vahabzadeh & Fillenz, 1994), tail pinch (Aston-Jones & Bloom, 1981b; 
Vahabzadeh & Fillenz, 1994), and foot-shock (Hirata & Aston-Jones, 1994; Rossetti et 
al., 1990), increase NA efflux and unit activity of LC noradrenergic neurones. Since 
these stressors are not commonly experienced by humans, this calls into question their 
validity when investigating the stress response. Moreover, these laboratory stressors are 
associated with somatosensory stimulation and cause overt physical discomfort (for 
review see: (Stanford, 1995)). Whether the changes in the brain produced by these lab 
stressors are relevant to the effects of non-noxious psychological stimuli is, therefore, 
debateable (Stanford & Salmon, 1989; Stanford, 1995). Moreover, it is believed that 
naturalistic stimuli such as ‘threat’ or Toss’ rather than somatosensory stimuli 
precipitate the onset of anxiety and depression, respectively in humans (see: (Stanford, 
1995)).
Naturalistic stressors, such as exposure to a novel environment might, therefore, be 
more appropriate for investigating the role of noradrenergic neurones in response to 
stress.
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5.1.2 Response of the locus coeruleus-noradrenergic system to naturalistic stressors
It has been postulated that the LC-noradrenergic system plays an important role as an 
‘alarm system’ (Redmond, Jr. & Huang, 1979). This is supported by the fact that release 
of NA enhances the reaction of the organism to internal or external stimuli, more 
specifically the processing of sensory information which accompanies it (Jacobs et al., 
1991).
The firing activity of LC neurones in response to novelty has been examined in 
freely-moving rats (Sara et al., 1994; Vankov et al., 1995). These studies show that LC 
cells respond in burst to imposed novel sensory stimuli or to novel objects encountered 
during free exploration. When the stimulus lacks predictive value and no behavioural 
response is required, the LC response shows rapid habituation (Sara et a l, 1994), 
demonstrating that LC neurones fire in response to the salience of a stimulus. LC cells 
thus respond to novelty or a change in incoming information, promoting selective 
attention to the relevant stimuli at the moment of change. Devauges and Sara (1991) 
using a complex food-motivated maze task, have also observed that the firing-rate of LC 
neurones is enhanced when an exploring rat encounters a novel object (Devauges & 
Sara, 1991). Furthermore, the time spent exploring the novel object is increased if the 
LC is stimulated electrically (Devauges & Sara, 1991) or decreased if NA release is 
inhibited by an a 2-adrenoceptor agonist, such as clonidine (Sara et a l, 1995).
NA released in target forebrain areas acts to sharpen or direct attention to relevant 
stimuli, thereby ‘alerting’ the animal and orienting them towards the stimuli (Aston- 
Jones & Bloom, 1981b; Foote et al, 1991). Supporting the role played by the LC in 
regulating attentional state or vigilance (Aston-Jones et a l, 1991a).
Strong evidence is available to support an increase in activation of LC neurones in 
response to the psychologically aversive features of a stimulus (Tanaka et a l, 1991b), 
further supporting the use of non-noxious naturalistic stressors, over those that posses a 
somatosensory component in their response. However, the exact role played by NA in 
response to adverse stressful effects is still unclear. It is possible that NA release 
follows a bell-shaped dose response curve (Stanford, 1995), and that the increase in NA
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in response to stressful stimuli represents a coping strategy, too much NA release, and 
the response can become detrimental to the animal.
Nevertheless, naturalistic stimuli, which do not result in physical discomfort, increase 
the firing activity of LC neurones. This supports the use of the non-noxious novel 
environment of the LDEB to investigate the stress response of the noradrenergic system 
in NK1+/+ and NK1-/- mice. We predict that noradrenergic neurones of NK1+/+ and 
NK1-/- mice will respond differently to the novel environment presented by the LDEB.
5.1.3 Behavioural response of NK1+/+ and NK1-/- mice in stress-inducing tests
The behavioural phenotypes of NK1+/+ and NK1-/- mice have been tested in various 
stress paradigms: e.g. resident-intruder, separation-induced vocalisation,
novelty-suppressed feeding, forced swim test and the tail suspension test. The results 
from these tests lead to the conclusion that the phenotype of the NK1-/- mice resembles 
that of the NK1+/+ counterpart treated with an established anxiolytic / antidepressant 
compound e.g. fluoxetine (Rupniak et al., 2001). However, the behaviours exhibited in 
NK1-/- mice in the open-field and elevated-plus maze are inconsistent. No difference 
between genotypes in the open field and elevated-plus maze was found by De Felipe et 
al, (1998) and Rupniak et al, (2001), whereas an increase in exploratory behaviour in 
the open field and a reduction in stress related responses in the elevated plus-maze has 
been found by (Santarelli et al., 2001; Santarelli et a l , 2002).
Behaviour produced in the LDEB is strongly strain dependent (Rodgers et al., 2002). 
129/SvEv strains of mice demonstrate higher levels of anxiety-like behaviour 
(conventional and / or ethologically) (Rodgers et a l , 2002). The studies conducted by 
Santarelli et al, (2001) were performed on NK1-/- mutants from a pure 129/SvEv 
background (Santarelli et a l, 2001). Therefore, genetic differences between the NK1-/- 
mice developed from a pure background strain of 129/SvEv mice and those developed 
from a hybrid line (129/Sv X C57BL/6) may account for the differences observed 
between the two groups.
The mice used in these LDEB studies are derived from C57BL/6 blastocysts implanted 
with genetically manipulated 129SvEv stem cells (De Felipe et al, 1998) which were
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crossed onto an MF1 background. The behaviour of NK1-/- mice bred from this strain is 
not different from that of their NK1+/+ counterpart in either the open-field or 
elevated-plus maze (Rupniak et a l , 2001; Murtra et al., 2000; David et al., 2004), 
however, there are marked genotype dependent behavioural differences between 
NK1+/+ and NK1-/- mice in the LDEB (Herpfer et al., 2005), which may be attributed 
to differences in the regulation of the noradrenergic nervous system between these two 
genotypes.
The LDEB has the additional advantage that it can be performed in combination with in 
vivo microdialysis. Therefore, changes in behaviour observed in the LDEB can be 
related to changes in NA efflux of NK1+/+ and NK1-/- mice.
5.1.4 Microdialysis studies of the noradrenergic response to naturalistic stimuli
Measurement of the NA metabolite 3-methoxy-4-hydroxyphenylethlene glycol (MHPG) 
provides a marker for a decrease or increase in NA release. Accumulation of MHPG is 
observed in the brains of rats watching conspecifics experiencing foot-shock (Iimori et 
al., 1982; Tanaka et al., 1991a). The increase in MHPG produced by this psychological 
stressor is localised to limbic regions such as the amygdala, LC and hypothalamus. 
Whereas the changes produced by laboratory stressors appear more widespread 
throughout the brain (Iimori et al., 1982).
Return of rats to an environment in which they previously experienced footshock, tests 
emotional stress without the physical component. Microdialysis studies have also 
demonstrated an increase in NA efflux in the hypothalamus of rats when they are 
returned to the environment in which they experienced footshock (Yokoo et al., 1990b).
Our lab has previously used the LDEB as a naturalistic stressor in a number of 
microdialysis studies. These studies found that different naturalistic stimuli, result in 
incremental changes in NA efflux, in the frontal cortex (Dailey & Stanford, 1995). An 
increase in cortical (Dailey & Stanford, 1995) and hypothalamic (McQuade et al., 1999) 
NA efflux, was observed, when rats were transferred to the novel, brightly lit 
environment of the LDEB, plus or minus an unfamiliar conspecific. A conditioned 
stimulus (tone), predicting transfer of a rat to the same novel aversive environment, also
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caused an increase in cortical but not hypothalamic NA efflux (McQuade & Stanford, 
2000).
Firing activity and NA efflux of LC and hippocampal noradrenergic neurones is, 
therefore, increased in response to novel and salient external stimuli or a change in 
incoming information (Simson & Weiss, 1989; Aston-Jones et al., 1991a; Sara et al., 
1994; Dailey et al., 1996; Kitchigina et al., 1997; McQuade et al., 1999). Strong 
evidence supports the use of non-noxious naturalistic stimuli e.g. the LDEB, to 
investigate the noradrenergic nervous system in the behavioural response / emotional 
impact of a naturalistic stressor.
5.7.5 Anxiety-like behaviours and the light dark exploration box
It must be emphasised that the LDEB is typically used as a model to screen anxiolytic 
drugs and so, by implication, reflects anxiety-like behaviour. However, for these studies 
it was used purely to profile the behavioural response to novelty, in such a way that 
genotype-dependent behavioural differences could be attributed to differences in the 
regulation of the noradrenergic system between NK1+/+ and NK1-/- mice. The effects 
of typical anxiolytics such as benzodiazepines (BDZs) were not used to validate the 
anxiety-like behavioural response in this study.
In the prototypical light / dark shuttle box (behaviour only monitored for 3 min), BDZs 
increase exploratory behaviour. This is measured as an increase in transitions between 
the light and dark compartments (Crawley & Goodwin, 1980). Costall et al, (1989) 
found that an increase in exploratory behaviour was associated with an increase in the 
time spent in the light compartment and parallels an increased duration in the light zone 
and an increase in transitions (Costall et al., 1989). Rearing activity of mice is also 
believed to be an indicator of exploratory behaviour (Rodgers et al., 2002).
Evidence suggests that the novelty of the white compartment initiates a number of 
avoidance behaviours in mice. Stretched-attend postures, where the mouse stretches 
forward and retreats to original position, and flat back approach, (classically known as 
risk-assessment behaviours), are believed to represent active avoidance responses, as is 
leaving the light compartment (Hascoet et al., 2001).
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A parameter that influences exploratory behaviour and, therefore, an important variable 
to control for, is age and neuronal maturation of the animals. Hascoet et al, (1999) have 
shown that the optimum age of mice in the LDEB test is 4 weeks. At this age mice 
spend 58 % of the total duration in the dark compartment. Older mice ( 8  weeks old) 
exhibit an increase in total activity, characterised by an increase in movements in each 
compartment, together with an increase in the number of transitions (Hascoet et al., 
1999). Therefore, mice in these present experiments were used at the age of 4-6 weeks 
(25-30g). Other variables that can influence experimental outcome include prior test 
experience (Holmes et al., 2001) and time of day when experiment is performed 
(Costall et al., 1989). All tests were, therefore, carried out on naive mice at the same 
time of day.
Since previous microdialysis studies have demonstrated an increase in NA efflux in rats 
when they are placed in the novel environment of the LDEB, it is likely that the novel 
environment, provided by the LDEB, would increase the firing activity of LC neurones 
in NK1+/+ and NK1-/- mice, and possibly increase NA efflux. These current studies are, 
therefore, particularly concerned with determining behavioural differences between 
NK1+/+ and NK1-/- mice in the LDEB, an environment which they may find stressful / 
aversive. Having determined any genotype dependent behavioural differences further 
interest lies in whether these behaviours can be attributed to a difference in the 
noradrenergic system of these mice. To investigate differences in the noradrenergic 
system, of NK1+/+ and NK1-/- mice, these studies also focused on the behavioural 
response to novelty following challenge with compounds known to modify NA, most 
notably a 2-adrenoceptor antagonists.
5.1.6 Effect of aradrenoceptor antagonists on behaviour
Several studies have drawn parallels between activation of LC noradrenergic neurones 
and behavioural arousal (Carli et al., 1983; Cole & Robbins, 1992; Robbins, 1997).
It has been postulated that a novel environment causes an increase in NA which is 
further potentiated by systemic administration of an a 2-adrenoceptor antagonist e.g. 
idazoxan (Devauges & Sara, 1990) eliciting an increase in the duration spent 
investigating novel objects.
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Conversely it has been reported that administration of idazoxan decreases exploratory 
behaviour in a novel environment in a multicompartment chamber (Berridge and Dunn, 
1987). Similarly, (Haapalinna et al., 1999) have found a decrease in the exploratory 
behaviour of rats dosed with the 012-adrenoceptor antagonists yohimbine or atipamezole 
in the staircase test. This group also report that atipamezole has no effect on 
spontaneous motor activity in the staircase test (Haapalinna et al., 1999).
These conflicting results demonstrate that an increase in NA release, following 
antagonism of 012-adrenoceptors, does not always result in an increase in exploratory or 
locomotor behaviour. Furthermore, they demonstrate that a 2-adrenoceptor antagonists 
do have different effects on behavioural response to novelty but these effects are as yet 
unclear and sometimes conflicting.
137
Chapter 5: Behaviour and microdialvsis in the light /dark exploration box
5.1.7 Aims
Although evidence is available documenting the effect of novel naturalistic stimuli on 
behaviour and NA efflux in rats, there are no studies documenting this response in mice. 
These studies are based on the hypothesis that the higher NA efflux in NK1-/- mice may 
be a result of the a 2-adrenoceptor malfunctioning in some way. It was, therefore, 
predicted that the difference in basal NA efflux between the two genotypes would result 
in differences in the exploratory behaviour in a novel environment in the LDEB.
Systemic administration of the a 2-adrenoceptor antagonist, RX821002, was used to 
investigate whether antagonism of the ct2-adrenoceptor modifies this behavioural 
response to novelty, and whether this differs between genotypes.
Subsequent studies, focused on the effect placement in the LDEB has on NA efflux, in 
NK1+/+ and NK1-/- mice, using in vivo microdialysis. Systemic administration of 
RX821002 was again used to determine whether antagonism of the <X2-adrenoceptor 
effects NA efflux when mice are placed in a novel environment, and whether this is 
different between NK1+/+ and NK1-/- mice.
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5.2 Protocols
5.2.1 Behavioural light dark exploration box protocol
Experiments were conducted between 13:00-15:00 and 15:30-17:30 p.m. every day. 
Two LDEB were used side by side, so that animals were run in pairs. Animals were 
placed in the neutral zone (2 lux) to habituate for 60 min. This 60 min habituation 
period was chosen to allow time for efflux to stabilise when the LDEB protocol was 
combined with in vivo microdialysis. At 14:00 p.m. mice were dosed with either saline 
10 ml / kg i.p. or RX821002 (0.3 mg / kg i.p.) and left in the dark side of the exploration 
box for a further 30 min. The mice were then lifted out from the dark zone and placed in 
the centre of the light novel compartment ( 1 0  lux) facing away from the guillotine style 
door, which was raised to allow animals to traverse freely between the two 
compartments. Behaviour was then monitored for a further 30 min using a Sony 
Handycam Vision video recorder (see Section 2.7.1.2 for behaviours scored). At the end 
of the experiment the animals were removed from the LDEB and killed using an 
overdose of CO2 and cervical dislocation. The LDEB was then cleaned thoroughly with 
alcohol and water. The experiment was repeated at 15:30 p.m. (see Figure 5.1 for 
protocol).
< ► < ► < ►
Groupl: 13:00 -14:00 14:00-14:30 14:30-15:00 p.m.
Group2: 15:30 -  16:30 16:30 -17:00 17:00-17:30 p.m.
Figure 5.1: Experimental protocol for behavioural testing using the light / dark 
exploration box.
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5.2.2 Microdialysis in the light dark exploration box protocol
Probes were implanted as described in Section 2.6.2.
Due to diurnal variation in NA efflux and the behavioural dependence of the LDEB on 
the time of day (Costall et al., 1989), the timing of the behavioural experiment in the 
LDEB was synchronised with harvesting of extracellular NA during in vivo 
microdialysis. However, due to the necessary probe stabilisation, and the time required 
to obtain three consecutive stable basal samples, it was decided to bring the experiment 
forward 60 min. Animals were removed from their homecage, where they had been left 
overnight after probe implantation, and placed in the neutral zone ( 6  lux) for 60 min to 
allow for probe equilibration. Following equilibration, samples were collected every 20 
min until 3 consecutive stable samples established a stable baseline (typically 60 min). 
Mice were then dosed with either saline (10 ml / kg i.p.) or RX821002 (1 mg / kg i.p.) 
and placed back in the neutral zone. This dose of RX821002 was chosen based on the 
results from Chapter 4. A dose of 1 mg / kg i.p. produced a significant increase in NA 
efflux compared to saline treated NK1+/+ mice, in their home cage, and avoided 
possible adverse effects that may have been encountered with a higher dose. A 10-min 
sample was then collected, followed by a 20-min sample to allow for the 30-min 
pre-treatment time. Following pre-treatment, mice were placed in the centre of the light 
novel compartment (160 lux), facing away from the guillotine style trap door, which 
remained in place throughout the experiment. The counter-balanced lever arm attached 
to the swivel was secured to an upright stand attached to the side of the light zone. NA 
efflux was monitored for a further 120 min. (see Figure 5.2 for protocol)
Fhke
Eqnillhnidoii
M tn flM ifti
. FfcfVffd*-! flM|AJfc' wSIPSHp
CoHedkMiefNA
1 1 :0 0 -1 2 : 0 0 12:00-13:00 13:00-13:30 13:30-15:30 p.m.
Figure 5.2: Experimental protocol for in vivo microdialysis in the light / dark 
exploration box.
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5.2.3 Data analysis
Behavioural data were analysed using two-way ANOVA with Levene’s test for normal 
distribution, followed by one-way ANOVA to reveal differences between groups. If the 
Levene’s test was significant, data were analysed using Kruskull Wallis non-parametric 
ANOVA, followed by Mann-Whitney U (non-parametric) analysis. Co-variate analysis 
was also performed using total locomotor activity as a covariate, to identify differences 
that may have been masked or exaggerated due to a higher level of total spontaneous 
locomotor activity in one of the genotypes.
For microdialvsis data the NA content is expressed as fmol / 20 min without correction 
for probe recovery. When investigating the effect of the novel environment on NA 
efflux, the net change in NA efflux was calculated in order to compensate for any 
differences in basal NA across subjects. This involved subtracting the average of the last 
three basal samples, taken whilst the mouse was in the neutral compartment, from all 
samples (Dailey et al., 1996). Both absolute and net microdialysis data were analysed 
using repeated measures ANOVA with ‘bin’ and ‘time’ as ‘within subjects’ factors and 
‘genotype’ and ‘drug’ treatment as ‘between subjects’ factors. If data violated the 
Mauchley’s test for sphericity, then the Greenhouse-Geisser ‘e’ correction factor was 
used. If ANOVA revealed a main effect of ‘bin’,‘drug’, ‘genotype’ or a ‘drug x 
genotype’ interaction, the data were further analysed using a post-hoc one-way ANOVA 
or least significant difference (LSD) to identify significant differences between groups 
or pairs of data. The criterion for statistical significance was set at P  ^  0.05.
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5.3 R esu lts
5.3.1 Behavioural response to the light /  dark exploration box in NK1+/+ and 
NK1-/- mice
5.3.1.1 Effect o f NK1 receptor disruption on behaviour
Of the 12 behaviours scored, 5 behavioural responses differed between the two 
genotypes (Figure 5.3; Table 5.1).
• Total activity in both the light and dark zones of the shuttle box was higher in 
NK1-/- mice (Fi,27 = 5.13; P = 0.03).
•  Total number of rears were higher
in NK1-/- mice (Fi,2 6 = 5.49; P = 0.028).
• Total time spent in the light zone was lower in NK1-/- mice (F126 = 4.97; 
P = 0.036).
Of particular interest was the observation that NK1-/- mice perform fewer, and spend 
less time in, risk assessment behaviours:
• NK1-/- mice spent less time in flat-back approach (F 1,25 = 12.4; P = 0.002) and,
• performed fewer stretched-attendpostures, (F 1,25 = 49.5; P < 0.001).
To determine if any genotype-dependent behaviours were due to differences in 
locomotor behaviour, observed between NK1+/+ and NK1-/- mice, this was treated as a 
covariate in ANCOVA. After ANCOVA, three behaviours still differed between the 
genotypes. However, the apparent difference in total rearing behaviour was solely 
because of their difference in locomotor activity.
• Time in the light zone was less in NK1 -/- mice (F 1,26 = 8 .6 ; P = 0.008).
• Time spent in flat-back approach and number of stretched-attend postures 
were less in NK1-/- mice (Fi 2 5 = 7.29; P = 0.013 and Fi)2 5 = 39.58; P = 0.001) 
respectively.
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mm NK1+/+ RX821002 (0.3 mg/kg i.p.] 
U~7\ NK1-/- RX821002 (0.3 mg/kg i.p.)
FIGURE 5.3: Behaviours that show a main effect of ‘genotype’ in 
the light / dark exploration box. Asterisks indicate differences 
between individual treatment groups. For statistical details see 
Table 5.1. **P< 0.001. Values are mean ± s.em. n = 7.
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Behaviour Two-way ANOVA NK1+/+ Vehicle NK1 -/- Vehicle NK1+/+ RX821002 NK1-/- RX821002
Main effect of genotype
N u m b e r  o f  
S t r e t c h e d - a t t e n d  
p o s t u r e s
B e f o r e  A N C O V A
g g
A f t e r  A N C O V A
8 8
4 4  +  5 . 7 1 3  ± 1 . 4 3 0 . 7  ± 3 . 8 8 . 5  ±  0 . 6
F l a t  b a c k  a p p r o a c h  
(S)
B e f o r e  A N C O V A
g g
A f t e r  A N C O V A  
g g
1 2 4 . 8  ± 2 8 . 1 9 . 9  ± 3 . 1 5 3 . 4  ± 1 3 . 2 9 1 7  ± 4 . 8
T o t a l  t i m e  i n  l i g h t  
(S)
B e f o r e  A N C O V A  
g
A f t e r  A N C O V A  
g g
7 4 2 . 3  ±  1 4 2 . 2 4 3 5 . 5  ± 9 5 . 8 1 2 2 6 . 2 5  ±  1 9 6 . 8 8 3 3 . 1  ±  1 5 6 . 5
N u m b e r  o f  r e a r s
B e f o r e  A N C O V A  
g g
A f t e r  A N C O V A  n o  
s i g n i f i c a n c e
3 6  ± 8 . 6 6 6 . 5  ±  1 6 . 1 3 8 . 3  ±  8 . 4 9 2 . 3  ±  1 8 . 9
L o c o m o t o r  a c t i v i t y g 2 2 3 . 4  ± 4 1 . 8 4 0 6 . 9  ±  1 0 7 . 5 2 3 5 . 4  ±  4 5 4 3 6 . 4  ±  9 9 . 8
TABLE 5.1: behaviours demonstrating a main effect of genotype in the light / dark shuttle box. Values are mean ± s.e.m. n = 7. Two-way 
ANOVA: main effect of ‘genotype’: ‘g’ P<  0.05, ‘gg’ P < 0.01.
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5.3.1.2 Behaviours affected by a2-adrenoceptor antagonism independent o f genotype
A number of behaviours were altered by RX821002, irrespective of genotype (Figure 
5.4; Table 5.2).
•  Total number of grooms (F126 = 5.72; P = 0.025 ‘drug’)
• Total time spent grooming (F125 = 12.79; P = 0.002; ‘drug’)
• Time spent in the light zone (F126 = 7.89; P = 0.01; ‘drug’) 
were all increased in both genotypes.
• Stretched-attend postures were reduced in NK1+/+ and NK1-/- mice, before 
ANCOVA (F125 = 5.53; P = 0.028; ‘drug’).
•  Flat back approach appeared reduced in NK1+/+ mice and appeared increased
in NK1-/- mice, (Fi^s =-4.92; P = 0.04; ‘drug’) but no ‘drug x genotype’
interaction was evident.
After ANCOVA the same effects were observed.
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Total number of grooms Total time spent grooming
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FIGURE 5.4: Behaviours that show an overall effect of ‘drug’ in the 
light / dark exploration box. Asterisks indicate differences between 
individual treatment groups. For statistical details see Table 5.2. 
** P <  0.001. Values are mean ± s.e.m. n = 7.
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Behaviour Two-way ANOVA NK1+/+ Vehicle NK1-/- Vehicle NK1+/+ RX821002 NK1 -/- RX821002
Main effect of drug
Total time grooming 
(S)
Before ANCOVA 
dd
After ANCOVA 
dd
133.6 ±57.1 210.2 ±40.1 359.6 ± 17.3 363 ± 89.6
Total number of 
grooms
Before ANCOVA 
d
After ANCOVA 
d
7 ±2.5 12 ±1.4 14.3 ±2.1 17.9 ±3.1
Total time in light 
(S)
Before ANCOVA 
dd
After ANCOVA 
d
742.3 ± 142.2 435.5 ±95.8 1226.3 ± 196.8 833.1 ± 156.5
Number of 
Stretched-attend 
postures
Before ANCOVA 
d
After ANCOVA 
d
44 ±5.7 13 ±1.4 30.7 ±3.8 8.5 ± 0.6
Time spent in flat back 
approach 
(S)
Before ANCOVA 
d
After ANCOVA 
d
124.8 ±28.1 9.9 ±3.1 53.4 ±13.29 17 ±4.8
Table 5.2: Behaviours demonstrating a main effect of drug in the light / dark exploration box. Values show mean ± s.e.m. Two-way ANOVA: 
main effect o f ‘drug’: ‘d’ P<  0.05, ‘dd’ P <  0.01.
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5.3.1.3 Behavioural effects o f a2-adrenoceptor antagonism that depend on genotype
Systemic administration of the 012-adrenoceptor antagonist RX821002 (0.3 mg / kg i.p.) 
produced a number of behavioural changes in response to novelty that were observed in 
NK1+/+ mice only (Figure 5.5; Table 5.3).
•  Time spent grooming in the light zone was increased in NK1+/+ mice only. 
(Fi,2 5 = 8.1; P = 0.009; ‘drug x genotype’ interaction)
•  Time to return to the light zone was significantly reduced in NK1+/+ mice only 
(F1 24 = 4.55; P = 0.045; ‘drug x genotype’ interaction).
Although RX821002 had no significant effect on locomotor activity, again, locomotor 
activity was chosen as the covariate for ANCOVA, to determine if any of the apparent 
‘drug x genotype’ interactions observed could be explained by genotype differences in 
locomotor activity.
After ANCOVA:
•  Number of rears in the dark was reduced in NK1+/+ mice only (Fi,27 = 5.83; 
P = 0.024; ‘drug x genotype’ interaction).
• Number of returns to the light zone was reduced in NK1+/+ mice only 
(Fi,26 = 8.45; P = 0.008; ‘drug x genotype’ interaction).
• Latency to leave the light zone was increased in NK1+/+ mice only (F^24 = 5.55; 
P = 0.03; ‘drug x genotype’ interaction).
This indicates that the greater locomotor activity of NK1-/- mice, was masking ‘drug x 
genotype’ interaction. A significant ‘drug x genotype’ interaction was still present in 
time spent grooming in the light (F125 = 7.63; P = 0.012) and time to return to the light 
zone (F124 = 4.36; P = 0.05), suggesting that the difference in locomotor activity 
between NK1+/+ and NK1-/- mice did not affect these behaviours altered by 
012-adrenoceptor antagonism in NK1+/+ mice.
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FIGURE 5.5: Behaviours that show a ‘dose x genotype’ interaction in 
the light / dark exploration box. Asterisks indicate differences 
between individual treatment groups. *P < 0.05; **P< 0.01. a) and b) 
significance before and after ANCOVA. c), d) and e) significance only 
after ANCOVA. Values are mean ± s.e.m. n = 7. For statistical details 
see Table 5.3. 149
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Behaviour Two-way ANOVA NK1+/+ Vehicle NK1 -/- Vehicle NK1+/+ RX821002 NK1 -/- RX821002
Drug x Genotype interaction
Number of returns Before ANCOVA 
nothing 
After ANCOVA 
ii
22.43 ± 4.7 21.3 ±6 8.7 ±1.4 25.4 ±4.8
Time grooming in the 
light 
(S)
Before ANCOVA 
dd gg ii 
After ANCOVA 
dd gg ii
94.8 ± 44.6 58.4 ±25.7 332 ±31.2 84.6 ±38.1
Latency to leave light 
zone (S)
Before ANCOVA 
nothing 
After ANCOVA 
dd i
67 ± 12.6 73.2 ± 24.4 177.1 ±29.9 91.8 ±22.6
Number of rears in the 
dark
Before ANCOVA 
nothing 
After ANCOVA 
i
16.4 ± 4.9 15.7 ±5.2 7.3 ±2.3 22.7 ± 5.9
Time to return to light 
zone(S)
Before ANCOVA 
i
After ANCOVA 
i
30.9 ± 6.6 14.6 ±3.2 12.6 ±2.2 17.7 ±5.2
T able 5.3: Behaviours which show a drug x genotype interaction in the light / dark shuttle box. Values are mean ± s.e.m. n = 7. Two-way 
ANOVA: main effect of ‘drug’: ‘dd’ P  < 0.01; main effect of ‘genotype’: ‘gg’ P  < 0.01; ‘drug x genotype’ interaction: ‘i’ < 0.05; ‘ii’ P < 0.01.
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5.3.2 In vivo microdialysis in the light/dark exploration box
5.3.2.1 Basal nor adrenal ine effl ux between genotypes
No difference between basal NA efflux was found between NK1+/+ and NK1-/- mice 
(F139 = 2.36; P = 0.13; T^o-To;‘genotype’; Figure 5.6a). Average basal NA efflux was 
9.88 ± 2.06 frnol / 20 min in NK1+/+ mice and 6.77 ± 1.23 fmol / 20 min in NK1-/- 
mice. There was also no difference between groups destined for different drug 
treatments (F 1,39 = 1.56; P = 0.22; ‘drug’; Figure 5.6a).
5.3.2.2 Effect o f saline or RX821002 injection on noradrenaline efflux in NK1+/+ and 
NK1-/- mice
Raw data: Before placement in the novel zone, at time T20, RX821002 (lmg / kg i.p.) 
increased NA efflux in NK1+/+ mice, only (Figure 5.6a). This increase in NA efflux 
was greater than in NK1-/- mice treated with RX821002 {P = 0.01) and greater than 
both saline treated NK1+/+ (P = 0.025) and NK1-/- (P = 0.004) mice. Saline injection 
did not increase NA efflux in either genotype (Figure 5.6a).
5.3.2.3 Effect of placement in the novel light zone on noradrenaline efflux
Raw data: From T 4o -T g o  a main effect of ‘drug’ was found (¥1,35 = 9.15; P = 0.005), and 
a ‘drug x genotype’ interaction (F135 = 4.73; P = 0.037). Post-hoc analysis revealed that 
RX821002 increased NA efflux in NK1+/+ mice, only, and only for the first 60 min 
after placement in the light novel compartment. This increase in NA efflux in 
RX821002 treated mice was greater than NK1-/- mice treated with RX821002 
(P = 0.006). The increase in NA efflux in RX821002 pre-treated NK1+/+ mice was also 
greater than saline pre-treated NK1+/+ (P = 0.001) and NK1-/- (P = 0.001) mice (Figure 
5.6a).
Net data: Analysis of the net increase in NA efflux did not reveal a difference between 
groups (Figure 5.6b). From T40-T80 the main effect of ‘drug’ was approaching 
significance (Fi)35; P = 0.059). However, the ‘genotype x drug’ interaction was not 
significantly different (F 1,35 = 3.11; P = 0.087).
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a) Effect of placement in the light I dark exploration 
on noradrenaline efflux 
in NK1+/+ and NK1 -/- mice
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FIGURE 5.6: Effect of placement in the light dark / exploration box on
a) raw noradrenaline efflux and b) net noradrenaline efflux in NK1+/+ 
and NK1-/- mice. *P< 0.05. Values are mean ± s.e.m. n = 9-13.
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5.4  D is c u s s io n
5.4.1 Effect of placement in a novel environment on behaviour in NK1+/+ and 
NK1-/- mice
5.4.1.1 Effect o f NK1 receptor disruption on behavioural response to novelty
Before ANCOVA analysis, these present studies found an effect of genotype on 5 
behaviours. These included decreased risk assessment behaviours and time spent in the 
light zone in NK1-/- mice, whereas total spontaneous locomotor and rearing 
behaviours were increased in NK1-/- mice. A previous study, using the same strain of 
mice in the LDEB, found that after ANCOVA analysis, all of the 12 behaviours scored 
differed between genotype (Herpfer et a l, 2005).
Time spent in the light zone, latency to leave the light zone and the number o f returns
to the light zone are behaviours typically believed to represent active avoidance of an 
aversive stimulus. NK1-/- mice spend less time in the light zone, which may be due to 
an increase in active avoidance behaviour. Alternatively, disruption of the NK1 receptor 
could result in an increase in the time spent actively exploring the two compartments, 
with the overall effect that they spend less time in the light zone and have a higher 
locomotor activity. Since NK1+/+ mice spend more time performing risk assessment 
behaviours than NK1-/- mice, it is also possible that the higher amount of time spent in 
the light zone by NK1+/+ mice, is due their engagement in risk assessment behaviour.
In these studies, as shown previously (Herpfer et al, 2005), NK1-/- mice exhibit higher 
spontaneous locomotor activity. Increased activity of the LC, and central noradrenergic 
neurotransmission, is believed to be critical for behavioural arousal (Carli et a l, 1983; 
Cole & Robbins, 1992; Robbins, 1997; Sauvage & Steckler, 2001). As shown in 
Chapter 3, halothane-anaesthetised NK1-/- mice possess higher basal NA efflux, 
demonstrating a difference in the regulation of the noradrenergic system between these 
two genotypes. A difference in the regulation of the noradrenergic system between 
NK1+/+ and NK1-/- mice may result in an increased sate of arousal, leading to 
increased spontaneous locomotor activity observed in NK1-/- mice. The higher
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spontaneous locomotor activity in NK1-/- mice, could also contribute to the decreased 
time these mice spend in the light zone.
Rearing is generally interpreted as an exploratory behaviour. NK1-/- mice demonstrate 
an increase in this particular behaviour, compared to NK1+/+ mice. Stimulation of LC 
neurones electrically increases the time rats spend investigating / exploring novel 
objects (Devauges & Sara, 1991). Inhibition of the LC using an (X2-adrenoceptor agonist 
e.g. clonidine decreases this exploration because of sedation (Sara et al., 1995), whereas, 
the a 2-adrencoceptor antagonist idazoxan enhances the response of LC neurones to 
novelty (Sara et al., 1994). The increased rearing behaviour of NK1-/- mice could, 
therefore, be due to an increase in NA efflux, as shown in Chapter 3. After ANCOVA 
analysis, with locomotor activity as the covariate, the genotype dependent difference in 
rearing behaviour was abolished. The increase in rearing behaviour, therefore, is 
explained by an overall increase in the locomotor activity of the NK1-/- mice, which 
again could be attributed to the higher activity of the noradrenergic system in these mice.
The most striking effect of disruption of the NK1 receptor was seen on the risk 
assessment behaviours with NK1-/- mice performing fewer stretched-attend postures 
and spending less time in the flat back approach. Stretched-attend postures and flat 
back approach reflect risk assessment in potentially threatening environments (Holmes 
et al., 2001). The decreased risk assessment behaviours, in NK1-/- mice, suggest a 
decreased stress response to a novel environment. One possible explanation may be that 
disruption of the NK1 receptor modifies the noradrenergic system in such a way that 
NK1-/- mice are better able to cope with the novel adverse environment presented by 
the LDEB. Since noradrenergic transmission in the brain is essential for coping with 
stress (Anisman, 1985), it is possible that disruption of the NK1 receptor modifies the 
noradrenergic system so that NK1-/- mice are better able to ‘cope’ with the stressor 
novelty.
Alternatively it is possible that genetic disruption of the NK1 receptor impacts on other 
neurotransmitter systems, for example 5-HT, also. In NK1-/- mice, the 5-HTiA receptor 
is down-regulated and desensitised (Froger et a l , 2001; Santarelli et a l , 2001). Risk 
assessment behaviours are decreased by 5-HTia antagonists (Rodgers & Cole, 1994).
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The difference in risk-assessment behaviour may, therefore, be due to down-regulation 
of the 5-HTia receptor in NK1 -/- mice
5.4.1.2 Effect o f ct2-adrenoceptor antagonism independent o f genotype
A number of behaviours were modified by RX821002 independent of genotype. These 
were an increase in the total number of grooms and total duration spent grooming. 
Grooming is a complex and essential ritual to rodent behaviour (Kalueff & Tuohimaa, 
2005). In rodents, grooming can represent a common attitude of body care, a 
displacement behaviour due to a stressful environmental situation and / or a behavioural 
pattern, expression of which is affected by specific damage to its neural substrates (for 
review see: (Spruijt et al., 1992)). Mouse grooming can be altered by various stressors, 
and is thought to be a coping strategy to deal with the stressful situation (Dantzer, 1993), 
which could explain the increase in this particular behaviour.
Time spent in flat back approach and the number of stretched-attend postures in 
RX821002 pre-treated NK1-/- mice were slightly increased and decreased respectively. 
In NK1+/+ mice RX821002 decreased both flat back approach and stretched-attend 
postures. Since RX821002 binds to 5-HTia receptors where it acts as an antagonist (Kx 
20-30 nM), (Grijalba et al., 1996; Newman-Tancredi et al., 1998; Ogilvie & Clarke, 
1998), and previous studies have shown that 5-HTia receptor antagonists decrease risk 
assessment behaviours (Rodgers & Cole, 1994), it is possible that binding of RX821002 
to 5-HTia is a confounding factor in these studies.
These effects of RX821002 independent of genotype, do suggest that RX821002 is 
having some residual effect on 012-adrenoceptors in both NK1+/+ and NK1-/- mice. It is 
possible that these effects are mediated through a 2-adrenoceptor expressed on neurones 
which do not express NK1 receptors, since it is possible that <X2-adrenoceptors are 
modified only on those neurones which co-express a 2-adrenoceptors and NK1 receptors.
5.4.1.3 Effect o f a2-adrenoceptor antagonism dependent on genotype
It is a generally held view that an increase in NA release in the brain is one of the 
underlying causes of anxiety (Redmond, Jr. & Huang, 1979). There is also evidence to
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challenge this idea, that suggests that an increase in LC activity that accompanies 
stressful situations may also acts as a compensatory, coping mechanism (Weiss et al., 
1994).
Before ANCOVA analysis, significant ‘drug x genotype’ interactions were observed on 
time spent grooming in the light and time to return to the light zone. After taking into 
consideration individual differences in locomotor activity, an effect of RX821002 in 
NK1+/+ mice, only, was also observed on number of returns to the light zone, number 
of rears in the dark and latency to leave the light zone. This suggests that the higher 
locomotor behaviour, in NK1-/- mice, was masking effects of RX821002 dependent on 
genotype.
Although the LDEB, in these studies, was not used to determine anxiogenic / anxiolytic 
responses it is interesting to note that anxiolytics e.g. BDZs increase exploratory rearing 
behaviour of rodents in the dark zone (Costall et al., 1989; Shimada et al., 1995). The 
marked decrease in rearing behaviour in the dark zone in RX821002 pre-treated 
NK1+/+ mice, but not in NK1-/- mice, may, therefore, suggest an anxiogenic effect of 
this a 2-adrenoceptor antagonist observed only in NK1+/+ mice. Anxiolytic BDZs, also 
increase the latency to leave the light zone of mice in the LDEB (Costall et al., 1989). 
Here, NK1+/+ mice treated with RX821002 demonstrate a marked increase in the 
latency to leave the light zone. In contrast, this behaviour was unaffected by RX821002 
in NK1-/- mice. There are two possible explanations for these findings. There could be a 
decrease in anxiety-like behaviour so that NK1+/+ pre-treated mice spend more time 
exploring the novel compartment. This could account for the increase in latency to leave 
the light zone. Alternatively it is likely that the novel environment increases the activity 
of the LC-noradrenergic system. This increase in noradrenergic activity would be 
potentiated by systemic administration of the ci2 -adrenoceptor antagonist RX821002. 
An increase in central noradrenergic activity induced by RX821002, could lead to 
feelings of alarm or fear (Redmond, Jr. & Huang, 1979) or vice versa. Fear can elicit a 
freezing behaviour in rodents (Graeff, 1994). Ethologically, freezing behaviour can be 
thought of as one type of predator avoidance reaction (Blanchard et al., 1975; Takahashi 
et al., 2005). The level of fear could dictate the animals response, and it is possible that 
an increase in novelty may turn exploratory behaviours or escape reactions into freezing 
(see: (Haapalinna et al., 1999)), leading to the increased latency to leave the light zone
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in the NK1+/+ mice, supporting an anxiogenic like effect of RX821002 in NK1+/+ 
mice only.
The use of (X2-adrenoceptor antagonists, in these current studies, enabled identification 
of certain genotype-dependent behavioural differences that could be attributed to a 
difference in the regulation of the noradrenergic nervous system. Time to return to the 
light zone after first exit, is generally viewed as passive avoidance behaviour. 
012-Adrenoceptor antagonists e.g. RX821002 and atipamezole decrease the time to 
return to the light zone in NK1+/+ mice, so that they are indistinguishable from NK1-/- 
mice pre-treated with either saline or the a 2-adrenoceptor antagonist (Fisher et al., 2003; 
Fisher et al., 2004). Yohimbine decreases time to return to the light zone after first exit 
in NK1+/+ mice, only, so that they are indistinguishable from NK1-/- mice treated with 
vehicle (Stewart et al., 2002). Therefore, of the 12 behaviours scored during the LDEB, 
time to return to the light zone is the one of the most likely behaviours that can be 
attributed to a difference in the function of the noradrenergic system between NK1+/+ 
and NK1-/- mice.
Grooming in rodents is increased by arousing / stressful conditions e.g. novelty (See: 
(Spruijt et al., 1992). The marked increase in time spent grooming in the novel light 
compartment was observed in NK1+/+ but not NK1-/- mice, following pre-treatment 
with RX821002. It is possible that systemic administration of RX821002 potentiated the 
stress induced release of NA in response to novelty in NK1+/+ mice, only. Via 
activation of ai-adrenoceptors, this may facilitate ACTH secretion and an increase in 
grooming behaviour (Cecchi et al., 2002b; Cecchi et al., 2002a).
5.4.2 Microdialysis measurement o f noradrenaline efflux in a novel environment
The studies describe, for the first time, the effect of placement in a novel compartment 
on NA efflux in mice. Experiments conducted previously in this laboratory, on rats, 
have shown that placement in a novel environment increases NA efflux (Dailey & 
Stanford, 1995; Dailey et al., 1996; McQuade et al., 1999), as does a conditioned cue 
for placement in the aversive environment (McQuade & Stanford, 2000).
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5.4.2.1 Effect o f NK1 receptor disruption on noradrenaline efflux in the light /  dark 
exploration box
No genotype dependent difference in NA efflux was found when animals were placed 
either in the dark zone or the novel light zone. What is interesting to note, however, is 
the difference in basal NA efflux between mice placed in the dark zone to habituate, and 
those animals that had been left in their home cage over night and in which the 
experiment was conducted (Chapter 4). The average basal efflux of NK1+/+ mice left in 
their home cage was 4.72 ± 0.34 fmol / 20 min, compared with 9.88 ± 2.06 
fmol / 20 min in animals placed in the dark zone of the LDEB to habituate. The average 
basal NA efflux in NK1-/- mice left in their home cage was 5.22 ± 0.36 fmol / 60 min, 
compared with 6.77 ± 1.23. However, as these two experiments were not fully 
randomised with each other it is not possible to draw direct comparisons between the 
two.
5.4.2.2 Effect o f saline and RX821002 pre-treatment on noradrenaline efflux in the 
light /  dark exploration box
Analysis of the raw microdialysis data revealed that pre-treatment with RX812002 
increased NA efflux in NK1+/+ mice, only. This increase in NA efflux occurred before 
the mice were transferred to the novel light compartment. Pre-treatment with saline did 
not increase NA efflux in either genotype. The effect of the saline injection on NA 
efflux is rather variable, with some studies reporting an increase (Dailey et al., 1996) or 
no effect on NA efflux following saline injection (Mason et al., 1998).
However, analysis of net data showed no difference in the net increase in NA efflux 
following either RX821002 or saline pre-treatment. Suggesting that the higher basal NA 
efflux in the NK1+/+ mice destined for RX821002 treatment was responsible for the 
observed increase in NA efflux when the raw data was analysed.
5.4.2.3 Effect o f placement in the light novel compartment on noradrenaline efflux
The only group which demonstrated an increase in NA efflux following placement in 
the light novel compartment were NK1+/+ mice pre-treated with RX821002. However,
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the net increase in RX821002 pre-treated mice was not different between groups, again 
suggesting that the increase in NA efflux observed with the raw data was due to a 
higher basal NA efflux in this group of mice. The increase in NA efflux observed in 
NK1 +/+ mice treated with systemic RX821002 dissipated after the first 60 min of 
placement in the novel arena. This suggests an habituation to the novel compartment 
which is in agreement with previous microdialysis studies (Dailey et al., 1996; Dailey & 
Stanford, 1995; McQuade & Stanford, 2000; McQuade et al., 1999) and studies 
demonstrating that the increase in activity of the LC-noradrenergic system declines 
following repeated exposure to a sensory stimulus as the animals interest in them, or 
attention to them, declines (Jacobs, 1986; Rasmussen et al., 1986; Vankov et al., 1995; 
Herve-Minvielle & Sara, 1995). Furthermore, the increase in NA efflux in RX821002 
pre-treated NK1+/+ mice over the first 60 min of placement in the LDEB corresponds 
with the period during which behavioural monitoring took place, suggesting that the 
increase in NA efflux could contribute to behavioural changes induced by RX821002 in 
NK1+/+ mice: e.g. decreased time to return to the light zone and increased time to leave 
the light zone.
5.4.3 Caveats
The lack of ‘genotype x drug’ interaction of RX821002 on net NA efflux but an obvious 
effect on the raw NA concentration in the frontal cortex of NK1 +/+ mice suggests the 
variance of the sample masked the anticipated change, and that the n number should be 
increased. However, performing the Mead’s (1988) ‘Resource equation’ on this 
experiment proves sufficient numbers of animals were used (see: Festing et al., 2002). 
Therefore, it may be possible to say that there is a biological change but it just misses 
statistical significance.
The behavioural experiments and the in vivo microdialysis experiments carried out in 
the LDEB were performed separately. Previous studies conducted in this laboratory 
have demonstrated that implantation of a probe modifies the behavioural response to 
certain environmental stimuli (McQuade et al., 1999). These studies suggest probe 
implantation intensifies the behavioural response to a novel environment. Therefore, 
future studies could investigate the behavioural and NA efflux response of NK1+/+ and 
NK1-/- mice to the LDEB in a fully randomised experiment.
159
Chapter 5: Behaviour and microdialvsis in the lisht /  dark exploration box
5.4.4 Summary and conclusions
The behavioural response to novelty, a non-noxious naturalistic environmental stressor, 
is affected by genetic disruption of the NK1 receptor. NK1-/- mice demonstrate an 
increase in spontaneous exploratory behaviours e.g. rearing behaviour and locomotor 
behaviour. A decrease in active avoidance behaviour e.g. time spent in the light zone 
and a decrease in risk assessment behaviours e.g. stretched-attend postures and time in 
flat back approach is also found with NK1-/- mice.
Systemic RX821002 produces a number of behavioural changes independent of 
genotype:
Total number of grooms 
Total time spent grooming 
Time spent in the light zone
Number o f stretched-attend postures 
Time spent in flat back approach
}> In both NK1+/+ and NK1-/- mice.
In both NK1+/+ and NK1-/- mice, 
although time spent in flat back 
approach appeared slightly 
increased or unchanged in NK1-/- 
mice.
Systemic RX821002 produces a number of behavioural changes dependent of genotype:
Time to return to the light zone 
Rears in the dark zone 
Returns to the light zone
Time spent grooming 
Latency to leave the light zone
These behavioural changes are 
observed in the NK1+/+ mice only, 
supporting the hypothesis that in 
NK1-/- mice the 012-adrenoceptor is 
impaired in some way.
Placement of NK1-/- mice in a novel compartment does not result in an increase in NA 
efflux in either saline or RX821002 pre-treated animals. In contrast, placement of 
NK1+/+ mice in a novel environment increases NA efflux but only following systemic
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administration of RX821002. However, further experiments using microdialysis in the 
LDEB are required to confirm that this increase in NA efflux is not purely the result of 
an increase in basal NA efflux in this group of mice.
The next chapter describes experiments investigating the localisation and density of the 
enzymes involved in the synthesis of NA, along with the noradrenaline transporter 
(NAT), involved in the reuptake and inactivation of NA. A difference in the density of 
these enzymes or the NAT could contribute to the difference in basal NA efflux in 
NK1+/+ and NK1-/- mice. Studies in the following chapter also investigate the density 
and functional activity of the ct2-adrenoceptor, the prime candidate underlying the 
difference in NA efflux between NK1+/+ and NK1-/- mice.
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CHAPTER 6
INVESTIGATING arADRENOCEPTOR DISTRIBUTION AND 
FUNCTION IN NK1+/+ AND NK1-/- MICE
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6  INVESTIGATING a2-ADRENOCEPTOR DISTRIBUTION AND 
FUNCTION IN NK1-/- AND NK1+/+ MICE
6.1 I n t r o d u c t io n
This chapter presents results from a series of experiments profiling the localisation and 
density of a 2-adrenoceptors, using a combination of molecular approaches including 
immunohistochemistry (IHC), Western blot protein analysis and [3H]RX821002 
receptor autoradiography. The functional activity of 012-adrenoceptors was investigated 
using adrenaline-stimulated [35S]GTPyS binding. Noradrenergic neuronal markers: e.g. 
dopamine-p-hydroxylase (DpH), tyrosine hydroxylase (TH) and the noradrenaline 
transporter (NAT) are also compared in NK1+/+ and NK1-/- mice.
6.1.1 Background
Although the noradrenergic system of the rat has been extensively mapped (Svensson, 
1982; Maeda et al., 1991; Iijima, 1993), little is known about its distribution in the 
mouse CNS. Therefore, one of the aims of this project was to identify noradrenergic 
neurones in both the frontal cortex (M2) region, at the level of probe implantation, and 
the locus coeruleus (LC), using noradrenergic neuronal markers in NK1-/- and NK1+/+ 
mice. Methods chosen included immunohistochemical localisation of the enzymes DpH 
and TH. The distribution of NA terminals in the cortex is most clearly demonstrated by 
the immunocytochemical localisation of DpH, the enzyme responsible for conversion of 
dopamine (DA) to noradrenaline (NA) in the biosynthetic pathway. TH, the 
rate-limiting enzyme in the synthesis of adrenaline, NA and DA, is also a valuable 
marker for mapping the noradrenergic system. However, it is found in adrenergic, 
noradrenergic and dopaminergic neurones, so DpH is the more specific marker for the 
noradrenergic system. It is important to note that DpH is also found in adrenaline 
containing neurones, but, there are only a few present in the rodent brain, projecting in 
low density to forebrain regions.
As described in Section 1.4.3 the NAT is responsible for the clearance of NA from the 
synaptic cleft. The NAT is found on noradrenergic neurones, only (Lorang et al., 1994).
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This makes it a suitable marker with which to map noradrenergic neurones in NK1+/+ 
and NK1-/- mice.
Previous microdialysis studies showed a 4-5-fold increase in NA efflux in the frontal 
cortex of NK1-/- compared with their wild-type counterparts (Chapter 3). The 
hypothesis was that this may be due to a downregulation or desensitisation of 
autoregulatory 012-adrenoceptors either in the frontal cortex (FCtx) or LC. The M2 
region of the FCtx was chosen for analysis of the 012-adrenoceptors (function and 
density) as the microdialysis probe was placed in this brain area. As described in 
Section 1.4.4, agonist activation of 012-adrenoceptors decreases noradrenergic neuronal 
firing-rate and release. A decrease in either the density or functional activity of these 
receptors could be the cause of, or contribute to, the increase in NA efflux observed in 
NK1-/- mice. This would also echo the findings of Froger and Santarelli (Froger et al., 
2001; Santarelli et al., 2001), who demonstrated a decrease in both the density and 
function of autoregulatory 5-HTia receptors in NK1-/- mice. Downregulation and 
desensitisation of 5-HTia autoreceptors, results in an increase in the firing-rate of dorsal 
raphe (DR) neurones and an increase in 5-HT release in NK1-/- mice following 
treatment.
It is also possible that there is a difference in the amount / activity of the enzymes 
involved in the synthesis of NA (DpH and TH). The use of these enzymes as markers 
for mapping the noradrenergic system of the M2 region of the frontal cortex and LC in 
NK1-/- and NK1+/+ mice also enabled analysis of whether there was an observable 
difference in the density of these two enzymes, which could account for the difference 
in NA efflux. It is, however, important to note that a difference (or lack of) in the 
density of the enzymes involved in the synthesis of NA does not provide an index for 
their activity.
A number of approaches were taken to investigate a 2-adrenoceptor protein density and 
function. These included: preliminary IHC analysis; Western blot protein analysis; 
radioligand receptor autoradiography; and measurement of adrenaline-stimulated 
[35S]GTPyS binding to brain sections of NK1+/+ and NK1-/- mice to investigate the 
coupling of a 2-adrenoceptors to G proteins. This approach was based on a study by
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Froger et al, (2001) who compared the autoregulatory pre-synaptic 5-HTiA receptor, in 
the same background strain of NK1-/- and NK1+/+ mice (Froger et al., 2001).
By analogy with the results from Froger et al., (2001), it was predicted that the increase 
in basal NA efflux, in anaesthetised NK1-/- mice, could be attributed to either a 
downregulation and / or desensitisation of ct2-adrenoceptors. This could be occurring at 
either the noradrenergic terminals in the frontal cortex, where they act to decrease 
release of NA, somatodendritically, at the level of the LC, where they act to decrease 
firing-rate, or both. A decrease in the binding density of [ H]RX821002 and / or a 
decrease in [35S]GTPyS adrenaline-stimulated binding in NK1-/- mice would support 
this proposal.
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6.2  P r o t o c o l s
6.2.1 Mice
All experiments were conducted on tissue from adult male NK1-/- and NK1+/+ 
mice (n = 3-8 per genotype).
6.2.2 Immunohistochemistry
As described in Section 2.8 and Appendix 1.
6.2.3 Western blot protein analysis 
As described in Section 2.9.
6.2.4 fH ]RXUl002 and f  HJrauwolscine receptor autoradiography 
As described in Section 2.10.
6.2.5 Adrenaline-stimulated f sS]GTPyS binding assay 
As described in Section 2.11.
6.2.6 Data analysis
Data obtained from Western blot protein analysis, [ H]RX821002 ligand binding and 
[35S]GTPyS were analysed using an independent samples t-test. [35S]GTPyS data were 
also analysed using the Wilcoxon matched-pairs signed-ranks test.
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6.3  R e s u l t s
6.3.1 Immunohistochemical localisation of the a,2 a-adrenoceptor, 
dopamine/3-hydroxylase, noradrenaline transporter and tyrosine hydroxylase 
in the frontal cortex and locus coeruleus o f NK1+/+ and NK1-A mice
The initial IHC for DpH, the NAT and TH revealed extensive localisation of the 
enzymes and transporter in both the M2 region of the FCtx, (Figure 6.1a-f), and LC 
(Figure 6.2a-d). However, no differences between the genotypes were found. DpH and 
TH were used as histochemical markers to map the location of the LC (Figure 6.2a-d). 
IHC studies confirmed the expression of NK1 receptors on LC neurones (Figure 6.3). 
The initial immunohistochemical findings suggest that there are fewer 
a 2a-adrenoceptors in the LC of NK1-/- mice compared with their wildtype counterparts 
(Figure 6.4a-b).
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Bregma + 2.10 mm
f)
F ig u r e  6.1a-f: Dopamine-P-hydroxylase in a) NK1+/+ and b) NK1-/- mice. 
Noradrenaline transporter in c) NK1+/+ and d) NK1-/- mice. Tyrosine hydroxylase 
in e) NK1+/+ and f) NK1-/- mice. X 40 magnification at the level of the frontal 
cortex (M2 region), scale = IOjiM. Arrows indicate fibers.
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Bregma 
-5.34 mm
Bregma 
-5.4 mm
Bregma 
-5.3 mm
iregma 
5.34 mm
F i g u r e  6.2: a-c) Identification of the locus coeruleus (LC) using
dopamine-|3-hydroxylase, X 1.6 magnification, scale = 1 mm, and d) tyrosine 
hydroxylase X 5 magnification, scale = 1 mm, as the histochemical marker with 
DAB as the visualisation reaction. The LC is labelled blue in the mouse brain atlas 
images.
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Figure 6.3: Expression of NK1 receptors in the locus coeruleus a) X 10 
magnification, scale = 3 mm and b) X 20 magnification, scale = 0.25 mm, with Cy3 
as the visualisation reaction.
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F i g u r e  6.4: Expression of <X2 a-adrenoceptors in the locus coeruleus (LC) of a )  
NK1+/+ and b) NK1-/- mice. Preliminary immunohistochemistry of the LC 
suggested a reduced density of a 2 *-adrenoceptors in the LC of NK1-/- mice X 40 
magnification. Arrows indicate a 2 a-adrenoceptor labelling.
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6.3.2 Western blot analysis o f  a.2a-adrenoceptor and noradrenaline transporter 
protein
There was no difference in either a,2a-adrenoceptor or NAT protein in the FCtx, Hipp or 
LC of NK1+/+ and NK1-/- mice (Figure 6.5a-c; Table 6.1).
Amount of <X2 a-adrenoceptor and NAT protein expressed as percentage of
NK1+/+ mice
a 2 a-adrenoceptor FCtx % Hipp % LC %
NK1+/+ 100 ± 1.79 100 ±1.54 100 ±3.34
NK1-/- 99.87 ± 2.25 101.37 ± 1.95 107.31 ±2.67
NAT FCtx % Hipp % LC %
NK1+/+ 100 ±22.75 100 ±12.32 100 ±8.94
NK1-/- 83.64 ± 11.49 132 .69 ±25.69 117.23 ±5.88
T a b l e  6.1: Western blot protein analysis of the amount of <X2 a-adrenoceptor and 
NAT protein in the FCtx, Hipp and LC of NK1+/+ and NK1-/- mice. Values are 
mean ± s.e.m. (n = 5-6), expressed as a percentage of the density of protein found in 
NK1+/+ mice. FCtx: frontal cortex; Hipp: hippocampus; LC: locus coeruleus; 
NAT: noradrenaline transporter.
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FIGURE 6.5a-c: Western blot protein analysis of c^-adrenoceptors and 
the noradrenaline transporter (NAT) in the frontal cortex (FCtx), 
hippocampus (Hipp) and locus coeruleus (LC). Values are presented as 
percentage of NK1+/+ mice from n = 5-6.
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6.3.3 Quantitative a2 -adrenoceptor autoradiography with /3HJRX821002 and 
f  HJrauwolscine in NK1+/+ and NK1-/- mice
In these studies, receptor density was assessed at an approximate K<i (single 
concentration point) for the radioligand.
[ H]RX821002 binding was found throughout the brain (Figure 6 .6 a-d). Limbic brain 
regions, receiving a dense noradrenergic innervation from the LC, were also analysed. 
These included: the amygdala (amyg), bed nucleus stria terminalis (BNST), cerebellum 
(CBM), hippocampus (Hipp), lateral septum (LSI), locus coeruleus (LC), olfactory 
bulbs (OB), periaqueductal grey (PAG) and the frontal cortex (M2 region). Areas with 
the highest density of a 2a-adrenoceptors were: the LSI, BNST and PAG (Table 6.2). 
The binding density in all these brain regions was not different in NK1+/+ and NK1-/- 
mice. In particular, no difference was found between NK1+/+ and NK1-/- in the area of 
the LC and FCtx (Figure 6.7a-b). The lowest binding density of [3H]RX821002 in both 
genotypes was found in the CBM (Table 6.2). Binding of the 
a 2C-adrenoceptor-preferring radioligand, [ H]rauwolscine, was above film background 
only in the caudate putamen, area CA1 of the hippocampus and the nucleus accumbens 
(Figure 6 .6 e-f).
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a,
NK1-/-
a ,
NK1+/:
N K 1+/+
a 2
b)
d)
a 2c
e) NK1+/+ 
A ccum
NK1+/+ f) NKl-/-
-V * ' ,
<*2c
F IG U R E  6 .6 : a-d) [3HJRX821002 and e-f) [3H |rauw olscine binding in horizontal 
sections o f  N K 1+/+  and N K l- /-  m ice. The selected  au toradiographic im ages (a-d) show  
the distribution  o f  0 4 -adrenoceptor [3H ]R X 821002 binding in the o lfactory  nucleus 
(O n), lateral septum  (L SI), striatum  (C P u), bed nucleus o f  the stria term inalis (B N ST ), 
subparafasicu lar thalam ic nuclei (SPF), caudal CA1 region o f  the h ippocam pus (C A 1), 
entorhinal cortex (E nt), m esencephalic trigem inal nucleus (M eS) and locus ceru leus  
(L C ), Frontal cortex (F C tx), M 2 region. B inding o f  the a ^ -a d ren o cep to r  p referrin g  
radioligand, [3H ]rauw olscine, w as found only in the striatum  (C P u) and A ccum bens 
(nucleus accum bens) and CA1 region o f  the hippocam pus. R eceptor density  is expressed  
as fm ol /  m g w et tissue. V alues are m ean ±  s.e.m . For each region , b ilateral 
m easurem ents w ere m ade from  at least three brain sections. N =  3. Scale bar =  3 .5  mm.
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Brain region Receptor density (fmol / mg tissue ± s.e.m.)
NK1+/+ NKl -/-
Amygdala 50.02 ± 22.9 53.42126.6
Bed nucleus stria 
terminalis
107.39 ±18.47 83.061 12.72
Cerebellum (Granule 
cell layer and molecular 
layer)
18.98 ± 14.77 20.091 15.31
Hippocampus (CA1, 
CA2, CA3, dentate 
gyrus, subiculum, 
parasubiculum and 
presubiculum)
58.15±7.77 47.481 13.51
Locus Coeruleus 100.47 ± 9.1 92110.48
Lateral Septum (dorsal, 
intermediate and 
ventral part)
94.3918.15 95.991 6.22
Frontal cortex (M2) 63.49 1  37.57 68.55 1  33.72
Entire olfactory bulb 63.021 17.59 53.35 1  11.85
Periaqueductal Grey 92.481 16.75 70.9913.12
T a b l e  6.2: a 2 a-Adrenoceptor density was measured in brain regions by 
quantitative autoradiography using 1 nM [3H]RX821002 as ligand. Values 
represent specific binding. Receptor density is expressed as fmol / mg tissue ± 
s.e.m. and represents mean determinations of at least three sections from n=3 
animals. Non-specific binding was determined in the presence of 100 pM 
RX821002. Non-specific binding was not detected on autoradiographs and so film 
background was taken as non-specific binding (approximately 1-2 fmol / mg 
tissue).
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Density of a 2-adrenoceptors in the locus coeruleus 
of NK1+/+ and NK1-/- mice
1 2 0  -i
I NK1 +/+ 
] NK1-/-
b)
140
Density of a 2-adrenoceptors in the frontal cortex 
of NK1+/+ and NK1-/- mice
CM a>100 
00 3
2  *»
N K 1 + /+  
] N K 1 - /
F ig u r e  6.7: Bar chart depicting quantified differences between NK1+/+ and 
NK1-/- mice in a) the locus coeruleus and b) the frontal cortex (M2 region), n = 3.
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6.3.4 Analysis o f the functional activity of ct2 -adrenoceptors in NK1+/+ and NK1-/- 
mice using adrenaline-stimulated f sS]GTPyS binding
Optical density measurements of [35S]GTPyS autoradiographic measurement were made 
within the LC and M2, under four experimental conditions:
• Non-specific
• Basal
• Adrenaline-stimulated
• RX821002 alone
In both NK1+/+ and NK1-/- mice, adrenaline (100 pM) increased [35S]GTPyS labelling
*>c
(Table 6.3, Figure 6 .8 ). Adrenaline stimulated [ S]GTPyS binding in most brain 
regions, except within white matter, mesencephalon and CBM (Figure 6 .8 c-d).
c
Adrenaline-stimulated [ S]GTPyS binding was reduced to basal levels by the specific 
(X2-adrenoceptor antagonist RX821002 (100 pM; Figure 6 .8 a-f). RX821002 alone, did 
not appear to have any observable effects on basal adrenoceptor activity (Figure 6 .8 a-f).
The pattern of adrenaline-stimulated [ S]GTPyS binding corresponds well with the 
distribution of 012-adrenoceptor binding sites, as determined by receptor
”3
autoradiography using [ HJRX821002 (Figure 6.7a-d). High binding densities of
а.2-adrenoceptor and adrenaline-stimulated [35S]GTPyS binding are found in the LSI, 
BNST, DG, mesencephalic trigeminal nucleus, and LC (Figure 6.7a-b and Figure
б .8 c-d). Moderate densities of both markers were found in the striatum and entorhinal 
cortex, substantia nigra, field CA1 of Ammon’s horn and throughout the cerebral cortex. 
Low / negligible values of both markers are found in the CBM, white matter tracts and 
mesencephalon (Figure 6.7a-b and Figure 6 .8 c-d).
Comparison of the genotypes showed no difference in the adrenaline-stimulated 
[35S]GTPyS binding in either the LC (Figure 6 .8 c-d; Table 6.3) or frontal cortex (M2 
region) (Figure 6 .8 e-f; Table 6.3), the main areas of interest in these studies. However, 
it is interesting to note that NK1-/- mice demonstrated lower adrenaline-stimulated 
[35S]GTPyS binding in 5 out of the 8  films analysed (Figure 6.9).
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RX821002
a) NK1+/+
Epinephrine Basal
■- i-
Bregma -  5.34 mm
b) NK1-/-
Epinephrine Basal NSB RX821002
FIG U R E  6.8a-b: R epresentative autoradiographs o f o^-adrenoceptor m ediated  
increase in [35S]G TPyS binding to brain sections from  a) N K 1+/+  and b) N K 1-/- m ice 
at the level o f  the locus coeruleus. C oronal (15pm ) sections w ere labeled by [35S]G TPyS  
(0.1 nM ), w ithout (basal) or w ith  lOOpM epinephrine, at the level o f  the LC. 
N onspecific (N SB ) labeling w as obtained from  adjacent sections exposed  to 100 pM  
epinephrine plus 100 pM  R X 821002. n =  8. T he area o f  the locus coeruleus can be 
identified  as labelled blue in the P axinos and W atson im ages. Scale =  4000 pm.
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c) NK1+/+
Epinephrine RX821002
4k
* %
Epinephrine Basal NSB RX821002
FIGURE 6 .8 c-d: Representative autoradiographs of ^-adrenoceptor 
mediated increase in [35S]GTPyS binding to horizontal brain sections 
from c) NK1+/+ and d) NK1-/- mice, at the level of the locus coeruleus. 
Infralimbic cortex (IL), lateral septum (LSI), subparafasicular thalamic 
nuclei (SPF), mesencephalic trigeminal nucleus (Me5), locus ceruleus 
(LC), caudate putamen (CPu), bed nucleus of the stria terminalis 
(BNST), dentate gyrus (DG), substantia nigra (SN), entorhinal cortex 
(ent), medial vestibular nucleus (MVe), choroid plexus (ChP). Scale = 
3.5mm.
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e) NK1+/+ Bregma + 2.1 mm
Epinephrine RX821002
f) NK1 -/-
u v Bregma + 2.46 mm
Epinephrine Basal NSB RX821002
FIG U R E  6 .8 e-f: R epresentative autoradiographs o f  0 4 -adrenoceptor m ediated  
increase in [35SlG TPyS binding to brain sections from  e) N K 1+/+ and 0  N K 1-/- m ice 
at the level o f  the frontal cortex. C oronal (15pm ) sections w ere labeled by 
[35S]G TPyS (0.05 nM ), w ithout (basal) or w ith  lOOpM epinephrine, at the level o f  the  
FCtx. N onspecific (N SB ) labeling w as obtained from  adjacent sections exposed to  
100 pM  epinephrine plus 100 pM  R X 821002. n =  8 . Scale =  2500 pm.
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F ig u r e  6.9: Line graphs of different autoradiographic films depicting the 
relationship of [35S]GTPyS binding in the LC between NK1+/+ and NK1-/- mice. In 
the majority of autoradiographs [35S]GTPyS binding was lower in NK1-/- mice.
[35S]GTPyS binding (% over baseline)
LC FCtx (M2)
NK1+/+ 42.07 ± 19.74 49.76+ 17.31
NK1-/- 21.55 ± 12.95 61.23 ±21.71
T a b l e  6.3: Adrenaline-stimulated [35S]GTPyS binding to the locus coeruleus and 
frontal cortex of NK1+/+ and NK1-/- mice.
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6.4  D is c u s s io n
6.4.1 Regional binding of fH]RX821002 and f  HJrauwolscine
Autoradiographic analysis of [3H]RX821002 binding revealed extensive binding of this 
radioligand throughout the brain of both NK1+/+ and NK1-/- mice. No difference in 
binding density in the brain regions analysed was found between NK1+/+ and NK1-/- 
mice. [3H]Rauwolscine demonstrated a more restricted regional pattern of binding 
throughout the brain of NK1+/+ and NK1-/- mice, again, no difference in binding 
density was found between NK1+/+ and NK1-/- mice. The regional binding of 
[3H]RX821002 and [3H]rauwolscine in the brain of NK1+/+ and NK1-/- mice resembles 
that found by Holmberg et al., (Holmberg et al., 2003) in inbred FVB/N mice and in the 
rat (Hudson et al., 1992). Regional [3H]RX821002 binding was analysed in limbic brain 
regions receiving a dense noradrenergic input from the LC.
6.4.1.1 Amygdala
Binding in the amygdala was detectable only with [3H]RX821002, implying the 
predominance of the oi2a-adrenoceptor subtype in this brain region. However, no 
difference in a 2a-adrenoceptor binding density was found between NK1+/+ and NK1-/- 
mice. Immunohistochemical (Rosin et al., 1996; Talley et al., 1996) and autoradiographic 
studies have found both the ot2a and a 2c-adrenoceptor subtypes in the amygdala of the rat 
(Boyajian et al., 1987) and mouse (Holmberg et al., 2003). In situ hybridization studies 
report moderate (X2a-adrenoceptor labelling and light oi2c-adrenoceptor labelling in the 
amygdaloid complex of the rat (Scheinin, 1994) and mouse (Wang et al., 1996). The lack 
of detectable binding of the a 2C-adrenoceptor in the amygdala in these studies is
'I
unexpected, therefore. The present studies used the same concentration of [ H]RX821002 
(1.0 nM) and [3H]rauwolscine (0.4 nM) as Holmberg et al, (2003), who did find 
(X2C-adrenoceptor labelling in the amygdala. Therefore, it is possible that the lack of 
detectable oi2c-adrenoceptor labelling in the amygdala is attributable to film exposure time.
The amygdala is an essential structure for fear processing (for review see: (LeDoux,
1998), formation of fear memories (Maren, 1999; Nader et al., 2000) and mediating 
learned fear (Walker & Davis, 1997). The moderate amount of [3H]RX821002 binding to
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CL2 -adrenoceptors in the amygdala supports an important role for NA release in this brain 
region, in mediating various responses to stressful stimuli through the amygdala (for 
review see: (Tanaka et al., 2000)).
6.4.1.2 Bed nucleus o f the stria terminalis
Whereas the amygdala is important for learned fear, the BNST plays an important role in 
mediating unlearned fear (anxiety-like) behaviours e.g. startle (Lee & Davis, 1997; Davis 
et al., 1997; Gewirtz et a l, 1998; Schweimer et al., 2005).The highest concentration of 
NA in the brain is found within the BNST (Kilts and Anderson., 1986). Stress causes an 
increase in NA efflux in the BNST of rats (Delfs et al., 2000; Fuentealba et al., 2000; 
Wang et al., 2001). In the BNST, NA exerts a tonic inhibitory action, regulated via 
(X2-adrenoceptors (Forray et al., 1999). This is supported by the high amount of 
a 2-adrenoceptors found in the BNST in the present studies.
6.4.1.3 Cerebellum
Both the granule cell layer and molecular layer of the cerebellar cortex were measured. 
However, [3H]RX821002 binding was higher in the granule cell layer compared with the 
molecular layer of the CBM. Again, [3H]rauwolscine binding was not above film 
background. Both imunohistochemistry (Aoki et al., 1994; Rosin et al., 1996; Talley et al.,
1996) and in situ hybridisation (Nicholas et al., 1993; Scheinin et a l, 1994; Wang et al., 
1996; Winzer-Serhan et al., 1997b; Winzer-Serhan et al., 1997a) studies have 
demonstrated the localisation of both (X2a and a 2C-adrenoceptors in the CBM.
Cerebellar NA is important for the adaptive ability to coordinate locomotor tasks e.g. the 
irregular rod runway paradigm, a novel motor task (Watson & McElligott, 1984; Bickford 
et al., 1992). In the CBM, as in all brain regions, NA acts as a neuromodulator, 
augmenting the actions of neurotransmitters such as GAB A (Bickford, 1995). The 
presence of a,2-adrenoceptors in this brain region, therefore, is expected.
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6.4.1.4 Hippocampus
The hippocampus receives intense noradrenergic innervation. The highest binding in the 
hippocampus was found with [3H]RX821002, supporting the predominance of the 
(X2a-adrenoceptor subtype. This is in agreement with that found by (Holmberg et al., 2003). 
[3H]Rauwolscine binding was also found in the CA1 area of the hippocampus, supporting 
a study demonstrating that both these subtypes modulate release of NA in this brain 
region (Trendelenburg et al., 2001).
6.4.1.5 Locus coeruleus
Only [3H]RX821002 binding was found in the LC. The lack of expression of 
a 2c-adrenoceptors in the LC demonstrated by a lack of [ HJrauwolscine binding, was also 
found by (Holmberg et al., 2003). The a 2a-adrenoceptor is believed to be the predominant 
subtype in the rodent brainstem as demonstrated by immunohistochemical (Rosin et al., 
1993) and in situ hybridization studies (Scheinin, 1994). The role played by LC-located 
ot2a-adrenoceptors in mediating the hypertensive, sedative and antinociceptive actions of 
a i-adrenoceptor agonists, such as clonidine, have been well demonstrated (De Sarro et al., 
1987; Scheinin & Schwinn, 1992; Hunter et al., 1997; Altman et al., 1999). Although not 
demonstrated here, the presence of a 2c-adrenoceptors located on LC noradrenergic 
neurones cannot be excluded. Particularly as these two subtypes both contribute to the 
feedback regulation of NA release (Hein et al., 1999).
6.4.1.6 Lateral septum
Only [ H]RX821002 binding was detected in the lateral septum, suggesting the 
predominance of the a 2a-adrenoceptor subtype in this brain region. Dense labelling of 
(X2a-adrenoceptors in the rat septal area has been found using immunohistochemistry 
(Talley et al., 1996). In situ hybridization studies show the presence of a large amount of 
mRNA for the oi2a-adrenoceptor in the septum of mouse (Wang et al., 1996) and rat 
(Nicholas, 1993; Scheinin, 1994) brains. The lack of [3H]rauwolscine binding, and hence 
a 2c-adrenoceptors, is in line with the majority of in situ hybridization studies from other 
laboratories (Scheinin, 1994; Wang et al., 1996). The septum acts as a relay station, 
integrating the limbic telencephalon (forebrain) with the hypothalamus and the brainstem
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(hindbrain) (Antonopoulos et al, 2004). The lateral septum modulates descending limbic 
cortical pathways to diencephalic areas. NA inhibits lateral septum neuronal activity by 
activating ot2-adrenoceptors (Liu & Alreja, 1998).The dense binding of [ H]RX821002 in 
this brain area is not surprising.
6.4.1.7 Frontal cortex
Only [3H]RX821002 binding was observable in NK1+/+ and NK1-/- mice, supporting the 
predominance of the a 2a-adrenoceptor in the cortex. 90 % of cortical adrenoceptors are of 
the oi2a subtype, as determined using rat cortical homogenates (Uhlen et al., 1992). Since 
noradrenergic neurotoxins e.g. DSP-4 do not effect radioligand binding (Heal et al., 1993), 
the majority of cortical a 2-adrenoceptors are post-synaptic, and of the a 2a-adrenoceptor 
subtype (Heal et al., 1995). All of the frontal cortex noradrenergic projections arise from 
the LC (Foote et al., 1980a; Loughlin et al., 1986b; Loughlin et al., 1986a; Loughlin et al., 
1982). NA enhances cognitive processing by the prefrontal cortex through actions at 
post-junctional <X2a-adrenoceptors: (for review see: (Amsten, 1997)). a 2a-Adrenoceptor 
agonists e.g. guanfacine, have cognitive-enhancing abilities, as demonstrated by the 
improved performance of aged monkeys in the delayed response performance (Amsten, 
1997), through actions at post-junctional oi2a-adrenoceptors. a 2a-Adrenoceptor agonists 
are particularly effective at enhancing working memory performance under distracting 
conditions (Amsten & Contant, 1992). The presence of [3H]RX821002 binding in these 
studies supports the actions of NA through a 2a-adrenoceptors in the frontal cortex.
6.4.1.8 Olfactory bulb
In the olfactory bulbs of both NK1+/+ and NK1-/- mice, a higher number of binding sites 
was recognised with [3H]RX821002 than [3H]rauwolscine, further supporting the 
predominance of oi2a-adrenoceptors. The low density of ot2C-adrenoceptor in the olfactory 
bulb is in agreement with that found by (Boyajian et al., 1987) and (Holmberg et al, 
2003). However, both a 2a-adrenoceptor and a 2c-adrenoceptor mRNA is found in the 
olfactory nuclei (Wang et al., 1996). NA innervation of the olfactory bulb is exclusively 
from the LC (McLean et al., 1989), where it is thought to be important for olfactory 
learning. The LC input to the olfactory bulb is crucial for early olfactory learning, as LC 
lesions with 6 -hydroxydopamine impair acquisition of conditioned odour preferences in
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the newborn rat (Sullivan et a l , 1994). The role of NA in the olfactory bulb, as elsewhere, 
is believed to be modulatory, increasing the ‘signal-to-noise’ ratio in neuronal activation.
6.4.1.9 Periaqueductal grey
Only binding with [3H]RX821002 was observed in the PAG, indicating an absence of 
a 2C-adrenoceptors in this brain region. Immunohistochemistry revealed only a sparse 
distribution of the a 2c-adrenoceptor subtype in this brain region (Rosin, 1996). In situ 
hybridization studies demonstrate only light labelling of mRNA for the a 2C-adrenoceptor 
in the PAG (Nicholas et al., 1993). So, the apparent lack of [3H]rauwolscine binding in 
these studies is not surprising if the a 2C-adrenoceptor is present in only small amounts. 
Noradrenergic neurones projecting to the PAG are thought to be important for 
coordinating the autonomic and motor behavioural response to stress, as well as 
mediating fear and panic reactions, (for review see: (Schenberg et al., 2001)). A 
reciprocal, monosynaptic projection links the ventrolateral PAG to extranuclear dendrites 
of noradrenergic LC neurones. This monosynaptic pathway may partly mediate analgesia, 
reduced responsiveness to external stimuli, and decreased excitability of somatic 
motoneurones (Bajic et al., 2000). Both the LC and central nucleus of the amygdala 
innervate the PAG (see: (Sullivan et al., 1999)). The input from the amygdala is important 
for modulating freezing fear behaviour and pain (da Costa Gomez & Behbehani, 1995; 
Manning, 1998; Misslin, 2003; Oliveira et al., 2004). The binding of [3H]RX821002 to 
ot2-adrenoceptors in these brain regions is, therefore, not surprising (Redmond, Jr. & 
Huang, 1979).
6.4.1.10 Striatum
In these studies, binding of both [3H]rauwolscine and [3H]RX821002 were detected in the
•  1 • • •striatum. A high density of the a 2C-preferring radioligand [ Hjrauwolscine in the striatum
has also been described previously by Holmberg et al., in the mouse (Holmberg et al.,
2003). Both in situ hybridization and immunohistochemical studies report high expression 
of mRNA for the a 2C-adrenoceptor subtype in the striatum of the rat (Boyajian et a l, 1987; 
Nicholas et al., 1993; Scheinin et al., 1994; Rosin et al., 1996; Winzer-Serhan et al., 
1997b; Uhlen et al., 1997) and mouse (Wang et al., 1996). However, whether or not there 
is any appreciable noradrenergic innervation of the striatum has been questioned; hitherto
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only a modest noradrenergic input to the striatum has been found (Swanson & Cowan, 
1979). The dense expression of the a 2C-adrenoceptor subtype in the striatum, an area of 
high dopaminergic innervation (Boyajian et al., 1987; Rosin et al., 1996), has, therefore, 
prompted the proposal that it may be DA that activates these receptors (see: (Holmberg et 
al., 2003)). Furthermore, (X2c-adrenoceptor knock-out mice show a decrease in 
homovanillinc acid (a DA metabolite) (Sallinen et al., 1997), demonstrating a role played 
by these receptors in DA turnover. a 2C-Adrenoceptors have an inter-neuronal localisation 
in GABAergic medium-sized spiny projection neurons in the rat striatum, where they may 
modulate both the direct and indirect pathway of the basal ganglia (Holmberg et al., 1999).
The striatum plays a major role in coordinating movement and producing 
pre-programmed movements (engrams). The localisation of the a 2C-adrenoceptor subtype 
in this brain area, supports the role played by a 2C-adrenoceptors in motor performance. 
The role played by a 2C-adrenoceptors is demonstrated by the locomotor stimulatory 
activity of the indirect DA agonist, ^-amphetamine. Mice over-expressing this receptor 
show a blunted increase in locomotion (Sallinen et al., 1998), suggesting that 
a 2c-adrenoceptors have an inhibitory influence on the hyperlocomotion elicited by 
^-amphetamine.
6.4.2 Choice o f radiolabel
[3H]RX821002 has the advantage that, as an antagonist, it labels the entire population of 
ot2-adrenoceptors whereas agonists label the high affinity state of the receptor 
preferentially. The current results confirm the contention of Langin et al., (1989) and 
Hudson et al., (1992), that [3H]RX821002 is an excellent radioligand for the receptor 
binding studies of (X2-adrenoceptors as it displays high affinity and very low 
non-specific binding.
[3H]RX821002 was chosen for these studies for a number of reasons. After tritiation 
RX821002 retains its pharmacological selectivity and consequently makes it an 
excellent radioligand for use in receptor binding studies (see: (Clarke & Harris, 2002)). 
[3H]RX821002 has the lowest percentage of non-specific binding compared with other 
ct2-adrenoceptor antagonists such as [3H]yohimbine, [3H]idazoxan and [3H]rauwolscine, 
which are also used for radioligand binding studies (Langin et al., 1989). Although it is
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generally thought of as an (X2-adrenoceptor non-subtype selective antagonist, studies 
have suggested RX821002 shows a high selectivity for the a 2a-adrenoceptor subtype 
(Langin et al., 1989; Uhlen et al., 1998). In potassium phosphate buffer, as used here, 
[3H]RX821002 has a moderately higher affinity for the human oi2a-adrenoceptor subtype 
than for ot2C or 012b (Halme et al., 1995). Equilibrium dissociation constants (K&) for 
[3H]RX821002 in potassium phosphate buffer were, 0.48 nM for the oi2a-adrenoceptor,
3.07 nM for a 2b-adrenoceptor and 0.63 nM for a 2C-adrenoceptor.
To ensure labelling of the a 2a-adrenoceptor, [ H]rauwolscine was included in these 
studies. Rauwolscine preferentially labels the oi2c-adrenoceptor subtype in cells 
transfected with human (K[ 1.0), mouse (K[ 0.8) or rat (K& 0.8) a 2-adrenoceptor subtype 
genes (Harrison et al., 1991; Link et al., 1992; Marjamaki et al., 1993). Due to its low 
affinity for rat a 2a-adrenoceptors (K^ 34 nM), compared with the rat a,2c-adrenoceptor (K&
1.6 nM) (Uhlen et al., 1998) low concentrations of rauwolscine can, therefore, be used to 
differentiate between ot2a and a 2C-adrenoceptors in autoradiographic studies (Boyajian et 
al., 1987; Boyajian & Leslie, 1987). It was, therefore, believed that subtraction of the 
[ Hjrauwolscine binding density, from that of the [ H]RX821002 binding density, would 
give a good indication of the a 2a-adrenoceptor population. [ H] rauwolscine binding was 
limited to the striatum, CA1 area of the hippocampus and accumbens, only, supporting 
previous reports of the predominance of the ot2a-adrenoceptor subtype in the CNS.
6.4.3 Caveats
T h e s e  s t u d i e s  u s i n g  [ H]RX821002 a n d  [ H]r a u w o l s c i n e  d e m o n s t r a t e  n o  d i f f e r e n c e s  i n  
t h e  a 2 - a d r e n o c e p t o r  p o p u l a t i o n  b e t w e e n  NK1-/- a n d  NK1+/+ m i c e .  I t  i s  p o s s i b l e  t h a t  t h e  
a u t o r a d i o g r a p h i c  t e c h n i q u e  i s  n o t  s e n s i t i v e  e n o u g h  t o  d e t e c t  s m a l l  c h a n g e s  i n  
012- a d r e n o c e p t o r  d e n s i t y  t h a t  m a y  a c c o u n t  f o r  t h e  l a c k  o f  r e s p o n s e  t o  RX21002 i n  NK1-/- 
m i c e .  A l t e r n a t i v e l y ,  t h e  l a c k  o f  r e s p o n s e  t o  RX821002 d e m o n s t r a t e d  i n  NK1-/- m i c e  
c o u l d  b e  a t t r i b u t e d  t o  a  m e c h a n i s m  d o w n s t r e a m  o f  t h e  r e c e p t o r  r e c o g n i t i o n  s i t e .  
o t 2 - A d r e n o c e p t o r s  a r e  G  p r o t e i n - c o u p l e d  r e c e p t o r s .  T h e r e f o r e ,  t h e s e  s t u d i e s  p r o g r e s s e d  t o  
l o o k i n g  a t  t h e  f i r s t  s t e p  i n  t h e  r e c e p t o r  t r a n s d u c t i o n  s e q u e n c e :  t h e  a b i l i t y  o f  
a 2 - a d r e n o c e p t o r s  t o  b i n d  G T P .
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6.4.4 f sS]GTPyS analysis o f the functional activity of a^adrenoceptors in NK1+/+ 
and NK1-/- mice
" X  3Although no difference in [ H]RX821002 and [ H]rauwolscine binding density was 
found between genotypes, this does not exclude the possibility that the difference in 
basal NA efflux could be due to a functional uncoupling of the ot2-adrenoceptor from its 
G protein or second messengers downstream of the recognition site. Uncoupling of the 
0L2 -adrenoceptor from the G protein can occur in the absence of receptor downregulation 
(O’connor et al., 2005).
However, no difference in adrenaline-stimulated [ S]GTPyS binding was observed 
between NK1-/- and NK1+/+ mice in either the LC or frontal cortex (area M2). The 
current studies have, therefore, been unable to identify molecular correlates for the 
increase in basal NA efflux observed in anaesthetised NK1-/- mice compared to their 
NK1+/+ counterparts. Further investigations into the downstream signalling pathway of 
the a 2-adrenoceptor are required to determine if NK1 receptor disruption is a cause or a 
consequence of the increase in basal NA efflux in NK1-/- mice, and the lack of response 
to an 012-adrenoceptor antagonist observed in these studies.
6.4.5 Future candidates to investigate downstream o f the a2 -adrenoceptor
6.4.5.1 Adenylate cyclase activity
Second messenger signalling of 012-adrenoceptors is mediated via adenylate cyclase 
(AC). Activation of these receptors typically decreases AC activity, which decreases 
cAMP production. PKC-stimulated activity of adenylate cyclase type2 (AC2) is 
inhibited by G protein-coupled receptors that activate G0 proteins, but potentiated by Gi 
proteins. This difference between G0 and Gj proteins implicates a potential switch in the 
cAMP-PKA signalling pathway, by Gi/0-coupled receptors, depending on which G 
protein is available for activation (Nasman et al., 2002). The molecular switch may be 
different in the two genotypes; A consequence of disrupting the NK1 receptor may be 
that the NK1-/- mice stimulate AC through Gi leading to increased release of Ca2+ from 
internal stores. Future studies could investigate the rate of cAMP synthesis in NK1+/+ 
and NK1-/- mice.
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6.4.5.2 G protein linked inwardly rectifying potassium channels
A c t i v a t i o n  o f  (X 2 - a d r e n o c e p t o r s  r e s u l t s  i n  t h e  o p e n i n g  o f  G  p r o t e i n  l i n k e d  i n w a r d l y
I ^ j
rectifying K channels (GERKS) and closure of Ca channels, resulting in a decrease in 
noradrenergic cell firing. Activation of NK1 receptors by SP produces the opposite 
excitatory effect on noradrenergic cell bodies: closure of GIRKs and opening cation 
channels (Shen & North, 1992). The LC has among the highest density of NK1 
receptors in the rat brain (Mantyh et al., 1989) and nerve terminals, showing SP-like 
immunoreactivity, form axodendritic synapses with catecholaminergic neurones (Pickel 
et al., 1979). The SP input to the LC is likely to arise from the nucleus reticularis 
paragigantocellularis (Dean et al., 1993), or the nearby parabrachial nucleus (see: (Shen 
& North, 1992)). Disruption of the NK1+/+ receptor may, therefore, lead to a 
compensatory adaptation in how the noradrenergic cells maintain their excitability. For 
example, the activity of LC located GIRKS may be decreased in NK1-/- mice, which 
could lead to an increased rate of LC noradrenergic cell firing. Further studies are 
required to confirm this.
6.4.5.3 Regulators o f G protein signalling
Regulators of G protein signalling (RGSs) negatively regulate G protein signalling. For 
example, RGS4, a Ga-interacting protein (GAIP), selectively enhances (X2a-adrenoceptor 
stimulation, of the intrinsic GTPase activity of the G protein a  subunit (Ga0i and Ga ,2 
subtypes) (Cavalli et al., 2000), thereby terminating signalling through the inhibitory 
012-adrenoceptor. A developmental up regulation of RGS4 in NK1-/- mice, could result 
in the increase in basal NA efflux, as RGS4 GTPase activation facilitates attenuation of 
the functional output of G protein-coupled signalling. Further studies, for example 
Western blot protein analysis, would be useful to determine if the amount of RGS4 
protein is altered in NK1-/- mice.
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6.4.5.4 G protein-coupled receptor dimerization
ju opioid receptors are also G protein-coupled receptors, and couple to similar second 
messenger systems as the a.2a-adrenoceptor (Jordan & Devi, 1998). There are few areas 
where expression of the NK1 receptor, p opioid receptor and a 2a-adrenoceptor receptor 
overlap: one exception is the LC. As well as being strongly implicated in stress and 
arousal, the LC is also involved in the development of opiate dependence (Nestler et al.,
1999).
Evidence supporting a functional interaction between the p opioid and (X2a-adrenoceptor 
is provided by mice lacking the a 2a-adrenoceptor (Stone et al., 1997). In these animals 
the analgesic potency to spinally administered morphine is decreased (Stone et al.,
1997). G protein-coupled receptor dimerization has been shown to be necessary for the 
functional activity of certain G proteins (Marshall et al., 1999; Nelson et al., 2001). 
Furthermore, in certain situations these interactions have been shown to result in 
changes in the activity of G protein-coupled receptors. For example, changes in ligand 
affinity, efficacy, trafficking, and/or desensitization (Gomes et al., 2001; Angers et al., 
2002; Pfeiffer et al., 2003). The physical interaction between a 2a-adrenoceptors and p 
opioid receptors plays an important role in modulating their signalling, which could be 
brought about, at least in part, by the agonist-induced changes in receptor conformation 
and / or association (Jordan et al., 2003). Activation of either the oi2a-adrenoceptor, or 
the p opioid receptor, results in an increase in the extent of signalling through the p-a2 a 
dimer, whereas activation of both receptors leads to a decrease in receptor signalling 
(Jordan et al., 2003). One possible hypothesis, therefore, for the increase in basal NA 
efflux in halothane-anaesthetised NK1-/- mice, could be an increase in signalling 
through the p-ci2a receptor complex by both endogenous ligands, resulting from 
disruption of the NK1 receptor. This could lead to a decrease in the extent of signalling 
and consequently an increase in NA release.
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6.4.6 Methodological considerations
6.4.6.1 Immunohistochemistry and Western blot protein analysis
The major drawback associated with the investigation of the a 2a-adrenoceptor subtype 
using IHC and Western blot protein analysis was the lack of a suitable, 
commercially-available, antibody, and the small amount of a,2a-adrenoceptor protein in 
the LC region.
Although preliminary IHC results of the (X2a-adrenoceptor in the LC region suggested a 
difference in the density of the receptor in the two genotypes, the results were not clear 
enough to quantify. It was hoped that Western blot protein analysis, which is believed to 
be a more sensitive technique than IHC, would provide quantifiable results. One of the 
major problems associated with the Western blot experiments was the lack of specificity 
of the antibody. This resulted in a high level of background making analysis of the 
protein bands difficult. This was resolved by switching the incubating buffer from 
semi-skimmed milk to bovine serum albumin, as it was believed the antibody was 
reacting with the semi-skimmed milk. The normal amount of protein used for Western 
blot analysis is 10 jig. In order for a signal to be found with the a 2a-adrenoceptor 
antibody, in the LC, it was necessary to increase the amount of protein to 30 pg, 
suggesting a low amount of receptor protein in this area of the brain.
Without using techniques such as a tissue punch to dissect out the LC, it is hard to 
obtain an accurate dissection of this brain area. So it is possible that areas around the LC 
were included in the dissection. However, the ot2b-adrenoceptor subtype is found only in 
the thalamus (Nicholas et al., 1993; Scheinin, 1994), and the localisation of the 
a 2C-adrenoceptor-preferring radioligand [ H]rauwolscine in the striatum demonstrates 
that the oi2a-adrenoceptor subtype is the most likely receptor located in the area of the 
LC.
6.4.6.2 Adrenaline-stimulated [35S]GTPyS binding
Available evidence supports the expression of a,2-adrenoceptors, ai-adrenoceptors and 
P-adrenoceptors in the same regions of the CNS (Nicholas et al., 1996). It is possible
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that adrenaline-stimulated [35S]GTPyS binding was occurring at ai-adrenoceptors and 
p-adrenoceptors. However, regions expressing high levels of ai-adrenoceptors and 
p-adrenoceptors, such as cerebellum and thalamus (Rainbow et al., 1984; Jones et al., 
1985), did not demonstrate high levels of adrenaline-stimulated [ S]GTPyS activity. 
Furthermore, ai-adrenoceptors and p-adrenoceptors are coupled to pertussis toxin 
insensitive Gq and Gs G proteins, respectively. It is believed that receptors that stimulate 
[35S]GTPyS binding are coupled to Gj/0 G proteins, only. Therefore, in these studies, 
most of the adrenaline-stimulated binding is likely to be due to the a 2-adrenoceptor, 
possibly the a 2a-adrenoceptor subtype, as this is the predominant (X2-adrenoceptor 
expressed in the CNS (Talley et al., 1996; Rosin et al., 1996). This is supported by the 
radioligand binding study with [3H]RX821002 and [3H]rauwolscine, showing negligible 
[3H]rauwolscine binding to the a 2C-adrenoceptor in the LC or frontal cortex (M2), the 
brain areas of particular interest in these studies.
Tissue sections from NK1+/+ and NK1-/- mice were processed together on films. It is 
interesting, therefore, to note that in 5 out of 8  films of the LC area, NK1-/- mice
'X ^demonstrated lower percentage above baseline adrenaline-stimulated [ S]GTPyS 
binding compared to NK1+/+ mice. It is, therefore, tempting to speculate that by 
increasing the n number in this study, a decrease in the functional activity of the 
a 2-adrenoceptors in NK1-/- mice would be demonstrated. ‘Power Analysis’ can be used 
to calculate the required sample size of simple data. Using ‘Power Analysis’ to calculate
^ c
the required n number for the adrenaline-stimulated [ S]GTPyS binding assay, we find 
that when n = 8 , there is only a 1 2 . 8  % chance that the experiment would detect a 
difference in the functional activity of o^-adrenoceptors between NK1+/+ and NK1-/- 
mice. A 90 % chance that the experiment would detect a difference in the functional 
activity of the o^-adrenoceptors between the two genotypes would require n = 108.2, a 
very substantial and expensive experiment. It is possible that the biological decrease in 
the functioning of the ct2-adrenoceptor in NK1-/- mice is too small to be detected 
statistically. Increasing the n number could result in significance being reached, 
alternatively, resources could be wasted.
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6.4.7 Summary and conclusions
The studies presented in this chapter were unable to find a definitive molecular correlate 
to explain the higher basal NA efflux and lack of response to an a 2-adrenoceptor 
antagonist in NK1-/- mice. Future studies should, therefore, be aimed at investigating 
targets downstream of the G protein-coupled receptor as a possible cause of the 
increased NA efflux in NK1-/- mice.
These studies were unable to identify a difference in the molecular substrates 
responsible for the control of synthesis, reuptake and release of NA between NK1+/+ 
and NK1-/- mice. The following chapter, therefore, describes an experiment aimed at 
determining whether a difference in the content of noradrenergic vesicles (which 
contain the releasable pool of transmitter) could underlie the difference in NA efflux 
between NK1+/+ and NK1-/- mice.
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CHAPTER 7
ANALYSIS OF THE CONCENTRATION OF NORADRENALINE IN  
NEURONAL STORAGE VESICLES OF NK1+/+ AND NK1 - /-  MOUSE
CORTEX
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7 ANALYSIS OF THE CONCENTRATION OF NORADRENALINE IN 
NEURONAL STORAGE VESICLES OF NK1+/+ AND NK1 -/- MOUSE
CORTEX
7.1 I n t r o d u c t io n
Experiments described in this chapter investigated whether the increase in NA efflux in 
anaesthetised NK1-/- mice is due to an increase in the releasable pool of NA in the 
terminal storage vesicles. Although o^-adrenoceptors control release of NA, other
• “74-factors including size of the releasable pool and intraterminal Ca concentration, which 
is influenced indirectly by a 2-adrenoceptors, should be explored.
7.1.1 Background
NA is stored in vesicles which can be viewed under the electron microscope and 
isolated by differential centrifugation (Fillenz & Stanford, 1981). The vesicular NA in 
sympathetic nerve terminals (noradrenergic) is divided into two functional pools: a 
small release pool and a larger storage pool which is not easily mobilised for release 
(Swedin, 1972; Glowinski, 1973). These vesicles take up and store NA from the 
neuronal cytoplasm. The vesicular content can be increased by a range of treatments, 
such as monoamine oxidase (MAO) inhibition, or injection of exogenous NA and 
depleted by intense physical stimulation (see: (Fillenz & Howe, 1971; Fillenz & 
Stanford, 1981)).
Early studies of transmitter release relied on measuring its concentration in the perfusate 
of a stimulated, perfused sympathetic nerve / end-organ preparation. Brown and 
colleagues (Brown, 1965) pioneered analysis of perfusate during and after stimulation 
of noradrenergic neurones using the cat splenic nerve and spleen. Brown, demonstrated 
that, in addition to NA, the perfusate collected from the spleen after splenic nerve 
stimulation contained DpH but not cytoplasmic proteins e.g. lactate dehydrogenase and 
tyrosine hydroxylase (Fillenz, 1990a). The presence of DpH, which is found only in NA 
storage vesicles, confirmed that NA was released from vesicle-bound packets of 
transmitter contained within the terminal vesicles via exocytosis.
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The terminal vesicles were isolated using differential centrifugation. This technique has 
been used in the past, to characterise the subcellular distribution of NA in sympathetic 
nerve terminals (Bisby & Fillenz, 1971). The technique has helped to identify the 
relative roles of reuptake and synthesis of transmitter in the maintenance of transmitter 
vesicular stores (Fillenz & Howe, 1975). Differential centrifugation has also confirmed 
that vesicles have a limited storage capacity for NA, that the NA content varies from 
organ to organ and that the degree of unsaturation determines how much additional NA 
can be taken up into the vesicles (Fillenz & Howe, 1971). Studies by Fillenz et al., have 
also shown that increasing the activity of noradrenergic neurones in vivo leads to 
parallel changes in the NA content of storage vesicles and the NA release rate (Fillenz 
& Stanford, 1978). Using differential centrifugation it is also possible to measure 
vesicular NA concentration in brain-derived synaptosomes. Synaptosomes are 
essentially ‘pinched’ off nerve terminals.
It was, therefore, thought possible that an increase in NA release in NK1-/- mice could 
be due to an increase in the size of the vesicular store of NA in cortical tissue. This was 
explored using differential centrifugation.
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7.3 R e s u l t s
No difference in the amount of NA content expressed as fmol / mg protein was found 
between NK1+/+ and NK1-/- mice (Table 7.1 and Figure 7.1).
Vesicular noradrenaline content in 
NK1+/+ and NK1-/-mice
NK1+/+
NK1-/-
F ig u r e  7.1: Noradrenaline concentration in cortical synaptosomes from NK1+/+ 
and NK1-/- mice. No difference in noradrenaline concentration was found between 
NK1+/+ and NK1 -/- mice. Values are mean noradrenaline concentration expressed 
as fmol / mg ± s.e.m. n = 5.
n Average P3  
protein content 
mg / ml ± s.e.m.
Average S4  
NA content 
fmol / ml ± 
s.e.m.
Concentration 
of NA S4/P3  
fmol / mg ± 
s.e.m.
NK1-/- 5 91.51 ±8.53 237.64 ± 8 . 6 8 2.69 ± 0.3
NK1+/+ 5 88.81 ±4.49 252.4 ±45.61 2.88 ±0.53
T a b l e  7.1: Noradrenaline content of microsomal pellet and final supernatant from 
the cortex of NK1+/+ and NK1-/- mice.
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7.4 D is c u s s io n
7.4.1 No difference in the vesicular noradrenaline content between NK1+/+ and 
NK1-A mice
These studies show that there is no difference in vesicular NA content in synaptosomes 
isolated from cortical tissue in NK1+/+ and NK1-/- mice. Therefore, a difference in NA 
concentration in neuronal vesicles does not underlie the 4-5 fold difference in basal NA 
efflux observed in halothane-anaesthetised NK1+/+ and NK1-/- mice. The studies 
contained in this chapter do not rule out the possibility of an adaptive change in the 
firing-rate of noradrenergic neurones as a result of disrupting the NK1 receptor. Further 
studies are, therefore, required to investigate the firing-rate of LC-noradrenergic 
neurones. If firing-rate is unchanged between NK1+/+ and NK1-/- mice it is likely that 
the difference in the regulation of the noradrenergic system in NK1-/- lies at the level of 
the stimulus-secretion coupling. Preliminary evidence in this lab is beginning to support 
this hypothesis (Yan-unpublished observations; Section 7.4.2.2).
However, these studies do not exclude the possibility of an increased number of vesicles 
in the readily releasable pool near the ‘active zone’ in NK1-/- mice, or that vesicles may 
be more readily mobilised in NK1-/- mice. The readily releasable pool comprises those 
vesicles located near to the ‘active zone’, where vesicle fusion with the axolemma takes 
place and which is richly endowed in Ca channels. The reserve pool comprises 
vesicles docked more remotely on the neuronal cytoskeleton (see: Stanford, 2001c). 
Alterations at various stages in the mechanism of vesicular release could account for the 
increase in basal NA efflux in NK1-/- mice (Figure 7.2).
7.4.2 Alternative possibilities
7.4.2.1 Alteration in the distribution o f vesicles
Both large and small dense core vesicles store NA (Fillenz, 1990b). However, small 
dense core vesicles (SDCVs) are believed to contain most of the NA in nerve terminals 
(Bisby & Fillenz, 1971; Fillenz & Stanford, 1978). The amount of NA available for 
release may depend on the extent to which these vesicles are filled with transmitter,
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which can vary from organ to organ (Fillenz & Stanford, 1981; Fillenz & Pollard, 1976). 
The release of NA relies on burst-firing of noradrenergic neurones.
7.4.2.2 Intracellular calcium
94 -Stimulus-secretion coupling is dependent on the internal Ca concentration of the
•  • 94 -neurone. Arrival of a nerve impulse results in the opening of Ca channels. Intracellular 
Ca2+ release occurs via the endoplasmic reticulum and other sites (calcisomes) (for
*y I
review see: (Siesjo, 1990)). The rise in intraterminal Ca concentration triggers the
fusion of vesicles with the nerve terminal membrane, and the release of NA via
exocytosis. a 2-Adrenoceptors negatively regulate Ca channels. The Py subunit
9 i
dissociates from the trimeric (apy) G protein, and binds to the Ca channel, shifting the 
voltage sensitivity to more positive potentials, so that the channels do not open so 
readily during rapid membrane depolarisation. Activation of the NK1 receptor has the
9 i
opposite effect on Ca channels. It is possible, that a compensatory consequence of
9 I
losing an excitatory input to the cell is that Ca channels in NK1-/- mice are less 
sensitive to the depolarisation blockade caused by <X2-adrenoceptors. Preliminary 
evidence in this lab is beginning to support this proposal. This preliminary evidence
j j
demonstrates that NK1+/+ mice are less resistant to Ca depletion in K -stimulated 
tissue compared with NK1-/- mice (Yan-unpublished observations).
7.4.2.3 Mobilisation o f vesicles
The phosphorylation / dephosphorylation of Synapsin I (a vesicle bound protein), is 
controlled by kinase proteins, and, regulates the cycling of vesicles between the readily 
releasable vesicular pool and the more remote vesicular storage pool (Hilfiker et al., 
1999a). Stimuli which increase Ca2+-dependent stimulus-secretion coupling induce 
phosphorylation of Synapsin I. Phosphorylation of synapsin induces dissociation of 
synapsin from the cytoskeleton and the vesicles, mobilising the vesicle to the release
• •  9 +pool. A number of protein kinases target synapsins. However, one in particular, Ca / 
calmodulin protein kinase II (CAM kinase II), is bound to vesicle membranes. It is
• 94 -believed that an influx of Ca triggers the phosphorylation of synapsin by CAM kinase 
II (Figure 7.2). It is possible, therefore, that in NK1-/- mice synapsin is phosphorylated 
more readily by CAM kinase II.
202
Chapter 7: Noradrenaline concentration in neuronal storage vesicles
7.4.2.4 Docking-priming o f the vesicles
The docking, fusion and release of vesicles is believed to involve distinct interactions 
between proteins bound to the axolemma, vesicles and soluble cytoplasmic proteins 
(Figure 7.3). Synaptotagmin (Figure 7.2) a vesicular bound protein is widely believed to
^ i
modulate the influence that Ca has on the docking of vesicles to the axolemma 
(Littleton & Bellen, 1995). The NFL-tail of synaptotagmin penetrates the vesicle, 
whereas, the COOH-tail extends into the cytoplasm. This tail binds Ca2+, possibly 
allowing synaptotagmin to act as a ‘Ca sensor. Synaptotagmin is also phosphorylated 
by CAM kinase II (Hilfiker et al., 1999b), which can regulate neurotransmitter release. 
Therefore, in NK1-/- mice the sensitivity of synaptotagmin may be increased, so that 
NA vesicles are more readily docked and primed for exocytotic release (Figure 7.2).
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Synaptophysin
Plasma
membrane
Mobilisation
CAM kinase II
Dockins-primins
Synaptotagmin
SNAP-25
Syntaxin Ca*T channel Neurexin 
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P
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Figure 7.2: Diagrammatic representation of potential release-regulating sites that 
may be altered by genetic disruption of the NK1 receptor. 1) An increase in 
phosphorolylation of synapsin by CAM kinase II would lead to an increase in 
vesicular mobilisation in NK1-/- mice. 2) An increase in the Ca2+ sensitivity of 
synataptotagmin, or, an increase in internal Ca2+ concentration, would lead to an 
increase in the docking-priming of vesicles for release, in NK1-/- mice (Adapted 
from Kandel et a/., 1991). For a detailed review of all the factors involved in the 
excytotic cycle (See Benfanati et al., 1999)
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7.5  S u m m a r y  a n d  c o n c l u s io n s
Investigations into the NA content of cortical NA vesicles in NK1+/+ and NK1-/- mice 
have revealed no difference between the two genotypes. However, this does not exclude 
the possibility of an increase in the number of NA vesicles mobilized to the readily
9+releasable pool, nor an increase in Ca sensitivity of various constituents of the 
pathway involved in the stimulus-secretion exocytotic pathway. Candidates contributing 
to the increased basal NA efflux in NK1-/- mice could lie at any point in the vesicular 
release pathway. Further studies are therefore required to confirm this.
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8 SUMMARY AND GENERAL DISCUSSION
8.1 S u m m a r y  o f  k e y  f i n d i n g s
Initial microdialysis studies confirmed the earlier pilot findings that 
halothane-anaesthetised NK1-/- mice display a 2-5-fold higher basal NA efflux in their 
frontal cortex compared with their wildtype counterparts (Chapter 3; Fisher et al„ 2004; 
Stewart et al., 2004; Herpfer et al., 2005). These microdialysis studies further 
demonstrated that NA efflux in halothane-anaesthetised NK1+/+, but not NK1-/- mice, 
is increased following systemic administration of the a 2-adrenoceptor antagonist, 
RX821002 (0.3 mg/kgi.p.).
The second experiment described in Chapter 3 was designed to mirror that performed 
by Herpfer et al., (2005). The studies of Herpfer et al, (2005), focused on the role of 
terminal a 2-adrenoceptors in the control of NA efflux, by combining cortical infusion of 
RX821002 with systemic administration of desipramine (DMI). By combining cortical 
infusion of DMI with systemic administration of RX821002, the studies described here, 
provide extended information on the role of both terminal and somatodendritic 
ci2-adrenoceptors in the regulation of NA efflux in NK1 +/+ and NK1-/- mice. By 
comparing the current findings, with those of Herpfer et al., (2005), it appears that the 
regulatory influence of somatodendritic and terminal a 2-adrenoceptors, on NA efflux, 
becomes evident during situations which are presumed to alter the firing-rates of 
LC-noradrenergic cells and release of NA.
Cortical infusion of RX821002, resulted in the same incremental increase in NA efflux 
in both NK1+/+ and NK1-/- mice, demonstrating that terminal a 2-adrenoceptors 
tonically constrain cortical NA efflux in both genotypes (Herpfer et al., 2005). 
Furthermore, cortical infusion of RX821002 augments the DMI induced increase in NA 
efflux in NK1+/+ mice, only, suggesting a dysregulation of the terminal ct2- 
adrenoceptor in NK1-/- mice. Systemic DMI, by increasing NA efflux, is likely to 
increase the autoregulatory activity of both terminal and somatodendritic adrenoceptors 
(See: Chapter 3). Therefore, in the studies of Herpfer et al, (2005) cortical infusion of 
RX821002 revealed a difference in the regulation of terminal 012-adrenoceptors at lower 
rates of LC-noradrenergic cell firing.
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In contrast to the findings of Herpfer et al, (2005), the studies reported here (Chapter 3) 
demonstrated no augmentation of the RX821002 (0.3 mg /kg i.p.) induced increase in 
NA efflux in NK1+/+ mice, following local infusion of DMI into the frontal cortex. 
This suggests a ‘ceiling effect’, following systemic administration of RX821002 in 
NK1+/+ mice, which constrains a further increase in NA efflux. Since local cortical 
infusion of RX821002, which antagonises only terminal a,2-adrenoceptors, results in the 
same incremental increase in NA efflux in both genotypes (Herpfer et a l , 2005), the 
difference in the tonic regulation of NA release, between NK1+/+ and NK1-/- mice, is 
likely to lie at the level of cell bodies in the LC. Therefore, in contrast to terminal 
ct2-adrenoceptors, the activity of which is revealed at lower LC firing-rates following 
systemic DMI, the difference in activity of somatodendritic (X2-adrenoceptors is 
revealed at higher rates of LC firing following systemic RX821002.
In the studies described here NA efflux in NK1-/- mice was not altered following drug 
challenge with either systemic RX821002, or local infusion of DMI, administered 
separately or in combination. The lack of effect of the a 2-adrenoceptor antagonist, 
RX821002, on NA efflux in NK1-/- mice, is consistent with the current hypothesis that 
genetic disruption of the NK1 receptor attenuates the activity of this autoregulatory 
receptor.
Systemic administration of DMI, by inhibiting reuptake through both somatodendritic 
and terminal NATs results in the same incremental increase in NA efflux in both 
genotypes (Herpfer et al., 2005). By increasing endogenous noradrenergic tone at 
somatodendritic ct2-adrenoceptors it is likely that systemic DMI decreases the firing-rate 
of LC neurones (Mateo et a l, 1998; Svensson & Usdin, 1978; Invemizzi & Garattini,
2004) resulting in a blunted increase in NA efflux. Local cortical infusion of DMI is 
unlikely to change the firing-rate of LC-neurones. Therefore, it is possible that NA 
efflux following infusion of DMI may be so great in NK1-/- mice that the system, 
which is primed for maintenance of a higher basal noradrenergic activity, attempts to 
maintain a homeostatic level of NA by removal of NA through alternative transporters 
e.g. the dopamine transporters, organic cation transporters or via Uptake 2.
In contrast to NA efflux during continuous anaesthesia, there was no genotype 
dependent difference in basal NA efflux in freely-moving animals (Chapter 4). It is,
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therefore, fortuitous that preliminary studies were conducted under anaesthesia, as the 
difference in regulation of the noradrenergic system between NK1+/+ and NK1-/- mice 
would otherwise have been overlooked. Furthermore, in contrast to the anaesthetic 
situation, freely-moving mice of both genotypes did not respond to 0.3 mg / kg i.p. of 
RX821002. Although these two experiments were not randomised, and so direct 
comparisons are not valid, this could suggest an increase in the sensitivity of 
ot2-adrenoceptors during anaesthesia. This is consistent with earlier reports of an 
increase in the efficacy of the a 2-adrenoceptor agonist, clonidine (Saunier et al., 1993), 
during anaesthesia. As an adjunct in halothane anaesthesia, the ED50 of clonidine is 4.81 
± 0.8 jig / kg, whereas discontinuation of halothane results in a 5-fold increase in the 
E D 5 0  of clonidine (25.48 ± 8.26 pg / kg) (Saunier et al., 1993).
In Chapter 5, studies then progressed to investigate the effect of placement in the light / 
dark exploration box (LDEB) on a number of behavioural parameters in NK1+/+ and 
NK1-/- mice. The LDEB uses a novel environment as a non-noxious stressor to 
compare the ethological profile of behaviours that differ between NK1+/+ and NK1-/- 
mice (Stewart et al., 2002; Fisher et al., 2003; Fisher et al., 2004; Herpfer et al., 2005). 
Analysis of a number of behaviours is a particular strength of the LDEB protocol. Other 
LDEB models tend to oversimplify the behavioural response to the novel environment, 
by recording fewer behavioural responses and recording for a shorter duration of time 
(typically 3-4 min). Using the LDEB we have been able to demonstrate robust 
genotype-dependent differences in behaviour. The studies conducted here demonstrate 
that NK1-/- mice have:
•  Higher spontaneous locomotor activity
• Higher rearing behaviour
• Fewer risk assessment behaviours
• Spend less time in the light zone
Herpfer et al., (2005) demonstrated that all of the behaviours scored differed between 
genotype. However, for number o f returns and number o f rears, this was evident only 
after genotype-dependent differences in locomotor activity were taken into account, 
using ANCOVA analysis. In contrast to the studies performed by Herpfer et al., (2005), 
which demonstrated an increase in the number of rears in NK1-/- mice compared to
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NK1+/+ mice, following ANCOVA, ANCOVA abolished the genotype-dependent 
difference in this particular behaviour, in these current studies. This suggests the higher 
level of rearing behaviour observed in NK1-/- mice, is due to their higher locomotor 
activity compared to the NK1+/+ mice. However, the genotype-dependent differences 
in risk assessment behaviours and time spent in the light zone were still present after 
ANCOVA analysis. Therefore, these genotype-dependent behaviours were not due to a 
difference in locomotor behaviour between NK1+/+ and NK1-/- mice. Since 
behavioural arousal is intimately linked with activity of the LC-noradrenergic system 
(Smee et al., 1975; De Sarro et al., 1987) it is tempting to speculate that the higher 
locomotor behaviour in NK1-/- could be attributed to a difference in the regulation of 
the noradrenergic system between NK1+/+ and NK1-/- mice.
RX821002 was used to identify whether any genotype dependent behavioural 
differences could be attributed to a difference in noradrenergic transmission and, by 
implication, a difference in the a 2-adrenoceptors. Following systemic administration of 
RX821002 a number of behaviours differed in NK1+/+ mice. The following behaviours 
were changed by RX821002 in NK1+/+ mice only:
• Time spent grooming in the light was increased
• Latency to leave the light zone was increased
• Time to return to the light zone was decreased
• Number o f rears in the dark was decreased
• Number o f returns to the light zone was decreased
With the exception of a decrease in the time to return to the light zone, and an increase 
in the latency to leave the light zone which are essentially a decrease in passive 
avoidance behaviour, these behavioural changes are generally consistent with an 
anxiogenic-like effect of RX821002. However, we have no comparable data pointing to 
the a 2-adrenoceptor mechanism whereby novelty leads to anxiety. A long held belief is 
that an increase in the activity of the LC system augments fearful or anxious responses 
(Redmond, Jr. & Huang, 1979). However, there is also evidence to suggest that an 
increase in the LC activity that accompanies anxious or stressful situations, is a 
compensatory, coping mechanism (Weiss et al., 1994). Furthermore, pharmacological 
reports with a 2-adrenoceptor antagonists are quite inconsistent. They range from effects
210
Chapter 8: General Discussion
of anxiogenesis (Handley & Mithani, 1984) to anxiolysis (La Marca S. & Dunn, 1994; 
Cole et al., 1995). It is, therefore, possible that in these current studies potentiation of 
NA release following systemic administration of RX821002 is likely to produce 
‘fear-like’ and perhaps ‘anxiogenic-like’ responses in our mice. Regardless of whether 
or not this interpretation of the ‘emotional’ significance of these behavioural changes is 
correct, that these behavioural effects, following pre-treatment with RX821002, are not 
observed in NK1-/- mice provides strong support for a dysregulation of the 
noradrenergic system in NK1-/- mice, perhaps attributable to a 2-adrenoceptors.
None of the genotype-dependent behavioural changes following RX821002 
pre-treatment are shared by pre-treatment with DMI (Herpfer et al., 2005). However, 
systemic administration of DMI resulted in a decrease in total time spent grooming 
(Herpfer et al., 2005), whereas RX821002 resulted in an increase in total time spent 
grooming. The noradrenaline reuptake inhibitor DMI, and the a 2-adrenoceptor 
antagonist RX821002, have quite different mechanisms of action. It is possible that 
acute administration of DMI in the studies of Herpfer et al.; (2005) results in a decrease 
in extracellular NA, through a reduction in firing-dependent NA release (see: 
(Invemizzi & Garattini, 2004)). Administration of RX821002, via antagonism of 
a 2-adrenoceptors, is more likely to result in an increase in extracellular NA. Despite 
their different modes of action, it should be emphasised that both these compounds 
modify the behavioural response to the LDEB, of NK1+/+ and NK1-/- mice, in a 
genotype-dependent manner. However, the 012-adrenoceptor antagonists, RX821002 and 
atipamezole, both decrease the time to return to the light zone following first exit, in 
NK1+/+ mice, only (Fisher et al, 2003a; Fisher et al., 2004b). The result is that 
NK1+/+ mice resemble NK1-/- mice pre-treated with either vehicle or an 
a 2-adrenoceptor antagonist. It may, therefore, be possible to link this particular 
behaviour to a difference in the regulation of the noradrenergic system between NK1+/+ 
and NK1-/- mice. This difference may be due to an attenuated response of the ot2- 
adrenoceptor in NK1-/- mice. The possibility that RX821002 and atipamezole act as 
antagonists at NK1 receptors, and so produce the same behavioural response that is 
observed following genetic disruption of the receptor, can be excluded. Binding studies 
have revealed that neither atipamezole nor RX821002 have any appreciable affinity (> 
10 pM) for the NK1 receptor (Murray, Merck Sharp and Dohme-personal 
communication).
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A number of behavioural changes following RX821002 (0.3 mg / kg i.p.) were observed 
in both NK1+/+ and NK1-/- mice. These included:
• An overall increase in the total number o f grooms
• An overall increase in the total time spent grooming
• An overall increase in the time spent in the light zone
• A decrease in the risk-assessment behaviours, with the exception that time spent 
in the flat back approach was increased slightly.
This suggests retained activity of RX821002 in both genotypes, despite a decrease in 
the activity of <X2-adrenoceptors in NK1-/- mice. One possible explanation could be due 
to activation of post-synaptic adrenoceptors, which may be unchanged following 
genetic disruption of the NK1 receptor. Non-specific interactions with other 
neurotransmitter receptors, for example 5-HTiA, could also be a confounding factor.
Microdialysis performed in the LDEB (Chapter 5), has further demonstrated that 
following placement in the light novel compartment, NA efflux is increased by 
pre-treatment with RX821002 in NK1+/+ mice, only, over the same duration as the 
behavioural changes in the LDEB. However, the net increase in NA efflux, following 
RX821002 treatment, was not different, suggesting that the difference in the raw data is 
due to an underlying difference in the basal NA efflux.
In Chapter 6, a molecular biological approach was adopted to investigate the prime 
candidates (a2-adrenoceptors, noradrenaline transporters, dopamine-p-hydroxylase and 
tyrosine hydroxylase) that had been predicted to play an integral role in the difference in 
basal NA efflux in NK1-/- mice. The techniques used included:
• Immunohistochemical localisation of the above targets
• Western blot protein analysis of a 2-adrenoceptors and noradrenaline transporters 
in the LC and frontal cortex
• Autoradiographical analysis of the localisation and density of a 2-adrenoceptors
• Adrenaline-stimulated [35S]GTPyS binding to provide a measure of the function 
of the ct2-adrenoceptors
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However, none of the procedures used, provided conclusive evidence for a difference in 
any of the above targets (see caveats below).
8.2  W H Y  D O E S  G E N E T I C  d i s r u p t i o n  o f  t h e  E X C I T A T O R Y  N K 1 R E C E P T O R  i n c r e a s e
N O R A D R E N A L I N E  E F F L U X ?
Previous studies have demonstrated that SP, through its actions at the NK1 receptor, 
increases the firing-rate of LC noradrenergic neurones (Guyenet & Aghajanian, 1977; 
Cheeseman et al., 1983; Shen & North, 1992). Why does removal of this excitatory 
input to the LC result in an increase in NA efflux in NK1-/- mice also? Figure 8.1 
demonstrates a general schema of how genetic disruption of the NK1 receptor could 
result in an increase in noradrenaline efflux and a lack of response to RX821002 in 
NK1-/- mice.
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rH: GABAergic
NK1 receptor antagonists may 
suppress the responsiveness of 
a 2-adrenoceptors (Haddjeri & 
Blier, 2000). This hypothesis is 
further supported by these studies, 
using the NK1-/- mouse, a whole 
life animal model of NK1 receptor 
antagonism.
Chronic NK1 receptor antagonist 
treatment increases the burst-firing of 
locus coeruleus noradrenergic neurones 
in guinea-pig LC slices (Maubach et al., 
2002). Furthermore, systemic 
administration of NK1 receptor 
antagonists increases the firing-rate of 
LC neurones and NA efflux (Millan et 
al., 2001). This could occur through an 
action at NK1 receptors, which exert an 
indirect tonic inhibitory influence on 
locus coeruleus neurones, for example on 
an inhibitory input to PGi neurones or an 
excitatory input to PrH neurones. 
Therefore, it is possible that NK1 
receptor antagonists unmask an 
excitatory input to the locus coeruleus in 
the presence of a stressor (Hahn & 
Bannon, 1999; Hahn & Bannon, 1998).
PGi: glutamatergic
To spinal cord
F i g u r e  8.1: Possible mechanism by which genetic disruption of the NK1 receptor 
increases noradrenaline efflux. PB, parabrachial, LC, locus coeruleus, PGi, 
nucleus reticularis paragigantocellularis, PrH, nucleus prepositus hypoglossi, M2, 
frontal cortex, M2 region, DR, dorsal raphe.
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Based on results from a c-fos study it has been suggested that NK1 receptor antagonists 
indirectly enhance the activity of noradrenergic neurones (Hahn & Bannon, 1998) at 
receptors proximal to, but not on, noradrenergic cell bodies (Millan et al., 2001). It has 
been suggested that their action may be mediated at the level of the nucleus reticularis 
paragigantocellularis (Haddjeri & Blier, 2000), indirectly enhancing the glutamatergic 
input to the LC from this nucleus (Figure 8.1). Alternatively, NK1 receptor antagonists 
may decrease the inhibitory GABAergic inputs to the LC arising from the PrH (Figure 
8.1).
8.2.1 Attenuation of the a^adrenoceptor response
Of particular relevance to the studies undertaken for this thesis, is the observation that in 
rats i.v. administration of the first generation NK1 receptor antagonists WIN51708 and 
CP96345, attenuate the inhibitory effect of the ot2-adrenoceptor agonist, clonidine, on 
the firing-rate of LC noradrenergic neurones (Haddjeri & Blier, 2000). This could 
extend to a decrease in the response of a 2-adrenoceptors in NK1-/- mice to the 
endogenous agonist, NA, in these current studies, which may result in the higher basal 
NA efflux, observed in NK1-/- mice. This may result from a putative cellular interaction 
between a 2-adrenoceptors and NK1 receptors within noradradrenergic neurones as has 
previously been shown between SP and met-enkephalin (Velimirovic et al., 1995; Guan 
et al., 2005). For many, if not all, G protein-coupled receptors, the formation of homo- 
and heterodimeric receptors seems to be a general principle (see: (Pfeiffer et a l , 2003)). 
A major prerequisite for the physiological assembly of heterodimeric GPCRs in vivo is 
their coexpression in the same cell. NK1 receptors (Nakaya et al., 1994), 
a 2-adrenoceptors (Scheinin et al., 1994) and p opioid (Mansour et al., 1994; Van 
Bockstaele et al., 1996a) receptors are all expressed in the LC. Furthermore, the p 
opioid receptor forms stable heterodimers with the NK1 receptor (Pfeiffer et al., 2003) 
and (X2a-adrenoceptor (Jordan et al., 2003). The p opioid-NKl heterodimerization 
results in an alteration in the trafficking and resensitisation profile of the p opioid 
receptor (Pfeiffer et al., 2003) through delayed recycling and resensitisation kinetics. 
Interestingly, the rewarding effects of morphine are absent in mice lacking the NK1 
receptor (Murtra et al., 2000; Ripley et al., 2002) and increased NK1 receptor 
stimulation in mice lacking NA leads to reduced opioid efficacy (Jasmin et al., 2002), 
demonstrating an intimate relationship between these receptors. Therefore, a
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developmental consequence of disrupting expression of the NK1 receptor, may be an 
increase in the physical association (cross-talk) of p opioid and 012-adrenoceptors 
resulting in an attenuation of their signalling properties. Alternatively, there may be a 
cross-talk between a 2-adrenoceptors and NK1 receptors which is lost by genetic 
disruption of the NK1 receptor and this may attenuate signalling through the 
a 2-adrenoceptor in NK1-/- mice.
Alternatively, a result of genetic disruption of the NK1 receptor may be an alteration in 
the trafficking of the (X2-adrenoceptor to the cell surface membrane. LDCVs, are 
Golgi-derived neuropeptide-rich units that belong to the ‘regulated’ part of the secretory 
pathway (see:(Julius & Basbaum, 2005)). LDCVs mediate both neuropeptide release 
and trafficking of receptors to the pre-synaptic cell surface. It is possible, that in the 
absence of the NK1 receptor, a 2-adrenoceptors are no longer targeted to the ‘regulated’ 
protein secretory pathway, but rather become part of the ubiquitous or ‘constitutive’ 
pathway, which carries housekeeping proteins to the cell surface. For example, in an 
analogous manner, it has recently been demonstrated that the trafficking of the 8-opioid 
receptor to large dense-core vesicles (LDCVs) depends on its physical interaction with 
the SP domain of protachykinin, the precursor of SP (Guan et al., 2005). In the absence 
of SP in preprotachykinin A (PPT-A) mice, targeting of the 8-opioid receptor to the cell 
surface is mediated through the ‘constitutive’ secretory pathway. The functional 
significance of these two pathways is demonstrated by PPT-A knockout mice. The 
analgesic action of 8-opioid agonists is believed to arise through inhibition of Ca2+ 
channels mediated by the 8-opioid receptor. The analgesic action of a 8-opioid agonist 
completely disappears in PPT-A knockout mice, suggesting that these 8-opioid 
receptors, arising from the ‘constitutive’ pathway, are not functional or are not coupled
7+to the Ca channels in the same way that 8-opioid receptors arising from the ‘regulated’ 
pathway are (Guan et a l , 2005). This could extend to the activity of the a 2-adrenoceptor 
in NK1-/- mice. Genetic disruption of the NK1 receptor could result in targeting of 
012-adrenoceptors to the ‘constitutive’ pathway, leading to a decrease in the inhibition of
7 +Ca channels and consequently an increase in NA efflux and a decrease in the 
inhibitory activity of these receptors. Furthermore, immunocytochemistry can 
underestimate the contribution of the ‘constitutive’ pathway to plasma membrane 
receptor localisation (Guan et al., 2005). Thus a change in the receptor trafficking may
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have occurred in NK1-/- mice, at least in those neurones that would have expressed 
NK1 receptors.
8.2.2 Decreased activation of the inwardly rectifying potassium channel
Stimulation of G protein-coupled receptors coupled to Gi/0 proteins, leads to inhibition 
of adenylyl cyclase by the a  subunit of the heterotrimeric G proteins, as well as 
inhibition of voltage-dependent Ca2+ channels and activation of inwardly rectifying 
potassium channels (GIRKs) directly by the py dimers (Reuveny et al., 1994; Huang et 
al., 1995) in a membrane associated process (Williams et al., 1988; Miyake et al., 1989). 
Genetic disruption of the NK1 receptor may result in a change in the biophysical 
properties of LC neurones. Decreased hyperpolarisations, perhaps due to a decrease in 
the activation of GIRKs, via attenuated signalling through the oc2-adrenoceptor would 
mean that LC neurones display hyperpolarisations of shorter duration and are, therefore,
'y,
more excitable. Alternatively, there may be a change, perhaps a decrease, in Ca - 
activated K+ conductances, as has been postulated previously (Maubach et al., 2002).
8 . 3  C a v e a t s
Placement of rats in a light novel environment results in an increase in NA efflux 
(Dailey & Stanford, 1995; Dailey et al., 1996; McQuade et al., 1999). One set of 
experiments was, therefore, aimed at determining whether there are differences in NA 
efflux in NK1+/+ and NK1-/- mice on exposure to a novel environment, and whether or 
not NA efflux can be modified in a genotype dependent fashion (Chapter 5). If so this 
would provide further support for a difference in the regulation of noradrenergic 
neurotransmission between NK1+/+ and NK1-/- mice.
Analysis of raw microdialysis data demonstrated that NA efflux was increased only in 
RX821002 pre-treated NK1+/+ mice, when placed in the novel environment. However, 
analysis of net data did not show a difference in the incremental increase in NA efflux 
in vehicle or RX821002 pre-treated NK1+/+ and NK1-/- mice. This suggests that the 
higher basal NA efflux observed in NK1+/+ destined for treatment with RX821002 was 
responsible for the observed effect of RX821002 in the raw data. It is possible that 
increasing the sample sizes in this experiment would lead to a net increase in NA efflux
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that is highest in NK1+/+ mice pre-treated with RX821002. However, performing 
Mead’s (1988) ‘Resource Equation’ (see: Festing et al., 2002) demonstrates that a 
difference should be apparent, should one exist.
In Chapter 6 no difference was found in the density of a 2-adrenoceptors between 
NK1+/+ and NK1-/- mice using [3H]RX821002 autoradiography. It is possible that an 
insufficient number of animals (n = 3) was used to reveal any differences. This may also 
be the case concerning the adrenaline-stimulated [ S]GTyS binding assay, used to 
provide a measure of the G-protein coupling of the a 2-adrenoceptors. Although there 
was a general trend towards lower functional activity of a 2-adrenoceptors in NK1-/- 
mice compared with NK1+/+ mice, the variable nature of the technique may have 
masked a very small change. The variable nature of the technique, which has been noted 
by others (Newman-Tancredi et al., 2000), may, therefore, require additional animals to 
provide a conclusive answer as to the functional state of the a 2-adrenoceptors in 
NK1+/+ and NK1-/- mice.
8.4 P r o p o s a l s  f o r  f u t u r e  e x p e r i m e n t s
• Examine NA efflux in wildtype mice, following pharmacological manipulation 
of NK1 receptors. This could be achieved by chronic, or local administration 
into targeted brain areas, of GR205171, the NK1 receptor antagonist most 
suitable for use in rats and mice (pAT, = 9.5, (Gardner et al., 1996)). We would 
predict that chronic administration of GR205171 would result in an increase in 
NA efflux.
• Investigate the behavioural, electrophysiological and neurochemical profiles of a 
conditional NK1 receptor knock out mouse. Using the cre-lox P mediated 
method of receptor deletion (under the control of either the tyrosine hydroxylase 
or noradrenaline transporter promoter) it would be possible to examine the 
effects of selective genetic disruption of NK1 receptors expressed in LC 
neurones. Selective disruption of NK1 receptors expressed by noradrenergic LC 
neurones would help to identify whether NK1 receptor antagonists exert an 
excitatory effect through an indirect action.
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• Examine the electrophysiological activity of the LC in NK1+/+ and NK1-/- mice, 
in particular focusing on the GIRKs. Although the firing-rate of DR neurones in 
NK1+/+ and NK1-/- mice has been investigated, no studies have profiled the 
activity of the LC in these animals. In vivo LC neurones fire tonically (1 to 2 Hz), 
with their rate of firing closely correlated to the state of arousal of the animal. 
However, in an in vitro preparation, where all of the major inputs to the LC have 
been severed, they also show a similar rate of firing compared to the in vivo 
situation (Nestler et al., 1999), suggesting a pacemaker activity. It is possible 
that this pacemaker activity is different between the two genotypes, or has a 
different response to anaesthesia. This may underlie the difference in basal NA 
efflux observed between NK1+/+ and NK1-/- mice during halothane anaesthesia.
• Investigate the possibility of a cellular interaction (formation of heterodimers) 
between 012-adrenoceptors and NK1 receptors using coimmunoprecipitation 
followed by Western blot protein analysis. Such a physical interaction could 
provide a plausible explanation for cross-talk between NK1 receptors, 
(X2-adrenoceptors or \i opioid receptors. This physical interaction may result in 
an altered internalization or desensitization profile of the receptors, or an 
alteration in the mechanisms and functional consequences of downstream 
signalling.
• Microdialysis and synaptosomal studies have provided evidence for a 
DMI-resistant, fluoxetine-sensitive uptake site in the rat cortex (Hughes & 
Stanford, 1998; Hughes & Stanford, 1996). The lack of effect of cortical 
infusion of DMI in NK1-/- mice (See: Chapter 3) may be due to an upregulation 
of this particular binding site. Therefore, future studies could focus on the DMI 
and fluoxetine induced inhibition of [3H]NA uptake into cortical synaptosomes, 
following a noradrenergic neuronal lesion using 
N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine (DSP-4). This would provide in 
vitro evidence for the presence of an alternative uptake site, which may differ 
between the two genotypes.
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APPENDIX I
G e n o t y p i n g
• 5mm of tail tip is removed using a clean razor blade and placed into a sterile 1.5 
ml eppendorf tube.
• 750 pi of lysis buffer (Tail lysis buffer: 50 mM Tris pH 8 (Sigma) 100 mM 
EDTA pH 8 (Sigma) 10 mM NaCl (BDH) 1% SDS (Sigma) and 22.25pl 
Proteinase K (20mg/ml; Sigma) is added to each sample and vortexed briefly. 
Samples are then incubated overnight at 55°C, briefly vortexing two to three 
more times. If necessary, store at -20°C.
• If necessary defrost samples. Vortex briefly, then centrifuge for 3 min at 13000 
rpm. The supernatant is then transferred to clean 1.5 ml microfuge tubes and 200 
pi protein precipitation solution (Puregene, Minneapolis, USA) is added. Vortex 
the samples for 20 s and centrifuge for 3 min at 13 000 rpm.
• The supernatant is then removed and the pellet washed in 300 pi 70 % ethanol.
Then centrifuged for 3 min at 13 000 rpm.
• The supernatant is removed and the tubes left open to dry to allow the ethanol to 
evaporate.
• 100 pi of TE (lOmM Tris pH 8 (Sigma), 1 mM EDTA pH 8 (Sigma) is added to
each sample. Samples can then be stored at 4 °C.
• Make up reaction mix:
Ultra pure water 32.5 pi
Taq DNA polymerase 10 X reaction buffer (Promega, Southampton,UK) 5.00 pi 
25 mM MgCb (Promega) 3.00 pi
lOpM dATP (Promega) 0.25 pi
lOpM dCTP (Promega) 0.25 pi
lOpM dGTP (Promega) 0.25 pi
10 pM dTTP (Promega) 0.25 pi
NeoF1 (0.5 pg/pl; Sigma Genosys, Cambridge, UK) 1.00 pi
NK1-F2 (0.5pg/pl; Sigma Genosys) 1.00 pi
NK1-R3 (0.5p/ul; Sigma Genosys) 1.00 pi
Taq DNA polymerase (Promega) 0.50 pi
DNA sample 5.00 pi
Total 50.00 pi
1 NeoF: S’-GCAGCGATCGCCTTCTATC-S’
2 NK1-F: 5’-CTGTGGACTCTAATCTCTTCC-3’
3 NK1-R: 5 ’ - ACAGCT GT CAT GG AGT AG AT AC-3 ’
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• Tubes are placed in a PCR temperature cycler (PTC-100 Programmable Thermal 
Controller, MJ Research, Boston, USA) and the following programme run:
95 °C 5 min 
60 °C 30 s 
72 °C 30 s 
94 °C 30s x 34 
60 °C 30s 
72 °C 5 min
• Add 5 pi loading buffer (0.25 % bromophenol blue (Sigma); 0.25 % xyelene 
cyanol FF (Sigma); 30 % glycerol (BDH)) to each sample and mix thoroughly.
• Run 11 pi of each sample on a 2 % agarose gel in TBE buffer (National 
Diagnostics, Hull, UK) containing 10 pg / ml ethidium bromide (Sigma) at 
120 mV for approximately 1 h.
• Visualise and photograph under ultraviolet transillumination
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APPENDIX II
Protocol 2.8.1 Immunohistochemistry with chromogenic detection
Reactions were carried out by gently agitating sections on a tissue rocker at room 
temperature.
• Sections were first rinsed in 0.1 M PB in 1.5 ml eppendorf tubes
• Placed in 3% normal goat serum (NGS) in TTBS to block non-specific binding. 
2 % H2O2 was also included to block endogenous peroxidase activity. Sections 
left on rocker for 1 h1.
• Incubate sections in primary antibody in NGS on a rocker for 2-3 d at 4°C.
• Sections washed three times for 10 min in 0.1M PB.
• Sections incubated in biotinylated goat anti-rabbit IgG (1:500 in TTBS; Vector 
Laboratories) for 2 h .
• Sections washed three times for 10 min is 0.1 M PB.
• Add avidin-peroxidase solution (0.5 % Reagent A and 0.5 % Reagent B in 
TTBS; Vectastain Elite ABC kit [Standard]; Vector laboratories) for 1 h.
• Sections washed three times for 20 min in 0.1 M PB.
• Sections washed briefly in 0.15 M Tris buffer.
• Sections are then developed using a DAB substrate kit for peroxidase (Vector)
• Reaction is stopped by washing sections twice for 5 min each in 0.1M PB.
• Sections are then rinsed briefly in 0.01M PB.
• Sections mounted onto gelatine-coated slides and left to air dry.
• Sections are then dehydrated in ethanol solutions of increasing strength (2 min
in distilled water, 70 % ethanol x 2; 95 % ethanol x 2; 100 % ethanol x 2; 2 min 
in each).
• Clear in histoclear (2 min x 2; National Diagnostics).
• Slides coverslipped using DPX mounting medium (BDH).
1 The blocking serum should be that o f  the animal in w hich the secondary antibody is raised.
2 The secondary antibody must be raised against the animal in w hich the primary antibody w as raised.
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APPENDIX III 
Protocol 2.8.2 Fluorescence Protocol
• Sections placed in 1.5 ml Eppendorf tubes in 0.1 M PB.
• Washed on rocker for 10 min.
• Block for 1 h to reduced non-specific binding in 3 % Normal Donkey/Goat 
serum in TTBs. The serum used must be that of the animal in which the 
secondary antibody was raised.
• Incubate sections in primary antibody for 2-3 days at 4°C or over night at room 
temperature.
• Sections washed three times for 10 min each in 0.1 M PB.
• Sections incubated in biotinylated secondary antibody for 2 h (1:200 in NGS; 
Vector Laboratories).
• Sections washed three times for 10 min each in 0.1M PB.
• Sections incubated in dark in Flourescein Avidin D (1:4000 in TTBs; Jackson 
Cy3) for 45 min.
• All sections were then removed washed three times for 10 min in 0.1 M PB.
• Sections subsequently mounted in 0.01 M PB and left to dry in the dark.
• Slides were coverslipped in antifade kit.
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APPENDIX IV
Protocol 2.8.3 TSA indirect amplification method with FITC fluorescence
• Sections placed into 1.5 ml eppendorfs with 0.1M PB.
• Sections blocked in 3 % normal goat serum and 0.3 % Triton X-100 in 0.1 M PB
for 1 h.
• Sections incubated in primary antibody overnight at room temperature or 2-3 d 
at 4°C.
• Sections washed three times for 10 min each in 0.1M PB
• Sections incubated in secondary antibody biotinylated goat anti-rabbit IgG 
(1:200 in TTBs) for 90 min.
• Sections washed three times for 10 min each in 0.1M PB. Meanwhile make up
the avidin-peroxidase solution (0.4 % Reagent A and 0.4 % Reagent B in TTBs;
Vectastain Elite ABC Kit [Standard]; Vector)
• Sections washed three times for 10 min each in 0.1M PB.
• Sections incubated in avidin-peroxidase solution for 30 min. Meanwhile, remove 
biotinylated tyramide solution from the fridge and leave to thaw.
• Sections washed three times for 10 min each in 0.1M PB.
• Sections incubated in Biotinylated tyramide (1:75 in diluent; TSA™ Biotin
System; NEN Life Science Products, Boston, USA) for 7 min.
• Sections washed three times for 10 min each in 0.1M PB
• Sections incubated in the dark in Fluorescein Avidin D (1:600 in 0.1M PB;
Vector Laboratories) for 2 h.
• Sections washed three times for 10 min each in 0.1M PB.
• Sections mounted, in 0.01M PB, onto Superfrost Plus Microscope Slides (BDH)
and left to dry in the dark.
• Slides coverslipped with Citifluor (Citifluor, London, UK) or Prolong® 
Antifade Kit (Molecular Probes, Leiden, The Netherlands).
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